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Summary 
In this thesis, organic synthesis methodologies were developed involving 
dangerous gases. The idea was to provide tools to the academic and 
industrial research society to work in a safe manner with these products. In 
general, in an academic lab setting, organic reactions involving gaseous 
reagents are avoided because of both practical and safety concerns. 
Therefore, alternatives for these reactions are needed. 
A convenient and safe method was developed to generate carbon monoxide, 
a synthetically useful but highly dangerous gas. The gas is formed in a closed 
system where it is consumed as well. This new method uses formic acid, 
mesyl chloride and triethylamine to generate carbon monoxide, 3 
commodity chemicals available in every organic synthesis lab and is one of 
the cheapest ways known to generate carbon monoxide on laboratory scale. 
This methodology was applied by means of a two-chamber reactor to the 
development of minimalist α-helix peptidomimetics, scaffolds that can 
display amino acid side chains in a geometrically similar way as a protein α-
helix. Palladium-catalyzed aminocarbonylation reactions were used to 
assemble the helix mimetics. Previously unreported pyrazine based 
oligoamide α-helix mimetics were generated in this fashion. 
Next, the use of sulfur dioxide as reactant in organic synthesis was examined. 
Facing similar problems as with carbon monoxide, we developed a method 
for the large scale laboratory synthesis of DABSO, a common gas surrogate 
for sulfur dioxide, again making use of two-chamber reactors. 
Finally, flow chemistry was used to expand classic batch synthetic tools. In a 
first part, the use of a carbon monoxide precursors was explored using 
continuous flow technology. Another chapter involves the application of flow 
chemistry to the synthesis of glycerol carbonate from glycerol. Glycerol is an 
industrial waste product of the production of biodiesel while glycerol 
carbonate is considered a green chemical. 
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Samenvatting 
In deze thesis hebben we gepoogd bij te dragen aan het uitvoeren van 
organische reacties waarbij gassen gebruikt worden als reagens, waardoor 
deze toegankelijker worden voor de academische onderzoeker. In het 
algemeen vragen deze reacties namelijk speciale voorzieningen. Alle 
problemen met gassen (veiligheid, lage oplosbaarheid, hoge drukken, 
toxiciteit, …) zorgen ervoor dat men niet echt staat te springen om deze te 
gebruiken.  
We hebben een veilige manier ontwikkeld voor het gebruik van 
koolstofmonoxide op laboratoriumschaal. Dit is namelijk een synthetisch 
interessant maar zeer toxisch gas. Het gas wordt gegenereerd én 
geconsumeerd in een twee-kamer reactor. De manier waarop het gas 
gegenereerd wordt is één van de goedkoopste methoden die gekend is, 
waarbij geen toxische nevenproducten worden gegenereerd. Deze 
methodologie werd toegepast voor de ontwikkeling van α-helix mimetica. Dit 
zijn verbindingen die aminozuurzijketens op dezelfde ruimtelijke manier 
plaatsen als een proteïne α-helix dat doet. Deze verbindingen kunnen 
hierdoor medisch relevant zijn. Door gebruik te maken van 
koolstofmonoxide via palladium-gekatalyseerde aminocarbonylering zijn we 
er in geslaagd om de ongerapporteerde pyrazinegebaseerde oligoamide α-
helixmimetica te synthetiseren.  
Ook werd het gebruik van zwaveldioxide als reagens in organische reacties 
onderzocht. Dit gas is gelijkaardig aan koolstofmonoxide in de zin dat het 
vergelijkbare interessante synthetische mogelijkheden biedt maar ook zeer 
gevaarlijk is om mee te werken. Vanuit die optiek hebben we een protocol 
ontwikkeld voor de grote schaal synthese van DABSO, een gekende 
gasprecursor voor zwaveldioxide, weerom gebruik makend van een twee-
kamer reactor.  
Een ander aspect van deze thesis is het gebruik van flowtechnologie als een 
expansie op de huidige batch synthese methodologieën. Hierbij wordt op 
een continue manier een synthese uitgevoerd. Dit werd toegepast voor 
koolstofmonoxideprecursoren alsook voor de synthese van 
glycerolcarbonaat, een groen reagens, uit glycerol, een industrieel 
afvalproduct van de biodieselsynthese.  
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List of abbreviations 
ACN  Acetonitrile 
Boc  tert-butyloxycarbonyl, protecting group 
BPR  Back pressure regulator 
bs   Broad singlet 
COware  Two-chamber reactor from the Skrydstrup group 
CSA  Camphersulfonic acid 
Da   Dalton, molecular weight unit 
DABCO  1,4-diazabicyclo[2.2.2]octane 
DABSO   
DCM  Dichloromethane 
DIAD  Diisopropylcarbodiimide 
DIPEA  N,N-diisopropylethylamine (Hünig’s base) 
DIY  Do it yourself 
DMAP  4-Dimethylaminopyridine 
DMC  Dimethyl carbonate 
DMF  Dimethyl formamide 
DMSO  Dimethyl sulfoxide 
e.g .  exempli gratia 
eq   Equivalents 
FT-IR  Fourier-transform infrared spectroscopy 
GC   Gas chromatography 
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GLC  Glycerol carbonate 
GPR  Gas pressure regulator 
HOMO  Highest occupied molecular orbital 
HPLC  High pressure liquid chromatography 
HR-MS  High resolution mass spectrometry 
HTS  High-throughput screening 
IC50  The half maximal inhibitory concentration 
IleRS  Isoleucine tRNA synthetase 
IPA  Isopropyl alcohol 
LUMO  Lowest unoccupied molecular orbital 
MIT  Massachusetts Institute of Technology 
Morpholine  
MPLC  Medium pressure liquid chromatography 
Ms  Mesyl 
N/A  Not applicable 
NaHMDS  Sodium hexamethyldisilazide 
NBS  N-bromosuccinimide 
NHC  N-heterocyclic carbene 
nM  Nanomolar (concentration) 
NMR  Nuclear magnetic resonance 
PBR  Packed bed reactor 
PPI  Protein-protein interaction 
ppm  Parts per million 
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PS   Polymer supported 
psi   Pound-force per square inch, a unit for pressure 
RT   Room temperature 
SAR  Structure activity relationship 
sec-BuOH  2-butanol 
SelectFluor  
SNAr  Nucleophilic aromatic substitution 
SOMO  Single occupied molecular orbital 
S-Phos   
TFA  Trifluoroacetic acid 
THF  Tetrahydrofuran 
ThrRS  Threonyl tRNA synthetase 
TLC  Thin layer chromatography 
Trt   Trityl, protecting group 
Ts   Tosyl 
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met veel enthousiasme op te volgen als assessoren. Mario, ook bedankt voor 
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Steven Verhelst and professor Ian Baxendale, thanks a lot for being my jury 
members and revising this work. Your time and comments are greatly 
appreciated. 
Iemand die ook een zeer belangrijke rol heeft gespeeld in mijn verhaal op de 
KU Leuven is niemand minder dan Brecht. Meer zelfs, moest ik aan één 
iemand in dit dankwoord de eigenschap uniek toekennen, ja… dan heb jij die 
prijs gewonnen. (Ok nee, toch niet, gedeelde eerste plaats met Cevain!) Of 
kennen de lezers van dit dankwoord misschien nog iemand die op de security 
check van de luchthaven plots beseft dat hij nog een dolk van quasi een halve 
meter aan zijn broek heeft hangen en dit dan ook nog eens uitgelegd krijgt 
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zonder confisquering van dit moordwapen? Of iemand die samen met “een 
man die in het bos woont” voor een dagje naar de zee gaat, vervolgens een 
gek Japans pak aantrekt om dan met zijn tweeën met messen te gaan 
vechten in de zee, gewoon “voor de leut”? Gaande van een kerel die 
sporadisch eens een gasfles besprong, tot de dag van vandaag waar hij recent 
vader geworden is, wat een metamorfose! Ik kijk ook echt op naar uw 
handigheid, want anders had de Pleasuretron 2000 mijn pad nooit gekruist… 
In ieder geval, vanaf de dagen waarin je de begeleider was van mijn 
masterthesis tot quasi de dag dat dit boekje gedrukt werd, zijn jouw 
hersenkronkels van cruciaal belang geweest in dit werk, iets wat ik nooit zal 
vergeten…  
Iemand waarvan ik van de eerste contacten al meteen wist dat we wel eens 
goede maten zouden kunnen worden is Klaas, de schrik van Hoogstraten en 
self declared bowlingexpert, ondanks de ‘petanqueworp’. Ondertussen zijn 
onze paden (een beetje) gescheiden, maar dat weerhoudt ons zeker niet om 
vantijd eens goed bij te praten. De manier waarop wij op dagdagelijkse basis 
zeverden tegen elkaar in het labo, dat zijn momenten om eeuwig te 
koesteren. Of het nu ging over vrouwen, chemie, random zever of vrouwen 
(hebben we het wel 1 of 2 keer over gehad, geloof ik), de humor die er aan 
te pas kwam hield ons messcherp. De elegante wijze waarop jij (al dan niet 
geïntoxiceerd, al waren de bloemenverkopende Paki’s daar minder 
enthousiast over) tevens een feestje in gang kan steken, daar kan menig 
persoon nog iets van leren. Wereldklasse is het. De labofeestjes in de oude F 
zijn gewoonweg niet los te maken van een feestende Klaas. Wie weet is het 
dan ook geen toeval dat we dit nooit hebben kunnen evenaren in het nieuwe 
gebouw, we waren onze katalysator voor eeuwig en altijd kwijt… Dat we nog 
lang maten mogen blijven, man! En als apotheose: AZOE EEN TIETE, PEKE! 
Bij deze ben je mij een bak bier verschuldigd, graag binnen de maand aan mij 
bezorgd.  
Over Cevain, Bitcoin miljonair, zou ik 10 pagina’s kunnen schrijven hier, en 
dan nog is het onmogelijk om een beschrijving neer te pennen zodat mensen 
die hem niet kennen, weten wat hun te wachten zou staan wanneer ze hem 
leren kennen... Ik haalde namelijk hierboven al aan dat hij met Brecht de 
eerste plaats deelt qua uniek zijn. Cevain, hoe jij de lijn serieus-zever kunt 
laten vervagen, dat is ongezien. Na ettelijke jaren goede vrienden te zijn, 
hangt er toch nog zoveel mystiek rond u en dat typeert u echt! De dynamiek 
met uw vriendin bijvoorbeeld, begrijpe wie kan?! Naast de string theory het 
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meest complexe raadsel van deze tijd. Als er maar één waarheid in het 
universum is, dan is het deze wel: houd Evelien goed bij u, want zo één 
komde echt NOOIT nimeer tegen. Ook uw kot vroeger met bijhorende 
bureau die begraven was onder de lege melkflessen en pizzadozen, en uw 
lifting gear in de andere hoek.. En toch niet het leven gelaten door salmonella 
of door de vloer gezakt te zijn, niets minder dan een wonder! Ik ben zelf 
iemand die regelmatig ongepaste opmerkingen kan maken, maar dat is niets 
vergeleken met uw kunsten op dit vlak, waarbij vooral uw timing en 
verrassingseffect zijn gelijke niet kent. Man, wat heb ik geschaterlacht, 
ongelofelijk! Ons gebulder tijdens de middag in de oude F was vaak te horen 
tot helemaal bij Spectro, wat waren dat de tijden! 
Stijn, de keukenprinses. Waar moet ik in hemelsnaam beginnen? Sinds jaar 
en dag mijn maatje, mijn persoonlijk adviseur in de keuken en mijn 
encyclopedie van wetenschappelijke feiten rond voeding. Ik kwam nooit 
eerder iemand tegen wiens ogen beginnen te fonkelen als hij spreekt over 
koffie, of bier, of brood, of kikkererwten, of kaas, of kruiden, of… Ondanks de 
regelrechte cock block van een 6 tal jaar geleden, zijn we zeer goede maten 
gebleven, haha! Ook 6 weken Australië hebben we overleefd zonder elkaar 
(nét) niet de kop in te slaan. Jouw ‘tegendraads doen om tegendraads te zijn’ 
karakteristiek siert u, daar zal Amy zeker van kunnen meespreken. Dat is ook 
sowieso de hoofdreden waarom uw pa u nen ‘onnozeleir’ vindt! Ik kan er nog 
wel wat meer bedenken eigenlijk! Misschien omdat wat jij ‘parate kennis’ 
acht (en dat is VEEL), dat daar niemand u iets moet over vragen, want dan 
krijgen ze het deksel hard op de neus! Of uw geheimzinnigheid rond 
afwezigheid/vakantie misschien? Man, wat heb ik daarmee gelachen! Er zijn 
zoveel herinneringen, gaande van Stijn die een potje satékruiden ad fundum 
kapt en er totaal slecht van gaat, tot de verdeel en heers kitchen overlord op 
het kerstfeestje, die allemaal een speciaal plaatsje hebben gekregen. 
Bedankt voor alles, echt waar! 
Koen, de man die gebroken heeft met peptiden om zich op gelators te 
storten. De peptiden zijn nog vol liefdesverdriet, arme stakkers… Een groot 
lawaai, dat zal ik mij vooral blijven herinneren over de heer Koen Nuyts. 
Enkele jaren terug toonde je een moment van tederheid tussen al dat 
geroep, en nam ik je onder mijn hoede om je te introduceren tot crossfit, tot 
op vandaag de dag nog steeds de basis voor uw breedgeschouderd postuur. 
You’re welcome. Dingen zoals de Colruyttripjes, uw uitbarstingen (zoals die 
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keer dat Cedrick als groen blaadje uw glasfilter had laten vallen), uw humor 
en uw Justin Bieber bureau zullen me lang bijblijven. 
Johannes, de NederBelgPool! Jouw eigenschappen als chemist zijn niet van 
de minste. Zomaar op je eentje verschillende papers halen, dat is niet voor 
iedereen weggelegd. Ik ben er dan ook zeker van dat de universiteit 
Antwerpen er een sterke macht bijheeft. Succes! 
Dan, Joachim van Quartier Schaerbeek, de groupie van Steel Panther! Er 
wordt regelmatig geschreven dat te laat komen in iemands bloed zit, dat hij 
er niet kan aan doen. Jij bent voor mij het levende voorbeeld van deze 
stelling! Ik denk dat ik tevens niemand ken die zo ongelofelijk goed kan 
luisteren als jij. Jij discussieert nooit om gewoon je eigen visie op te dringen, 
maar eerder om te luisteren naar de andere standpunten, en die eigenschap 
is op zijn zachtst uniek te noemen. Eerst en vooral: bedankt voor de ettelijke 
uren debat/discussie/filosofische uitwisselingen, waarbij ik soms zo hard in 
the zone geraakte dat ik bijna begon te tieren. Hier heb ik toch wel enorm 
veel aan gehad. Jij gaat het trouwens nog ver schoppen met je chemische 
kennis, jij levende literatuurlegende. Met je tondeuse daarentegen heb je 
dringend wat bij te leren... Het blijft mij trouwens keer op keer verbazen wat 
een aimabele man jij wel niet bent: bijna geen vooroordelen naar mensen 
toe en je tolereert zowat alles. Helaas wordt heel deze karakteristiek volledig 
teniet gedaan wanneer het over muziek gaat, want dan verander je plots in 
de meest intolerante persoon die ik ken! Liever snel naar de hel dan traag 
naar de hemel? “Een gevaarlijk lied met een TOTAAL verkeerde boodschap.” 
Zingen over seks? “Puberaal gedrag van de ergste graad.” Het spreekt voor 
zich: Jesus would not be proud. In ieder geval, moest je toch ooit beginnen 
neigen naar atheïsme moet je me zeker bellen, al zijn we beide hoogbejaard 
;-) Als laatste dien ik nog te zeggen dat ik hoop dat mijn huwelijkscadeau voor 
wat, euh, afwisseling kan zorgen. Al is het maar uit wetenschappelijke 
nieuwsgierigheid!  
Thomas, moderator van www.dumpert.nl, iemand die zeer creatief tot 20 
kan tellen, de koning van de logical fallacies en nog zoveel meer. Je was ook 
voor een hele poos een naaste collega, met veel gelach en gegier over de 
jaren heen. Merci voor alle filmpjes, alle reisverhalen en je uitstekende 
uitvoering van ‘laboverantwoordelijke’ zijn. Ik zal ook nooit vergeten hoe jij 
voor eeuwig de geschiedenis bent ingegaan als een absolute wereldster in 
anti-climaxverhalen! (Voor de geïnteresseerden: vraag hem maar eens naar 
een Russische vrouw die kwam couch surfen, maar zorg wel dat je eerst 
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neerzit.) Ook tegen absoluut onbeleefde apen op congressen stonden we 
samen sterk! In alle eerlijkheid dien ik de lezers nog in te lichten dat Thomas 
een soort van geavanceerde codetaal heeft ontwikkeld die tot op heden niet 
te kraken valt. Het betreft hier de term “en cetera”, heel sporadisch 
aangevuld met “of cetera”. Na talloze vergaderingen onder collega’s zijn we 
tot de conclusie gekomen dat we een prijs uitreiken voor de persoon die deze 
next level code kan kraken, want ons is het tot op heden gewoonweg niet 
gelukt. 
Wat later vervoegde Cedrick ons ook, de “katholieke”, ambitieuze West-
Vlaming. Geloof het of niet, maar als Cedrick een doel voor ogen heeft, valt 
dat zelfs te merken aan zijn… manier van wandelen! Gene zever. Niemand 
wandelt sneller door de gangen van den F, zoveel is zeker. Het gros van de 
lezers beseft misschien niet meteen dat Cedrick een bekende Vlaming is, met 
verschijningen op nationale televisie. Hij geeft tegenwoordig nog gratis 
handtekeningen, maar ik zou er snel bij zijn als ik van u was… En trots dat zijn 
mama is! Merci voor de vele eerlijke antwoorden op mijn vaak nogal rare 
vragen, en alle hulp in het labo. Ik denk trouwens, zonder te zeveren, dat er 
voor jou een carrière in de politiek is weggelegd. Zo een extreem gladde 
paling als jij (al kan Gert er ook wat van!), ik zou het zeker een kans geven! 
Laurens was ook van de partij, een man die liever met gelletjes speelt dan 
met vrouwtjes, tenzij het Japanse deernen betreft! Op een dag wordt hij een 
gekend auteur in Nature Materials, maar daar zullen we toch nog even 
moeten op wachten, vrees ik… Zie maar dat je deze Japanoloog nooit 
meevraagt, want de kans is groot dat hij niet kan omdat hij nog moet 
afwassen. Man, man, man! Nochtans ziet de toekomst er rooskleurig uit, 
gezien Laurens gekroond is tot nieuwe Chieftain van de spellekesavond. Mijn 
opvolging is verzekerd, een goeie zaak! 
Of course, Soultan cannot be forgotten in this acknowledgement, although 
his last sighting was in the Canadian wilderness, dancing with bears… Thanks 
for all the laughs, the fights (the battle of the forks with Eggmantas for 
example!), your party spirit, your smoothness (‘Of course!’) and so much 
more. I’m definitely sure you will do a great job in the land of maple syrup, 
as you are a versatile and capable scientist. A la prochaine, mec! 
Philippe ‘de Grote’, zoals Klaas het mooi doopte, gij waart, zijt en zult een 
serieuze meerwaarde voor de groep zijn. Buiten een harde werker en een 
zeer capabel chemist, durf jij out of the box te denken en met coole ideeën 
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op de proppen te komen. Daar zijn zowel de nieuwe snufjes in the office als 
op het world wide web levende voorbeelden van! Het is dan ook meer dan 
verdiend dat jij naast voltijds doctoraatsstudent ook de titel head of 
innovation hebt verdiend! Blijf vooral zo verder doen. 
Dries, de lepe pé. Gij zijt ne rare snuiter ze, ma dat weet ge zelf ook wel! Ik 
ben er zeker van dat ge uw doctoraat in schoonheid ga afronden. Tijdens je 
oefenzittingen valt er door je leidinggevende positie wel eens een vrouwtje 
in zwijm. Helaas pindakaas zijn deze vaak “jouw type” niet. Komaan man! 
Standaard verlagen, mijn gedacht! Wat minder aan die badmintonraket 
denken? Wanneer doen we ons matchke eigenlijk? Ik ga u sowieso kloppen… 
Alsof één Verschueren echt nog niet genoeg was, dan komt er prompt een 
andere de veteraan aflossen... Parents, lock up your daughters, Rik “Ricky 
Gervais” Verschueren (Henri voor de vrienden) is gearriveerd uit metropool 
Wortel! Ik heb oprecht spijt dat wij niet wat langer collega’s zullen zijn, want, 
om het zacht uit te drukken, wij hebben wel wat gemeen! Interesse in 
mensen, zowel qua psychologie als overtuigingen, is een zeldzame 
karakteristiek die we toch beiden bezitten. Ook op filosofisch vlak kwam ik 
zwaar aan mijn trekken door u. Het woord “specimen” zal mijn hele leven 
gelinkt blijven aan onze definitie, en terecht ook, want zeldzaam zullen ze 
blijven… Ge hield mij scherp, en de occasionele steek werd direct met veel 
geweld teruggevuurd! Ook op het vlak van humor zit het snor. A new ‘lord of 
the memes’ is born. Bedankt om deze toch wel uiterst belangrijke legacy 
voort te zetten. Merci voor de babbels, zowel diepgaand als ultraplat. Blijf 
vooral uw eigen gedacht volgen, want gij gaat nog ergens geraken! Hopelijk 
verliezen we het contact niet, dat zou een spijtige zaak zijn. Ik wens u alleszins 
ne specimen toe! 
Michael, thanks for being the Australian cunt that you are. You getting 
married was the perfect excuse to explore down under! Thank you for being 
a nice guy in general, which can be rare among PhD students. Also for all the 
talks, for all the drinks (coffee, but mainly beer), for all the PhD smack talk 
and for letting us stay in your parents’ garage in Sydney! It appears you will 
be staying in Belgium for some time to come, and I can say that I like that!  
Wim Dehaen Junior, ik heb helaas de titel voor ‘uniek zijn’ al weggegeven. 
Nochtans had jij ook wel kans op de titel nu ik erover nadenk… Helaas ben je 
niet blijven doctoreren op de KU Leuven, wat ik een uiterst spijtige zaak vond! 
Elke keer als ge terug in België passeerde en onze paden kruisten, lachte ik 
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me steeds opnieuw een kriek met u. Het moet gezegd, uw outfit draagt elke 
keer wat meer bij aan dat gebulderlach. Haha! Als gij uw pijlen blijft richten 
op een academische carrière, dan kan ik u alvast verzekeren dat ge het 
volgens mij extreem goed gaat doen. De manier waarop jij chemie ademt en 
een levende encyclopedie bent, dat kent zijn gelijke niet. Een kleine twee jaar 
terug kregen we te horen dat je vegan was geworden. Was dit de Wim die 
keer op keer lachte met vegetariërs, op zijn kenmerkende extreem 
sarcastische wijze? Of was het zuiver om op te vallen? Dit was in ieder geval 
voor mij een cruciaal moment van zelfreflectie en verandering op het vlak 
van voeding, iets wat ik je misschien nog nooit verteld heb. 
Lau, de klimmer en nog steeds rasechte Hasselaar. Bedankt voor het gezever 
door de jaren heen. Als je chemie ooit beu bent, dan zou je nog steeds 
cursussen beginnen geven om te leren ‘party crashen’, iets waar je toch wel 
in uitblinkt! 
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“When the idea of a new substance is born, nothing exists but symbols, a 
collage of odd atoms hooked together with bonds, all scribbled out on a 
blackboard or a napkin at the dinner table. The structure, of course, and 
perhaps even some spectral characteristics and physical properties are 
inescapably pre-ordained. […] [Other] properties cannot yet be known, for 
at this stage they do not exist.” 
Alexander Shulgin, PIHKAL  
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1. General introduction  
In this thesis, we are particularly interested in performing organic reactions 
with gases. In an academic lab setting, organic reactions involving gaseous 
reagents require special precautions. First, a gas is not easily contained and 
leakages are rather difficult to prevent when using conventional glassware. 
This implies serious dangers, especially if the gas is highly flammable and/or 
toxic. Whilst for relatively safe gases such as oxygen, a balloon filled with gas 
can be used in the reaction setup, this is far from the case with gases such as 
carbon monoxide, hydrogen fluoride, etc. In the latter cases, safety and 
practical restrictions limit the use of such a setup (Figure 1). Another main 
limiting factor when using a gas for a chemical transformation is the solubility 
of the gas in the reaction medium. Since a lot of gases used in synthesis are 
poorly soluble in solvents (e.g. carbon monoxide),1 high pressures are often 
required and a rapid decrease in solubility with increasing temperature is 
observed, according to Henry’s law. Working under high pressures, of course, 
also implies extra safety precautions for the lab chemist. Specialized high-
pressure facilities are equipped with leakage and pressure detectors and 
require specialized training of personnel. The scale of high-pressure reactions 
is often restricted to mitigate risks, which contributes to a challenging scale-
up. Another problem is one of thermodynamics. Gas-liquid reactions require 
a high interfacial area for an efficient mass transfer rate. Round bottomed 
flasks do not provide solace here, as the interfacial area decreases rapidly 
with increasing size of the flask (Figure 2). (Note that when stirring, the vortex 
increases the interfacial area, which is dependent on the stirring rate.) This 
is again problematic for a potential scale-up.  
All of the represented problems mentioned above (safety, scale-up, mass 
transfer rate, low solubility, high pressure) keep the academic chemist from 
performing organic reactions involving gases. There are however several 
ways to overcome these problems, e.g. flow chemistry,2 making use of gas 
surrogates,3-5 with the possibility of performing the reaction in a two-
chamber reactor.6-9  
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Figure 1: Schematic representation of a balloon setup. 
 
Figure 2: Interfacial area decrease with increasing flask volume. Reprinted with permission 
from Org. Process. Res. Dev., 2015, 327-360. Copyright American Chemical Society. 
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1.1 Flow chemistry 
1.2.1 General 
Synthetic organic chemistry research and round bottom flasks go hand in 
hand. Since the early stages of this field, the basic way in which one conducts 
a chemical synthesis has remained fairly unchanged for over two centuries.10 
Condensers, measuring cylinders, test tubes and round bottom flasks are still 
used on a daily basis by the synthetic chemist after being invented almost 
200 years ago. The era of batch chemistry is undergoing a drastic change in 
the last two decades, as several other potent methods are gaining more 
attention among researchers, such as continuous flow techniques,11 
microwave chemistry12 or ball milling.13  
When a reaction is performed under batch conditions, reagents are added 
into a vessel, forming a reaction mixture left to react. Temperature, reaction 
time, concentration and stoichiometry are typical key parameters. When 
having a look at the processing steps one has to perform for a single chemical 
transformation, up to six manipulations can be required (Figure 3). These 
supplementary manipulations are expensive and labor intensive, and are 
necessary due to low reactivity, poor selectivity, incomplete conversion 
and/or formation of side products. This is often attributed due to bad mixing 
and temperature control combined with highly reactive reagents.11 In 
addition, the physical dimensions of the devices used drastically limit the 
scale at which reactions can be carried out. The combination of the 
mentioned issues make change inevitable, and alternative approaches 
should be encouraged. 
 
Figure 3: Sequence involving a chemical transformation in batch. Reprinted with permission 
from Baxendale IR, J. Chem. Technol. Biotechnol., 2013, 519-552. Copyright Wiley. 
Such an alternative approach is flow chemistry. Flow chemistry is in its most 
basic sense defined as performing a chemical transformation in a continuous 
manner by pumping the reagents through a tube or pipe. Examples of flow 
syntheses at industrial scale are known for almost a century.14 The 
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application of flow techniques in an academic research environment is more 
recent. In the last two decades an increasing interest in flow based synthesis 
methods is observed, with commercial lab scale flow platforms (e.g. Syrris,15 
Chemtrix,16 VapourTec,17 Uniqsis,18 ThalesNano19 and many more) being 
considered the main driver of this phenomenon. A distinction is made 
between modular systems, where the setup is custom built from loose parts, 
and monolithic systems, where all components are integrated into a single 
device. In between, one has semi-modular systems, where a device can be 
edited in various ways by adding/removing functional modules. Due to the 
versatility of the semi-modular systems (such as the VapourTec R- and E-
series), these are becoming more popular, albeit at a higher price than their 
monolithic counterparts. More recently, researchers at MIT developed a 
refrigerator-sized flow system with incredible versatility (Figure 4).20 This 
state-of-the-art flow platform is able to synthesize pharmaceuticals starting 
from commercially available starting materials, over multiple synthesis steps, 
performing purification, solvent switches, crystallization and formulation 
inline. The synthesized pharmaceuticals meet the U.S. Pharmacopeia 
standards.  
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Figure 4: (A) Upstream synthesis modules. (B) Downstream purification and formulation 
modules. (C) Close-up of PFA tube reactor and membrane separation unit. (D) Detailed 
images of downstream modules. Reprinted with permission from Science, 2016, 61-67. 
Copyright AAAS.  
A schematic representation of a basic flow setup is depicted in Scheme 1. 
Reagent reservoirs contain the reagents (and often solvents) that are 
needed. From here, the use of pumps (from normal HPLC pumps to peristaltic 
ones) brings the reagent streams together in the T-mixer piece, where mixing 
occurs. The mixture is pumped through the reactor, where the actual 
reaction occurs. A plethora of energy input means can be used, going from 
(extreme) temperature,21-22 microwave irradiation,23-24 UV and visible light,25-
27 and sonication.28 Besides a coil reactor, reactor chips (for microflow and 
lab-on-a-chip applications)29 and packed bed reactors (for heterogeneous 
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catalysts and scavengers)30-31 are common alternatives. The residence time is 
defined as reactor volume divided by the total flow rate. Some exceptions to 
this are for example when using a packed bed reactor (PBR) filled with 
heterogeneous catalyst. In here, the reactor volume will be overestimated 
since one needs to subtract the total volume of the catalyst present in the 
PBR. Residence time is equivalent to reaction time in batch conditions, and 
can be seen as the time every fraction of reaction mixture spends in the 
reactor. A back-pressure regulator (BPR) is installed after the reactor, which 
could serve multiple purposes, such as bringing solvents above their boiling 
point or pushing multiphasic flows to homogeneity, without significantly 
increasing the risk of explosions. In a final stage, the reaction mixture can be 
subjected to some form of inline purification, such as scavenging (trapping 
side products),30 liquid-liquid extraction,32 catch-and-release,33 etc. The 
stream is then collected in a recipient, where quenching or precipitation of 
the product often already occurs. 
 
Scheme 1: Schematic flow setup. 
Some advantages of continuous flow technology include the following: 
 Scalability: When compared to batch chemistry, the continuous 
nature of flow technology in combination with the far superior 
control of reaction parameters drastically enhances scale up.34 While 
multiple strategies exist for readily scaling up flow processes, like 
leaving the setup run for a longer time (scaling out), or running the 
reaction in parallel via multiple setups (numbering up),35 the scale up 
of the reactor itself is more difficult. This requires careful scaling of 
relevant parameters and additional calculations. 
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 Safety: Continuous flow processes are in most cases safer than their 
batch counterparts. In a synthesis where a toxic/dangerous 
intermediate is formed, the actual amount of intermediate in a flow 
setup will be very low, compared to performing this in batch. As a 
result, the risk is significantly reduced. In analogy, when working 
under pressure in a flow setup, the risk of an actual explosion is very 
low. As a result, flow chemistry provides solace to revive the 
academic use of useful reagents such as diazomethane36 or 
phosgene37 (Scheme 2).  
 
Scheme 2: Continuous flow system of the amidation of N-Boc-Phe using phosgene in situ. 
Reprinted with permission from Chem. Commun., 2011, 12661-12663. Copyright Royal 
Society of Chemistry. 
 Extreme conditions: Flow setups are able to reach temperatures and 
pressures which are completely impossible to obtain in batch 
chemistry, in an academic environment.38 Several examples are 
reported in literature.39-40 Industry picked up on this, since 
ThalesNano brought the Phoenix Flow Reactor® on the market, a 
flow platform for high temperature and pressure reactions (up to 
450 °C and 200 bar).41 An example is depicted in Scheme 3.42 The Boc 
deprotection step occurs at 300 °C and 100 bar, with a residence 
time of 2 minutes. 
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Scheme 3: Flow setup of reference 42. In the second reactor, a high temperature Boc-
deprotection takes place. Reprinted with permission from Organic Letters, 2016, 1732-1735. 
Copyright American Chemical Society. 
 Flash chemistry: In a nutshell, flash chemistry is chemistry 
performed in flow which simply cannot be done in batch.43 These are 
usually extremely fast reactions involving very unstable species on 
time scales less than a second, which are not achievable in batch. An 
example is a protecting-group-free synthesis, an emerging field in 
flash chemistry (Scheme 4).44 An aryllithium species is formed in 
reactor R2, which in turn can react with a variety of electrophiles in 
reactor R3. Since the aryllithium species bears a ketone group, this 
intermediate is extremely reactive. The researchers found that the 
residence time of R2 needed to be 0.003 seconds or less, in order to 
prevent side reactions such as dimerization. As one can imagine, this 
is of course not possible in batch. Flash chemistry stresses the 
extreme control of parameters in flow chemistry, which is 
considered a main advantage. 
 
Scheme 4: Flow setup of a flash chemistry example. Reprinted with permission from Nat. 
Commun., 2011, 264. Copyright Nature Publishing Group. 
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 Telescoping: In modern flow chemistry, telescoping (or cascade or 
multi-step synthesis) is considered a hot topic, since it demonstrates 
the versatility and capability of flow chemistry. Telescoping can be 
used for pharmaceutical20 and natural product synthesis, where it is 
often combined with several types of inline purification. An example 
by the Ley group is depicted below (Scheme 5).45 In this report, 
oxomaritidine, an alkaloid natural product, is prepared in a 7 step 
synthesis linked into one single continuous flow sequence. The 
researchers started from commercially available building blocks and 
most of the reagents are polymer supported in packed bed reactors 
(PBRs), easing purification of the final product. After evaporation, 
the product was isolated in a purity of >90%. The overall yield of this 
7 step synthesis is 40%. The authors were curious what happened to 
the rest of the starting materials. It was found that the phenolic 
oxidation gave only a 50% yield. The remaining phenol was 
unexpectedly scavenged out of solution by the polymer supported 
base. 
 
Scheme 5: Flow synthesis of (±)-oxomaritidine. Reprinted with permission from Chem. 
Commun., 2006, 2566-2568. Copyright Royal Society of Chemistry. 
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 Automation: In recent years, automation is gaining more attention 
in flow technologies, with software and camera controlled state-of-
the-art protocols being reported by well-known academics in the 
field, such as Steven Ley and Klavs Jensen. A fully automated, self-
controlling, telescoped seven-step synthesis is reported by Ingham 
et al. and is partially depicted below (Scheme 6).46 This process 
incorporates Grignard, Ritter and cyclization reactions and 
extraction, solvent-switching, filtration and quenching are all 
performed inline. Cameras carefully observed reservoir levels upon 
which feedback was given to the control system, which monitored all 
parameters. The control system was designed with algorithms to 
handle minor deviations from steady state behavior without human 
interference. In turn, this was remotely monitored by a single 
researcher on his cell phone. After 7 steps, the product was collected 
and purified offline, providing an output of 8 mmol per hour. 
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Scheme 6: The fully telescoped flow process, which was controlled by one system and 
managed by a single researcher. Reprinted with permission from Angew. Chem. Int. Ed., 
2015, 2-18. Copyright Wiley. 
As a concluding remark we can definitely state that flow chemistry has 
earned an important spot in synthetic organic chemistry research, but it has, 
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of course, drawbacks as well. Very slow reactions for example are usually 
difficult to perform in flow because they would need an excessive residence 
time in the reactor. Another key problem is that every time when a new 
stream is introduced, the mixture gets more and more diluted. However, this 
problem can be overcome by inline evaporation and inline solvent switching. 
It is also believed that other non-scientific factors hamper complete adoption 
of flow techniques: flow platform systems are expensive, and when 
compared to batch processes, more chemical engineering aspects are 
involved (flow rate, retention time, etc.). 
1.2.2 Gas reactions in flow 
1.2.2.1 General 
As stated earlier, gas-liquid reactions require an efficient mass transfer rate 
which can be achieved by a high interfacial area.2 The latter is usually below 
100 m2 m-3 in conventional flasks, and can be up to 18000 m2 m-3 in a 
microchannel flow reactor.47 In general, flow is a better platform for gas 
reactions, as the higher pressure capability in flow systems enhances 
dissolution and allows a more controlled gas volume delivery. Under 
increased pressure all gas can dissolve and a homogeneous gas-liquid 
reaction takes place. This is often not the case, and the most common 
biphasic flow regime is known as segmented flow (Figure 5). However, the 
toroidal currents deliver excellent mixing and enhance mass transfer.48  
 
Figure 5: Segmented gas-liquid flow. Reprinted with permission from Org. Process Res. Dev., 
2015, 327-360. Copyright American Chemical Society. 
The area of flow-based gas-liquid reactions has become an increasingly 
popular field. Reports with carbon monoxide, ozone, hydrogen, carbon 
dioxide, oxygen, ammonia, dimethyl amine, ethylene, diazomethane, etc. 
have been published in the last decade.36-37, 49 In this thesis we will make use 
of gas-liquid reactions in flow, with using carbon monoxide. 
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1.2.2.2 Tube-in-Tube reactors 
Another approach for delivering gas to a reaction makes use of a gas-
permeable membrane that serves as a barrier. This is usually called a tube-
in-tube reactor and is made up of a Teflon AF-2400 membrane, which has 
high permeability for gases but not liquids. This was reported by the group 
of Steven Ley.49-50 VapourTec® picked up on this and now sells tube-in-tube 
reactors for their E- and R-series.51 A tube-in-tube design is depicted in Figure 
6. 
 
Figure 6: Conventional vs. reverse tube-in-tube design. Reprinted with permission from Org. 
Process Res. Dev., 2015, 327-360. Copyright American Chemical Society. 
A novel example is depicted in Scheme 7, again reported by the Ley group.52 
Herein, the authors made use of two tube-in-tube reactors to enrich a stream 
of dioxane with carbon monoxide and dimethyl amine for a palladium-
catalyzed aminocarbonylation. A BPR before and after the second tube-in-
tube reactor was necessary to keep the carbon monoxide in solution, hereby 
avoiding segmented flow. Various aryl iodides were transformed into their 
respective N,N-dimethylamides, which were isolated in high yields. The 
authors obtained better results when using hydrazine to efficiently reduce 
PdII species to Pd0. 
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Scheme 7: Aminocarbonylation of aryl iodides using two different gases. Reprinted with 
permission from Eur. J. Org. Chem., 2014, 6418-6430. Copyright Wiley. 
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1.2 Gas surrogates 
As demonstrated earlier, working with gases in synthetic organic chemistry 
can be quite problematic, at least on lab scale. While researchers continue 
to report on low-pressure transformations,53 other potential problems of 
certain gases such as toxicity, smell, flammability and storage of the gas are 
not fully addressed by means of working at lower pressure. A controlled 
generation ànd consumption of a gas in a closed setup overcomes these 
issues greatly. It is here that gas surrogates (also called gas precursors) can 
provide solace and these gas-releasing moieties have become popular when 
working at lab scale. In the case of very toxic gases, such as carbon monoxide 
(CO), sulfur dioxide (SO2), hydrogen cyanide (HCN) and fluorine (F2), the 
storage of pressured vessels on its own already brings serious safety risks and 
is often not very suited for an academic lab setting (extra costs, specialized 
fume hoods, requirement of trained personnel, etc.). Examples of gas 
surrogates include DABSO for sulfur dioxide54, SelectFluor for fluorine55-56 
(SelectFluor is not a precursor of the actual gas, but it is an electrophilic F-
source, and is therefore a substitute of using fluorine gas) and potassium 
hexacyanoferrate, a non-toxic precursor for hydrogen cyanide,57 to name a 
few (Figure 7).  
 
Figure 7: DABSO, a gas surrogate for SO2, SelectFluor, a gas surrogate for F2 (i.e. electrophilic 
fluorine source) and potassium hexacyanoferrate as a gas surrogate for HCN. 
The search of gas surrogates is the most extensively studied for carbon 
monoxide.3 This is of course due to the notorious toxicity of carbon 
monoxide, in combination with being odorless and colorless, making it 
completely undetectable by human senses. It is therefore that this gas is 
considered extremely dangerous and is also called ‘the silent killer’. Examples 
of CO surrogates include metal carbonyl complexes,58 formamides,59 N-
formyl saccharin,60-61 aryl formates,62-63 aldehydes,64-65 chloroform66 and 
formic acid.67-68 These precursors are usually used in palladium-catalyzed 
carbonylation, reported by Heck and coworkers in the seventies (Figure 8).69 
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This chemistry gives rise to numerous carboxylic acid derivates such as 
amides and esters. Other examples include carbonylative Suzuki,70 
carbonylative Sonogashira,71 etc. Some of these reported CO surrogates are 
very toxic themselves, expensive and/or generate byproducts. These 
byproducts can be unreactive spectator compounds, therefore complicating 
work-up and purification, or participate in the reaction. In both cases the 
application window of these substances is narrowed (due to functional group 
tolerance). These problems are all arising when using these CO precursors in 
situ. There is however the possibility of generating the gas ex situ, 
overcoming the aforementioned issues. This is possible via tube-in-tube 
reactors in continuous flow,72 as stated above, or by the use of two-chamber 
reactors when working under batch conditions (see below). 
 
Figure 8: Palladium-catalyzed carbonylation. 
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1.3 Two-chamber reactors 
Some examples of DIY reactors where two reaction tubes are connected with 
each other are reported in literature,66, 73-75 often specifically designed for the 
migration of a moiety (often a gas) from one chamber to the other. In 2010, 
Troels Skrydstrup and coworkers from Aarhus University in Denmark 
revolutionized this field. They initiated a research program in palladium-
catalyzed carbonylation9 and were also hesitant of using pressured carbon 
monoxide vessels and gas filled balloons. The development of COware, a 
patented two-chamber system,8 for the ex situ generation of CO was a 
consequence of this, overcoming numerous safety issues (Figure 9).  
 
Figure 9: COware, the patented two-chamber system of the Skrydstrup group. CO production 
from a solid precursor in the left chamber, which migrates through the bridge to undergo a 
CO consuming reaction in the right chamber. Reprinted with permission from Acc. Chem. 
Res., 2016, 594-605. Copyright American Chemical Society. 
The group simultaneously reported solid CO surrogates, such as 
silacarboxylic acids6 and bulky acyl chlorides.7 Their use is depicted in Scheme 
8. In the case of silicarboxylic acids, CO is released under the influence of 
potassium fluoride at 40 °C. On the other hand, bulky acyl chlorides generate 
CO under palladium catalysis. The bulkiness of both the ligand and the acyl 
chloride promotes reductive elimination of the palladium complex, by 
decarbonylation and β-hydride elimination.7 With both types of CO 
surrogates, a COware two-chamber setup was used. The generated near-
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stochiometric carbon monoxide was consumed in the other chamber by 
means of palladium-catalyzed carbonylation. 
 
Scheme 8: CO precursors reported by the Skrydstrup group. (a) Silicarboxilic acids. (b) Bulky 
acyl chlorides. 
Skrydstrup and coworkers later reported the use of a three chamber reactor 
(Scheme 9).76 In chamber C, carbon-13 enriched barium carbonate was 
decomposed by acid, releasing 13CO2. This carbon dioxide was subsequently 
captured in chamber B by a disilane in the presence of cesium fluoride. 
Carbon-13 enriched CO was thereby generated, which was then consumed 
in chamber A in a palladium-catalyzed carbonylation. This novel report 
demonstrates the capability of multi-chamber reactors for the migration of 
multiple gases at the same time, with the possibility to synthesize 13C-labeled 
pharmaceuticals directly from commercially available carbon-13 enriched 
barium carbonate. 
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Scheme 9: Application of a three-chamber reactor. CO2 is generated in chamber C and 
subsequently consumed in chamber B. Hereby, CO is generated and is consumed in an 
aminocarbonylation in chamber A. 
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1.4 Objectives 
In what preceded, we have seen that the enhancement of working with 
(dangerous) gases in an academic setting is a widely studied topic. Gas 
surrogates often provide solace, and techniques such as two-chamber 
technology or continuous flow processes are convenient tools for the 
application of these surrogates. It is our intention to contribute to this field, 
making organic reactions involving gases more approachable for the 
academic chemist by developing novel and safe ways for their utilization.  
Chapter 2 will focus on the discovery of a new carbon monoxide precursor. 
Currently, numerous CO precursors have been reported as a substitute for 
carbon monoxide on a laboratory scale. However, most of these CO 
surrogates are very toxic themselves, need elevated temperatures to release 
CO, are expensive and/or are specialty chemicals requiring multiple synthesis 
steps before use. It is our goal to contribute to this field by developing 
another CO precursor which preferably is cheaper, more efficient, safer and 
convenient in use. In addition, the CO precursor will be applied for palladium-
catalyzed carbonylation, which will be optimized. Some syntheses of 
medicinally relevant compounds will be added as well as isotopic 13C-
labelling. Both two-chamber reactors and continuous flow will be used as 
tools for this precursor (Scheme 10).  
 
Scheme 10: Strategy for the design of a new carbon monoxide precursor. 
Chapter 3 will cover the synthesis of unreported pyrazine based oligoamide 
α-helix peptidomimetics. The bridging amide linkers will be synthesized via 
palladium-catalyzed carbonylation, using the developed technology of 
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chapter 2. This will serve as an alternative strategy for the assembly of 
monomers, where usually amide coupling reagents are used. The use of 
catalytic carbonylation chemistry as a coupling method is advantageous since 
(1) no stoichiometric amounts of coupling reagents are used, (2) it offers a 
broad functional group tolerance and (3) it is able to handle substrates which 
are very low in nucleophilicity, such as aminopyrazines.77 Moreover, this 
methodology should allow the synthesis of hybrid systems (Scheme 11). 
 
Scheme 11: Strategy for the design of pyrazine based oligoamide α-helix peptidomimetics. 
In chapter 4, the switch was made to sulfur dioxide gas, which is in many 
aspects similar to carbon monoxide (interesting synthetic properties but very 
toxic). Sulfur dioxide is a ubiquitous commodity chemical which has several 
chemical applications in industrial processes, but is not researched 
thoroughly in academia. However, considering the importance of functional 
groups such as sulfones and sulfonamides in agrochemicals, pharmaceuticals 
and materials, there is a high interest in new and enhanced synthesis 
methods. It is here that we aim to contribute to new technologies using sulfur 
dioxide as a reactant for the synthesis of SO2-containing functional groups. 
Moreover, an attempt will be made to enhance the safety aspects of the 
synthesis of popular SO2 surrogates, such as DABSO. Key in this approach is 
the aim to step away from sulfur dioxide pressurized gas vessels, which imply 
serious safety concerns (Scheme 12).  
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Scheme 12: Objectives for working with sulfur dioxide. 
Finally, in chapter 5 we will aim to develop a continuous flow process starting 
from glycerol to synthesize glycerol carbonate (GLC) and/or glycidol in a 
scalable, green manner. It will be attempted to optimize a protocol which has 
industrial applicability. Therefore, dimethyl carbonate (DMC), due to its 
considered greenness, was the phosgene surrogate of choice and glycerol 
the other reagent, due to being an industrial waste procuct in biodiesel 
synthesis. In this way, DMC can be seen as a substitute for carbon monoxide 
(CO use is discussed in chapter 2 & chapter 3). Different catalysts will be 
screened, keeping in mind that industry prefers easy to separate, cheap and 
non-toxic ones. Both reported catalysts as new catalysts will be tested 
(Scheme 13).  
 
Scheme 13: Development of a continuous flow protocol for the synthesis of glycerol 
carbonate (GLC). 
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IN SEARCH OF A NEW CO 
PRECURSOR 
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2. In search of a new CO precursor 
2.1 Literature and discovery 
As already stated in chapter 1.2, the search for and application of new gas 
surrogates is well documented for the case of synthetically useful carbon 
monoxide (CO), due to it being odorless, colorless, extremely toxic and 
flammable.3 Globally, carbon monoxide might be responsible for more than 
half of lethal poisonings.78 In mammals, it binds to hemoglobin, thereby 
inhibiting oxygen transfer in vivo. The binding affinity of carbon monoxide for 
hemoglobin is about 200 times stronger than that of oxygen.79 The lack of 
oxygen transfer quickly results in permanent damage or even death. 
Symptoms of carbon monoxide exposure can be found in Table 1. The main 
natural sources of CO are volcanoes, fires and photochemical reactions in the 
troposphere.80 
Table 1: Symptoms of carbon monoxide exposure. Readopted from reference 78. 
Concentration 
(ppm) 
Symptoms 
35 
Headache and dizziness within 6 to 8 hours of constant 
exposure 
100 Slight headache in 2 to 3 hours 
200 Slight headache within 2 to 3 hours, loss of judgement 
400 Frontal headache within 1 to 2 hours 
800 
Dizziness, nausea and convulsions within 45 minutes. 
Insensible within 2 hours 
1600 
Headache, tachycardia, dizziness and nausea within 20 
minutes, death in less than 2 hours 
3200 
Headache, dizziness and nausea in 5 to 10 minutes, 
death in less than 30 minutes 
6400 
Headache and dizziness in 1 to 2 minutes. Death within 
20 minutes 
12800 Death within 3 minutes 
28 
 
 
 
Figure 10: Examples of reported CO surrogates. 
Currently, numerous CO precursors have been reported as a substitute for 
carbon monoxide on a laboratory scale (Figure 10). However, most of these 
CO surrogates are very toxic themselves, need elevated temperatures to 
release CO, are expensive and/or are specialty chemicals requiring multiple 
synthesis steps before use.  
It is our goal to contribute to this field by developing a CO precursor which is 
cheaper, more efficient, safer and convenient in use. In addition, the CO 
precursor will be applied to palladium-catalyzed carbonylation, which will be 
optimized. Some syntheses of medicinally relevant compounds will be added 
as well as isotopic 13C-labelling. 
Earlier work in our group demonstrated the use of 2,4,6-trichlorophenyl 
formate (2.1) as a useful CO surrogate in flow (Scheme 14).81 The byproduct 
of the CO generation, 2,4,6-trichlorophenolate, acted as nucleophile in the 
carbonylation, forming an active ester in the process. If one wants to avoid 
this, an ex situ CO generation would provide solace (two-chamber reactor or 
tube-in-tube flow reactor). Later experiments however showed that 2,4,6-
trichlorophenyl formate is not fully stable in solution since CO formation 
(bubbles) was sometimes observed when preparing stock solutions in DMF, 
making it unpredictable to handle. Also the trichlorophenol released during 
the reaction is a potentially harmful byproduct. 
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Scheme 14: Flow setup of earlier work from our group with 2,4,6-trichlorophenyl formate as 
CO precursor. 
While 2,4,6-trichlorophenyl formate (2.1) was used previously as CO 
precursor both by others and ourselves, the fact that it was not stable in 
solution was not ideal. Indeed, it is important to strike a balance: a gas 
surrogate should be intrinsically stable and only decompose in a predictable 
manner under well-defined conditions. Hence, at this point, it was our 
intention to look for alternatives. Several potential CO surrogates were 
hypothesized where formic acid was equipped with a leaving group (Figure 
11). For 2.2, a standard formylation protocol should be suited to synthesize 
the respective compound, while for 2.3 and 2.4 it was hypothesized that 
these could be synthesized from cheap and readily available tosyl chloride or 
cyanuric chloride, respectively, and formic acid under basic conditions. 
Pentafluorophenyl formate (2.2) was synthesized and isolated, but 
unfortunately, as could be expected fully degraded in a couple of days. 
Moreover, pentafluorophenol is fairly expensive and toxic, making it not 
ideal as a CO precursor building block. A mixture of cyanuric chloride and 
formic acid in the presence of base did not result in 2.3, no conversion was 
observed. A final idea was attempted with the synthesis of a mixed anhydride 
type system 2.4 (Scheme 15). Equimolar amounts of formic acid and tosyl 
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chloride were dissolved in THF. After this, 2 eq of triethylamine were added, 
and instant vigorous bubble formation was observed and confirmed to be CO 
gas by the alarm of the carbon monoxide detector. It was hypothesized that 
formic acid reacts with tosyl chloride once it is deprotonated, thereby 
forming a highly unstable intermediate (2.4), which upon deprotonation 
immediately leads to carbon monoxide formation since sulfonates are 
excellent leaving groups. Note that the generated byproducts are fairly 
innocent organic salts (ammonium chlorides and sulfonates), in contrast with 
other CO precursors generating toxic byproducts. 
 
Figure 11: Potential new CO precursors. 
 
Scheme 15: Discovery of a new CO precursor 
Being interested in the versatility of this reaction, as well as the solubility of 
the side products (an important factor for flow experiments), other reagents 
and solvents were tested. These revealed that this unreported CO precursor 
system is quite versatile: the sulfonyl chloride, the base and the solvent could 
all be varied, still resulting in CO liberation (Table 2). As it appears, 
decomposition occurs at 0 °C, room temperature and 60 °C. With these 
results in hand, palladium-catalyzed carbonylation was chosen as test case 
for this CO precursor system. 
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Table 2: Variation of parameters of new CO surrogate system. Equimolar amounts of sulfonyl 
chloride and formic acid were dissolved in the solvents and subsequently 2 equivalents of 
base were added. 
Entry 
Sulfonyl 
chloride 
Base Solvent CO? 
a TsCl Et3N THF Yes 
b TsCl Et3N DMF Yes 
c TsCl DIPEA Dioxane Yes 
d TsCl DIPEA ACN Yes 
e TsCl DIPEA Toluene Yes 
f TsCl DIPEA THF Yes 
g TsCl Et3N Toluene Yes 
h MsCl Et3N Toluene Yes 
i MsCl Et3N THF Yes 
j MsCl Et3N DMF Yes 
k MsCl Et3N Dioxane Yes 
l NsCl Et3N THF Yes 
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2.2 New CO precursor: applied in palladium-catalyzed 
carbonylation 
2.2.1 Flow approach 
The first approach to apply our CO precursor system was in a continuous flow 
setup. In theory, one has the choice to generate CO in situ via traditional flow 
reactors, or ex situ, via a tube-in-tube flow reactor. Both approaches will be 
explored. The combination of tosyl chloride as sulfonyl source and DIPEA as 
base delivered the most soluble organic salts. Therefore, these were the 
reagents of choice for following flow experiments. 
The in situ approach was first explored. The setup is depicted in Scheme 16. 
A solution of tosyl chloride and DIPEA was mixed with a formic acid solution 
in a glass microchip. This reagent stream was subsequently mixed with the 
catalytic system and substrated in a PTFE coil reactor. Note that no back 
pressure regulator was used. The reaction temperatures and solvents were 
varied, and the results are summarized in Table 3.  
 
Scheme 16: Flow setup of in situ CO generation and subsequent carbonylation. 
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Table 3: Results of in situ CO generation and subsequent carbonylation (Scheme 16). Variation 
of reaction temperatures and used solvents. 
Run Solvent T1 (°C) T2 (°C) GC Yielda 
a DMF 60 80 0% 
b DMF 60 100 0% 
c DMF 60 120 3% 
d DMF 60 150 14% 
e Toluene 60 120 0% 
f Toluene 60 150 1% 
g Toluene 100 150 2% 
h THF 60 120 3% 
i THF 60 150 5% 
j THF 100 150 10% 
a Based on GC-MS without internal standard. 
While the temperature of the glass reactor chip was assumed to be not 
important, a temperature of 60 °C was anyway applied in the initial 
experiments. First, DMF was used as solvent and no product formation was 
observed at 80 and 100 °C (run a & b). We did however observe bubble 
formation in the glass microreactor, indicating carbon monoxide release. 
Further raising the tempature of the coil reactor to 120 and 150 °C (run c & 
d) resulted in a GC yield of 3% and 14%, respectively. One could argue that 
at temperatures of 150 °C, DMF itself might contribute to CO formation. This 
should however not be the case, according to literature.3 Toluene was the 
solvent of use in following experiments (runs e-g). As it appeared, only very 
low amounts of product 2.5 were formed in toluene. THF as solvent gave 
better results (runs h-j). Unexpectedly, a better result was obtained when 
increasing the temperature of the glass reactor chip. However, no exclusion 
of experimental variation is possible. Moreover, in all runs, segmented flow 
was observed (gassing out of carbon monoxide).  
Keeping in mind that only 1.5 equivalents of CO are used, it was hypothesized 
that segmented flow was not in our favor. Therefore, a new flow setup was 
34 
 
used, depicted in Scheme 17. The nucleophile was changed from aniline to 
benzylamine, since aniline is a poor nucleophile and therefore not ideal for 
use in a model system. The number of equivalents of CO was raised to 2.5, 
the residence time was raised to 10 min and a back-pressure regulator at 75 
psi was used in order to avoid segmented flow. Unfortunately, the BPR got 
clogged, most probably due to precipitation of organic salts (DIPEA·HCl and 
DIPEA·TsOH).  
 
Scheme 17: Edited flow setup for in situ CO generation and subsequent carbonylation. 
At this stage, it was decided to stop pursuing the in situ CO generation flow 
setup and to switch to an ex situ CO generation, using a tube-in-tube flow 
setup. As described in chapter 1.2.2, this device contains a membrane which 
separates an outer and inner reactor. This membrane is only permeable to 
gases such as CO. The results are summarized in Table 4. 
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Table 4: Ex situ CO generation using a tube-in-tube reactor. 
 
Run Temperature BPR 1 BPR 2 GC yield 
a 100 °C 40 psi N/A 20% 
b 140 °C 40 psi N/A 30% 
ca rt 100 psi 75 psi 0% 
da 60 °C 100 psi 75 psi 0% 
ea 100 °C 100 psi 75 psi 0% 
f 100 °C 40 psi N/A 40% 
a THF:DMF (1:1) used instead of DMF in the outer tube. 
Initial results appeared promising (run a & b) when 20% and 30% GC yield 
were obtained at 100 and 140 °C, respectively. However, a clear segmented 
flow was observed, again due to outgassing of carbon monoxide. Again it was 
hypothesized that this was the main problem of these fairly low conversions. 
Furthermore, the reported GC yield was the average of obtained results (GC 
sample taken from collection flask. Over time, conversion varied when 
sampling every 5 minutes, ranging randomly from 15% to 70% (ergo not 
taking a sample from the total collection volume but directly filling a GC vial 
from the outlet). This indicated that no steady state was obtained. Based on 
a report by Ley and coworkers,52 the BPR of the inner reactor was raised to 
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100 psi and a BPR in the outer reactor was added that was set to 75 psi. 
Moreover, the solvent of the outer reactor was changed from DMF to 
THF:DMF (1:1). This resulted in a homogenous flow, in line with the Ley 
publication. However, to our surprise, 3 runs (c-e) did not result in any 
product. Run f was then performed as a repetition of run a, where again 
segmented flow was observed, but still a GC yield of 40% was obtained. The 
difference in GC yield with run a is fairly big (20%). It should be noted that 
again shifting results were obtained from GC samples from collecting a 
sample every 5 minutes. Therefore, it was assumed that no steady state was 
reached. 
In retrospect, it was realized that the gassing out we observed might have 
been due to raising the temperature above the used solvent its boiling point 
when no BPR was used. 
In early 2016 a report from Ley and coworkers was published, where oxalyl 
chloride, another known CO precursor,82 generated carbon monoxide which 
diffused through the membrane of a tube-in-tube reactor (Scheme 18).72 Via 
this setup, which applied significant longer residence times than our 
experiments (80 minutes vs. 10 minutes), 3 vinyl iodides and 7 (hetero)aryl 
iodides underwent alkoxycarbonylation. Although we believe our described 
approach could be further optimized, the combination of this report and the 
interest in a two-chamber approach (see chapter 2.2.2), our flow approach 
route was abandoned. In retrospect, 1,4-dioxane might have been a better 
solvent choice, since numerous reports use it for palladium-catalyzed 
carbonylation in flow.52, 72, 83 Another remark is that aryl iodides might be 
easier model systems, since they undergo palladium-catalyzed reactions 
more readily than aryl bromides. A final suggestion is raising the residence 
time, maybe by adding a coil reactor after the tube-in-tube reactor and, of 
course, preventing segmented flow.  
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Scheme 18: Alkoxycarbonylation of vinyl and aryl iodides via a tube-in-tube reactor setup. 
Reprinted with permission from React. Chem. Eng., 2016, 280-287. Copyright Royal Society of 
Chemistry. 
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2.2.2 Two-chamber approach 
This section is based on: 
C. Veryser, S. Van Mileghem, B. Egle, P. Gilles and W.M. De Borggraeve, Low-
cost instant CO generation at room temperature using formic acid, mesyl 
chloride and triethylamine, React. Chem. Eng., 2016, 142-146.84 The author 
came up with applying the CO precursor in a two-chamber setup, performed 
the initial experiments and contributed to further follow-up of the 
experiments and write-up of the paper. 
A lecture of professor Troels Skrydstrup at the Belgian Organic Synthesis 
Symposium 2014 described the use of two-chamber reactors as tools for ex 
situ carbon monoxide generation.6-8 It is here that the idea was sparked to 
instead of using a flow concept for our newly discovered CO precursor 
system, a two-chamber approach would be a more convenient way to 
demonstrate its utility in palladium-catalyzed carbonylation. As described in 
chapter 1.3, a two-chamber reactor consists of two chambers connected via 
a bridge (Figure 12). Usually, in one chamber, a gas is generated which 
diffuses to the other chamber, where it is consumed. As already stated, this 
ex situ approach was chosen over an in situ approach since sulfonyl chlorides 
are not compatible with a vast amount of nucleophiles, e.g. amines when 
one wants to perform an aminocarbonylation. Therefore, a two-chamber 
setup was chosen. 
 
Figure 12: Patented two-chamber reactor design. 
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In a first two-chamber experiment, a palladium-catalyzed carbonylation was 
carried out in chamber A, using bromobenzene (2.7, limiting reagent) and 
benzylamine (2.8) as aryl halide and nucleophile, respectively (Scheme 19). 
In chamber B, 1.5 equivalents of both formic acid and mesyl chloride were 
dissolved in toluene and 3 equivalents of triethylamine were added. Mesyl 
chloride was indeed our sulfonyl chloride of choice, mainly due to its low cost 
(cheaper than other sulfonyl chlorides), its physical properties (liquid at room 
temperature) and due to atom economy (better than other sulfonyl 
chlorides). Under the assumption that the conversion in the CO generating 
reaction is complete, 1.5 equivalents of carbon monoxide are generated. The 
two-chamber reactor was immersed in an oil bath at 80 °C and left stirring 
overnight. After purification, the product (2.6) was isolated in 85% yield. 
When repeating the same reaction with a CO balloon instead of the 
precursor, a significantly lower yield was obtained (71%). This clearly 
indicated that this was a nice start, needing only near-stoichiometric 
amounts of carbon monoxide in the process. 13C-NMR analysis confirmed 
that mesyl chloride and formic acid do not react without adding base. When 
adding base however, both mesyl chloride and formic acid peaks 
disappeared. A new peak emerged, which was confirmed to be from the 
mesylate anion, confirming our proposed mechanism in chapter 2.1. From 
this results, we chose bromobenzene (2.7) and n-hexylamine (2.9) as 
substrates for optimization. The results are summarized in Table 5. In entry 
a, using 3 equivalents of CO at 80 °C, the product (2.10) was obtained in 80% 
yield. Increasing the temperature to 100 °C already resulted in a nearly 
quantitative isolated yield (96%). Further lowering the number of equivalents 
of carbon monoxide (entries c-d) did not result in a significant difference in 
yield, compared to using 1.3 equivalents, which is near-stoichiometric and 
further avoids pressure build up. Delighted with these results, further 
parameters were tested. In entry e, the amount of palladium catalyst was 
lowered to 1 mol%, again giving no significant difference in isolated yield. In 
a final attempt (entry f), the reaction time was reduced to two hours. Once 
again, a nearly quantitative yield was obtained. 
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Scheme 19: First two-chamber reactor attempt. 
Table 5: Optimization studies of two-chamber carbonylation protocol. 
 
Entry T (°C) t (h) 
mol% 
Pd/Xantphos 
Eq CO Yield 
a 80 Ovn 5/5 3 80 
b 100 Ovn 5/5 3 96 
c 100 Ovn 5/5 2 95 
d 100 Ovn 5/5 1.3 93 
e 100 Ovn 1/1 1.3 94 
f 100 2 1/1 1.3 95 
With the optimized conditions at hand, it was time to further explore the 
scope of this protocol. As shown in Scheme 20, different benzamides and 
Weinreb amides (2.11-2.27) were synthesized in mostly good to excellent 
yields. Heterocycles such as pyridine (2.27) and thiophene (2.19) were 
41 
 
tolerated, as well as functional groups such as nitrile (2.16 & 2.21), chlorine 
(2.15 & 2.26), nitro (2.20), methoxy (2.22) and allyl (2.12). In a final stage 
three pharmaceuticals were synthesized: CX-546 (2.25),85 Moclobemide 
(2.26)86 and Nikethamide (2.27).87 There was made use of both formic acid 
and the commercially available carbon-13 enriched formic acid. The isotopic 
labelling of pharmaceuticals is useful for in vivo studies. CX-546 and 
Moclobemide were synthesized in excellent yields, and Nikethamide, being 
a little bit more challenging due to the pyridine ring, was synthesized in a 
good yield. The yields when using 13C-CO were in the same range, successfully 
obtaining these labelled pharmaceuticals. 
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Scheme 20: Scope of palladium-catalyzed carbonylation using two-chamber setup with CO 
precursor.  
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2.3 New CO precursor: further considerations and conclusions 
As stated above, this newly developed CO precursor system is convenient in 
use as mesyl chloride, formic acid and triethylamine are cheap commodity 
chemicals available in almost every organic synthesis lab. Furthermore, the 
decomposition occurs at room temperature, while most precursors need 
higher temperatures for CO liberation.7, 59, 66 In addition, some precursors 
require several synthesis steps and/or the use of a transition metal, a 
heterogeneous base or other expensive reagents.6-7, 76  
A small economical comparison was made between our reported CO 
precursor and a small selection of examples from literature (Note: these 
prices are from December 2015, and may have changed since). The data is 
summarized in Table 6. Our system is 30 to >150 times more cost efficient 
than the other reported precursors. Details of these calculations can be 
found below. We only evaluated the cost of the starting materials, no costs 
of solvent, work-up, carbon dioxide, heating, water use, purification, working 
hours etc. were taken into account. This overestimates the relative price of 
our precursor, since no work-up or purification is needed. With this in mind, 
it costs € 0.051 to generate 1 mmol of CO, which is even less than the cost of 
1 mL of anhydrous DCM (€ 0.08)! Our developed CO precursor is, to the best 
of our knowledge, one of the cheapest precursors known in literature. 
Table 6: Price comparison of recently published CO generating systems. a Price per mmol CO. 
Detailed information can be found in the tables below. 
Method CO generating system Pricea Relative price  
1 
 
€ 0.051  1 
2 
 
€ 2.294  45 
3 
 
€ 1.506  30 
4 
 
€ 8.479  166 
H OH
O
MsCl
Et3N
+ CO
CHCl3
CsOH.H2O
CO
Si OH
O
Ph
Ph
F-
CO
O
Cl
Cat. Pd0
CO
44 
 
5 
 
€ 2.051  40 
Another interesting economical aspect is the price comparison of 
commercially available 13CO precursors. Since 13C-formic acid is commercially 
available, our reported procedure also provides an obvious source of 13CO. 
Remark that this enriched precursor is at least 9 times less expensive per mmol 
13CO than any other reported commercial 13CO precursor (Table 7). Again, 
complete conversion to CO was assumed. As it appears, our system belongs to 
one of the most cost efficient 13C-carbonylation methods. Note that these 
price calculations are only indicative, as they will change over time. However 
the price difference is significant (≥ 9 factors). Also, the prices of other reagents 
are not incorporated, as they are significantly less expensive than 13C-labelled 
reagents. The 13CO precursors from methods 3 and 5 are not commercially 
available. These methods use 13CO2 gas as their 13CO precursor. This is cheaper 
than H13COOH, but implies working with gas vessels and requires synthesis 
steps to obtain the actual 13CO precursor. Indeed, the whole idea behind the 
CO precursors/two chamber concept is to step away from pressurized gas 
vessels on a laboratory scale. Therefore, the Skrydstrup group employed a 
three chamber reactor, where they generate 13CO2 from Ba13CO3 (a solid), 
which is subsequently reacted to 13CO.76 Therefore, the price of Ba13CO3 is 
added in Table 7. 
  
Si
Si
Ph
Ph
Cat. F-
CO
Ph
Ph
CO2+
45 
 
Table 7: Price comparison for the generation of 1 mmol of carbon-13 CO. 
Method 
(see 
above) 
CO generating 
system 
Commercial 
price per 
gram 
Commercial 
price per 
mmol 13CO 
Relative 
price  
1 
 
€ 307  € 14  1 
2 
 
€ 1056  € 126  9 
3 
 
- - - 
4 
 
€ 653  € 158  11 
5 
 
- - - 
3 & 5 13CO2 
€ 186 per 
liter = € 151 
per gram 
€ 7 0.5 
- Ba13CO3 € 1647 € 329 23 
 
In conclusion, we have developed an economical and convenient CO 
precursor. Via a simple two-chamber setup it is possible to use carbon 
monoxide in a safe and convenient way on a laboratory scale for organic 
reactions. This precursor is, to the best of our knowledge, one of the 
cheapest CO precursors known in literature. 13C-labelling is easily possible 
due to the relatively cheap and commercially available carbon-13 enriched 
formic acid.  
  
Si
13C
OH
O
Ph
Ph
F-
13CO
13C
O
Cl
Cat. Pd0
13CO
46 
 
  
47 
 
CHAPTER 3 
 
 
 
 
 
 
 
 
 
THE ASSEMBLY OF PYRAZINE 
BASED OLIGOAMIDE ALPHA-
HELIX MIMETICS 
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3. The assembly of pyrazine based oligoamide alpha-helix 
mimetics 
This section is based on: 
S. Van Mileghem, B. Egle, P. Gilles, C. Veryser, L. Van Meervelt, W. M. De 
Borggraeve, Carbonylation as a novel method for the assembly of pyrazine 
based oligoamide alpha-helix mimetics, Org. Biomol. Chem., 2017, 373-378.88 
The author contributed to most of the synthetic work, collected all data and 
wrote the paper. 
3.1 Literature and objectives 
3.1.1 Protein-Protein Interactions 
In a protein-protein interaction (PPI), two or more proteins interact 
(reversibly of irreversibly) with each other. These interactions can be 
homomeric (same protein) or heteromeric (different proteins). PPIs are vital 
biological processes, ranging from cellular communication to programmed 
cell death.89 Therefore, when perturbations emerge in PPIs, diseases and 
afflictions begin to arise.90 This makes PPIs highly attractive drug targets. 
With over 650 000 interactions, PPIs are a great opportunity for the discovery 
of new therapeutics.91 Up to a decade ago, drug development mainly 
targeted proteins which were considered druggable (ie. the possibility of 
modulating a target with a small molecule). Classic examples include G-
protein, proteases and kinases.92 PPIs on the other hand were once 
considered undruggable, which was mainly due to their large (1500-3000 Å²), 
flat, shallow and dynamic surfaces.93  
The question that arises is the following: how can a small molecule (<500 Da) 
possibly disrupt an interaction between proteins that is significantly bigger 
than the molecule itself? At first sight it appears that a small molecule 
inhibitor has to dwell in the outstretched interaction surface for shelter. 
However, by combining crystallography with site directed mutagenesis 
(alanine screening), researchers have shown how PPIs function.94 It appeared 
that in most cases, the interaction is highly dependent on just a small number 
of keys amino acid residues. These are located at the interaction surface, 
forming a so called hot spot.95 These hot spots are enriched in arginine, 
tryptophan and tyrosine.94 On top of that, another interesting experiment 
revealed that protein PPI surfaces are in fast dynamic movement, with 
pockets opening and closing, all in the order of nanoseconds.96 This reveals 
50 
 
that the interaction surface is in fact shifting and moving and cavities could 
be formed, in where a small molecule can gain access to locations fully 
enclaved between two proteins. These findings are good news for the 
potential of small molecule protein-protein interaction inhibitors (SMPPIIs), 
as binding to a hot spot should be sufficient to disrupt the entire complex. 
Currently, the number of SMPPIIs is increasing.97-98 Figure 13 depicts the 
classification of PPIs by whether one side of the interface consists of a 
primary (lineair) protein sequence (a fairly short peptide), a single region of 
a secondary structure (such as an α–helix) or multiple sequences requiring 
tertiary structures.98 At one extreme, the PPI spans 1-4 amino acids. There 
are currently 4 examples of small molecule mimetics of this type of PPI in 
clinical trials.98 Also PPIs containing a single secondary structure have been 
proven to be able to be inhibited by small molecules. Globular interfaces 
requiring tertiary structures on both sides of a PPI have fewer success, as the 
PPI consists of a much higher complexity.  
 
Figure 13: Classification of PPIs. The complexity of the PPI raises from primary to secondary 
to tertiary structures. Reprinted with permission from Chemistry & Biology, 2014, 1102-1114. 
Copyright Cell Press. 
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3.1.2 Strategies for protein-protein interaction inhibitor design 
Several strategies have been developed to help develop this challenging 
field.99  
Fragment screening and optimization has become a standard part of the 
medicinal chemists’ arsenal for more than a decade.100 The concept of this 
approach is conceptually simple: this technique uses fragments which are 
molecules with a molecular weight of 200 Da or less for screening. These 
fragments are screened for weak binding with a protein. After this, proper 
optimization of each unique interaction in the binding site and subsequent 
linking of these fragments into a single molecular entity should, ideally, yield 
a compound with a binding affinity that is the sum of the individual 
interactions. However, using this technique to tackle PPIs is not straight 
forward, since a low-affinity small fragment hit is not able to disrupt a PPI. To 
tackle this issue, biophysical analysis techniques such as thermal shift,101 
surface plasmon resonance,102 SAR by NMR103 and X-ray crystallography104 
are typically used in this approach. Once a hit is identified, protein NMR is 
often used to determine whether the fragment binds at the PPI interface. In 
the last decade, 14 highly potent inhibitors (IC50 < 100 nM) were developed 
by fragment based screening, indicating the technique’s potential.98  
Biological screening searches for macromolecular entities (> 5000 Da) from 
Nature, usually in the form of (complexed) proteins or antibodies.105 These 
usually have advantages such as excellent selectivity and a long half-life. 
However, it is not possible to orally administer these types of drugs, 
intravenously or subcutaneously administration is necessary. Moreover, 
membrane permeability is very low, making this approach unsuitable for 
intracellular targets.  
Virtual screening (or computational screening): given the structure of a PPI, 
it is possible to use computational tools to find potential small molecule 
binding pockets and assess drugability.99 Generated hits can then be tested 
in a bioassay for binding activity. It speaks for itself that this method is 
relatively cheap. However, this technique requires a high understanding of 
structural elements of a specific PPI, as well as molecular dynamics 
calculations, due to PPIs their dynamics (no static moieties).106 
High throughput screening (HTS) is a method where a library of compounds 
is screened.107 Subsequent medicinal chemistry optimization of hits takes 
place. When performing HTS to alter a PPI, a number of challenges must be 
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taken into account: low hit rates, weak hits and difficulties in removing false 
positives.99 Nevertheless, success with HTS has been achieved. An example is 
the successful screen against human papillomavirus E2-E1.108  
Rational design (peptidomimetics) is the design of (PPI) inhibitors that mimic 
peptides and will be discussed below. 
3.1.3 Rational Design of small molecule PPI inhibitors 
This approach designs inhibitors that mimic peptides. Usually these inhibitors 
do not follow Lipinski’s rule of five.109 Their odd druglikeness presents very 
different challenges and strategies compared to conventional drug design.110-
111 When the target to be mimicked is a protein secondary structure, the 
inhibitors are termed peptidomimetics.112 This field is subdivided based on 
the mimicked secondary structural element: α-helices, β-sheets and reverse 
turns. 
For PPIs, α-helix mimetics are more intensively studied than other 
peptidomimetics. This is mainly due to the fact that 60% of all known PPIs 
utilize an α-helix on the interaction surface, and 60% of these bind a single 
face of the helix.113 A protein α-helix adopts a right-hand coiled structure 
which is stabilized by intramolecular hydrogen bonds between the amides on 
the backbone (Figure 14). Hence, compounds which mimic one face of an α-
helix (usually the i, i+3/4 & i+7 amino acid residues) can, theoretically, 
already cover a large part of PPIs. 
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Figure 14: A protein α-helix. Dashed lines represent stabilizing intramolecular hydrogen 
bonds. 
Several approaches exist for the design of α-helix mimetics, as depicted in 
Figure 15. Mimicry of this three hot-spot residues of an α-helix can be 
achieved with a linear oligomer with repeating units (Aa), a linear molecule 
assembled from different monomers (Ab), a constrained peptide (Ac) or an 
attachment of residues on a central scaffold (Ad). Examples are the terphenyl 
scaffold114 (Aa type) or benzodiazepine mimetics115 (Ad type) (Figure 16). 
Both mimic one face of an α-helix. 
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Figure 15: Strategies for the design of α-helix peptidomimetics. Reprinted with permission 
from Nature Reviews: Drug Discovery, 2016, 533-550. Copyright Nature Publishing Group. 
 
Figure 16: Literature examples of same face α-helix mimetics. Terphenyl scaffold (left) and 
benzodiazepine scaffold (right). 
A remarkable class of molecules which have shown potential in the 
modulation of protein-protein interactions are the oligoamide systems.116 
Central in the design of these oligoamide systems is the modularity in 
synthesis. This elegant concept provides an unambiguous strategy for the 
assembly of monomeric units to multimers. Among the oligoamide type 
systems described in the literature (some examples in Figure 17),117-118 amide 
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bond formation is not always straightforward.119 The amide synthesis is 
typically performed via acyl chlorides or via the corresponding carboxylic acid 
with specialty coupling reagents (e.g. Ph3PCl2,120 Ghosez’s reagent121 and 
Mukaiyama reagent122) since the amine coupling partners are not always 
nucleophilic. Due to the elaborate synthetic work, significant efforts have 
been made towards solid phase synthesis and recently, late stage 
introduction of the amino acid side chains.121, 123 
 
Figure 17: Oligoamide α-helix peptidomimetics. 
Here, we report on palladium-catalyzed carbonylation as an alternative 
strategy for the assembly of monomers (Figure 18). The use of catalytic 
carbonylation chemistry as a coupling method is advantageous since (1) no 
stoichiometric amounts of coupling reagents are used, (2) it offers a broad 
functional group tolerance and (3) it is able to handle substrates which are 
very low in nucleophilicity.77 Previous experience with peptidomimetics124 in 
our group motivated us to pursue the synthesis of unreported pyrazine based 
oligoamide α-helix peptidomimetics via palladium-catalyzed carbonylation. 
This scaffold has the interesting feature of increasing hydrophilicity and 
solubility by adding hydrogen bond acceptors that can contribute to a so 
called wet edge.125-126 The modularity in design by using carbonylation 
chemistry enabled us to synthesize both pyrazine based multimers as well as 
a couple of hybrid dimers. 
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Figure 18: Our proposed pyrazine based oligoamide α-helix mimetics. 
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3.2 Results and discussion 
3.2.1 Retrosynthesis 
It was proposed that the pyrazine based multimeric structure (Figure 18) 
mimics the amino acid residues at the same face of the helix as its phenyl and 
pyridine counterparts,127 namely at the i, i + 4 and i + 7 positions. Building 
block 3.1 (or its protected version 3.2) consists of a pyrazine core which 
enabled the development of a modular route (Scheme 21). The idea is 
inspired by peptide synthesis where a sequence of activation, coupling and 
deprotection is repeated a number of times to synthesize (oligo)peptides. 
Similarly, in our strategy, building blocks 3.2 serve as a substrate for the 
growing oligoamide multimers via a palladium-catalyzed carbonylation with 
CO gas,128 which are then deprotected to prepare them for the next coupling. 
The main reason for using aminocarbonylation as the coupling methodology 
is due to its ability to couple substrates which are low in nucleophilicity, such 
as aminopyrazine derivatives.129 Moreover, the reaction conditions of 
carbonylation chemistry are mild and therefore more compatible with 
sensitive amino acid side chains present on the peptidomimetics.128 In order 
to avoid the use of a CO lecture bottle and CO filled balloons, our developed 
two-chamber set-up (see chapter 2.2) was in a later stage successfully 
implemented for the sake of safety. 
 
Scheme 21: Retrosynthetic approach to pyrazine based oligoamide α-helix mimetics. 
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In order to avoid homocoupling and polymerization, the first building block 
needs to have its halide group replaced with a moiety that cannot interfere 
in the following palladium-catalyzed coupling. This is a so called end-capping 
group, which in the peptide synthesis analogy corresponds to blocking the C-
terminal amino acid by formation of e.g. an ester or attachment to a solid 
support. The end-capping can be done via carbonylation chemistry or other 
cross-coupling chemistry, such as Suzuki coupling130 forming biaryl type 
compounds (Y = Ar). Deprotection of an end-capped scaffold yields 3.4 that 
is ready to be coupled with another Boc-protected building block (3.2) via 
carbonylation. Finally, another iteration of the deprotection/coupling 
followed by a final deprotection yields the pyrazine based α-helix 
peptidomimetic trimer (3.8). To demonstrate this proof of principle, a range 
of monomeric building blocks was synthesized which were assembled into a 
set of multimers. 
The Boc-protected aminopyrazines (3.2, Scheme 21) should allow easy 
preparation of mixed multimers, containing both pyrazine and other types of 
monomers (e.g. phenyl or pyridine scaffolds). This not only increases the 
potential structural diversity but also allows tuning the conformational 
rigidity of the multimers, which has been demonstrated to be advantageous 
for some PPI targets.131 
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3.2.2 Synthesis 
In a first stage the synthesis of pyrazine building blocks is performed. 
Aminopyrazine (3.9) is dibrominated using NBS in DMSO.132 Following 
bromination, the desired amino acid mimicking side chain133 was attached 
using a fully regioselective SNAr in THF.132, 134 Table 8 summarizes the scope 
of the synthesized pyrazine building blocks. Monomers 3.1a-c and 3.1h were 
prepared in excellent yields. Compound 3.1d mimics a tyrosine residue133 and 
is synthesized in a yield of 64%. 3.1e-g are trityl-protected monomers which 
are obtained in low to moderate yields. When incorporating trityl protected 
monomers in a multimer, a non-acidic deprotection protocol is required to 
remove the Boc groups, e.g. by refluxing these compounds in water.135 It 
should be noted that for the synthesis of monomers with an aliphatic amino 
acid residue (3.1a, 3.1b and 3.1h), purification is troublesome (similar Rf 
values for 3,5-dibromoaminopyrazine (3.10) and product). In these cases, a 
larger excess of both base and nucleophile is required if conversion is not 
complete. Indeed, double SNAr was not observed in any case so a larger 
excess was not a problem. 
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Table 8: Synthesis of the pyrazine building blocks.a 
  
Following the synthesis of the monomers, we embarked upon the assembly 
of multimers. Some examples are depicted in Scheme 22. Multiple 
monomers were double Boc-protected in good to excellent yields. After this, 
an alkoxycarbonylation was performed to synthesize methyl ester end-
capped building blocks 3.3a and 3.3b in good yields. Subsequently, the Boc 
groups were removed under acidic conditions. In a following step monomers 
3.4a and 3.4b were coupled with Boc-protected monomers, again via 
carbonylation. Two protected dimers were synthesized in fairly good yields. 
Again, acidic deprotection yielded dimers 3.6a and 3.6b. In a final sequence, 
these dimers were carbonylatively coupled with monomers 3.7a-d, to yield 4 
protected trimers in poor yields. TFA deprotection once again resulted in 
trimers 3.8a and 3.8b. While we have nicely proven our synthesis route was 
effective, the yields of the carbonylative trimerisation are a real bottleneck. 
 
Entry Base Product 
Yield 
(%) 
AA 
Residue 
3.1ab NaH  83 Ala 
3.1b NaHMDS 
 
88 Leu 
3.1c NaH 
 
81 Phe 
3.1d NaHMDS 
 
64 Tyr 
3.1e NaH 
 
35 His 
3.1f NaHMDS  10 Lys 
3.1g NaHMDS 
 
54 Glu 
3.1hc NaH 
 
91 Val 
a Conditions: 0.2 M pyrazine in THF, 1.5 eq alcohol, 1.5 eq base, 50 °C, overnight. b 1.1 
eq NaOMe in MeOH. c 10 eq iPrOH and 3 eq NaH. 
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Other solvents commonly used in carbonylation such as 1,4-dioxane or DMF 
did not result in a higher yield. These unprotected dimers are highly rigid and 
planar molecules, making intermolecular stacking a readily event. 3.6a and 
3.6b were highly insoluble in both organic solvents and water, even at 
elevated temperatures. Since in the carbonylative trimerisation, large 
amounts of dimer were recovered, it was hypothesized that these low 
obtained yields are due to a very poor solubility of the dimer starting 
material. 
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Scheme 22: Synthesis of pyrazine based methyl ester end-capped α-helix peptidomimetics. Reagents and conditions: (a) Boc2O, DMAP, DCM, 
reflux. (b) MeOH, Pd(OAc)2, Xantphos, CO, Et3N, 80 °C. (c) TFA, DCM. (d) 3.1a or 3.1b, Pd(OAc)2, Xantphos, CO, Na2CO3, toluene, 100 °C. (e) 
TFA, DCM. (f) 3.1a, 3.1b or 3.1c, Pd(OAc)2, Xantphos, CO, Na2CO3, toluene, 100 °C. (g) TFA, DCM. 
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X-ray analysis of 3.6b confirms the presence of intramolecular hydrogen 
bonds, in analogy to the oligoamide pyridine counterparts.136 This type of 
hydrogen bonding introduces stronger curvature in the molecule’s backbone 
compared to the benzamide systems, which can be beneficial as protein α-
helices also have the tendency to curve.137 An overlay image of our dimer 
3.6b with a benzamide138 and pyridinyl analog139 is shown in Figure 19. It was 
observed that the distance between the O-alkylated sidechains is slightly 
smaller than is observed for the benzamide system. This is a result of an 
additional hydrogen bond between the amide proton and pyrazine nitrogen, 
as was also the case for the pyridine dimer.139 The presence of this hydrogen 
bond is also responsible for the stronger downfield shift of the amide proton 
in comparison with the one in our hybrid systems (10.09 ppm for 3.6b vs 8.45 
ppm for 3.16) and the benzamide and pyridinyl amide systems described in 
literature.136, 139 Furthermore, a smaller angle of inclination is observed 
(155.9° versus 159.6° for our pyrazine system and the reported benzamide 
system, respectively). This clearly shows the structural resemblance between 
our and known systems. However, a more exact evaluation of which residues 
in a helix can be mimicked by these scaffolds would require a more detailed 
analysis (EKOS).140 
 
Figure 19: Overlay analysis of (from left to right) Wilson’s benzamide crystal (CCDC 870274), 
Hamilton’s pyridine crystal (CCDC 697087) and our pyrazine crystal (CCDC 1512413). 
In the case of carbonylative dimer formation, an amount up to 30% of 
Buchwald–Hartwig amination141 side product was observed, which was 
confirmed by X-ray crystallography. For the synthesis of 3.5b the amination 
product (3.5b’) was isolated in 29% yield (Scheme 23). These findings 
OverlayBenzamid Pyridinyl amide Pyrazinyl amide (6b)
5.9 Å
5.2 Å
5.5 Å
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correlate with a report of Buchwald et al.,142 describing that in a 
palladium/Xantphos system the preferred Buchwald-Hartwig animation 
reaction conditions are electron deficient aryl halides combined with 
electron deficient nucleophiles, which is both the case for our pyrazine 
substrates.  
 
Scheme 23: Buchwald-Hartwig amination as a side reaction in carbonylative dimerisation. 
In a next example, Suzuki cross-coupling was used as end-capping strategy. 
This is demonstrated in Scheme 24. Building block 3.1a was end-capped to 
obtain compound 3.11. Boc-protected building block 3.1c was attached via 
carbonylation, which after deprotection led to dimer 3.12. The yield of this 
carbonylative dimerization (21%) is lower than other dimerizations. We were 
not able to explain this significant yield difference. Alternatively, other aryl 
building blocks can also be introduced as the second monomeric unit via this 
modular synthesis. This is demonstrated in Scheme 25. Phenyl monomer 
3.15 was synthesized starting from p-nitrobromobenzene (3.13) via a 
vicarious nucleophilic substitution which was carried out in a mixture of THF 
and liquid ammonia.143 The resulting phenol 3.14 was treated with p-
fluorobenzyl alcohol in a Mitsunobu reaction to yield 3.15.144 Finally, this 
monomer was carbonylatively coupled with 3.11, which gave rise to hybrid 
dimer 3.16, which mimics an alanine and tyrosine residue of an α-helix on 
3.5b 
3.5b’ 
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the i and i+4 position. Note that this carbonylative dimerization yield is again 
in the usual obtained range (65%).  
 
Scheme 24: Alternative end-capping: Suzuki biaryl monomer subsequently transformed into 
dimer 3.12. 
 
Scheme 25: Proof of principle for the synthesis of a hybrid dimer, containing both a pyrazine 
and phenyl monomer. 
The synthesis of a few others hybrid dimers was attempted. Starting from 
the Suzuki end-capped pyrazine monomer 3.11, both a phenyl (3.17) and 
pyridine monomer (3.18) were carbonylatively coupled (Scheme 26). The 
purification was however troublesome. Normal phase MPLC did not result in 
pure products. Reverse HPLC did purify these mixtures, but the obtained 
yields were low. Moreover, in both cases, significant amounts of Buchwald-
Hartwig amination product were collected as well. 
66 
 
 
Scheme 26: Further attempts of synthesizing hybrid dimers. 
Another extension of our end-capping chemistry is the aminocarbonylation 
of the pyrazine substrates. However, these reactions were not as straight-
forward as expected. Using protected monomer 3.2b as substrate did not 
result in expected aminocarbonylated product 3.21 (Table 9). After further 
analysis of the reaction mixture with GC-MS and NMR, 3 unexpected 
products had formed: Boc-protected N-methylpiperazine (3.22), 
deprotected aminocarbonylated product (3.23) and a pyrazine urea 
derivative (3.24). When using more equivalents of nucleophile, the ratio of 
side products changed drastically. Initially it was hypothesized that having 
synthesized a basic compound, column chromatography was not able to 
purify them. Therefore, the nucleophile was switched to pyrrolidine. Similar 
results and trends were observed (entry 3-4). In entry 5, the primary amine 
cyclopropylamine reacted smoothly to the expected product, without the 
formation of the formerly obtained side products.  
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Table 9: Aminocarbonylation as end-capping strategy. Initial investigation. 
 
Entry Nucleophile Equivalents Ratio side productsa 
Yield 
3.21 
1 
 
1.5 1.9 - 
2 
 
4 0.2 - 
3 
 
1.5 1.8 - 
4 
 
4 0.3 - 
5 
 
4 - 75% 
a Ratio 3.23/3.24, determined by GC-MS. 
To our surprise, secondary amines react with anilinic carbamate groups, 
forming unsymmetrical ureas at elevated temperatures and deprotecting the 
pyrazine, as reported in literature.145 Hence, these Boc-groups were not 
stable under these conditions when using secondary amines. They were 
however completely stable when primary amines were used. This raised the 
question if it really was necessary to protect the pyrazine momoners with 
Boc groups. Therefore, we attempted some carbonylations with unprotected 
pyrazine monomers (Scheme 27). Fortunately, when performing this 
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carbonylation with unprotected monomer 3.1a, the piperazine end-capped 
product 3.25a was obtained. When using cyclopropylamine as nucleophile, 
the yield is significantly lower than when using the Boc-protected monomer 
(41% vs 75%). An attempt with methanol resulted in a poor yield, compared 
with its protected counterpart (9% vs 88%). Also, after reaction a insoluble 
solid was retrieved, which was believed to be polymerized pyrazine moieties 
(speculation based on NMR). 
 
Scheme 27: Carbonylation end-cap with unprotected monomer. 
Similar to the reported oligoamide systems, the water solubility of our 
multimers remains problematic. However, the introduction of a water 
solubilizing end-capping group is possible via the aminocarbonylation 
strategy and could solve this problem. When performing this carbonylation 
with unprotected monomer 3.1h, the end-capped product 3.26 was obtained 
(Scheme 28). This was then coupled with 3.2b. After deprotection this gave 
3.27, which mimics an α-helix with valine and leucine residues. The water 
solubility problem was however not solved by introducing the piperazine salt. 
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Scheme 28: Synthesis of dimer HCl salt by piperazine end-cap. Reagents and conditions: (a) 
N-methylpiperazine, Pd(OAc)2, Xantphos, CO, Na2CO3, toluene, 100 °C, 62%. (b) 1. 3.2b, 
Pd(OAc)2, Xantphos, CO, Na2CO3, toluene, 100 °C, 17% (43% with recovery of 3.2b). 2. TFA, 
DCM, 97%. 3. HCl, dioxane, Quant. 
Other possibilities for end-capping were attempted. The introduction of 
morpholine as end-cap seemed interesting, as it increases the polarity of the 
molecule and is less planar. Both SNAr and Buchwald-Hartwig amination were 
attempted, but the yields were very low (Scheme 29). In both cases, 
deprotected side products were obtained, hampering purification. This 
indicated again that these Boc groups were not stable in combination with 
secondary amines at elevated temperatures. In summary, these 
transformations would probably work better when working with 
unprotected monomer (see above). 
 
Scheme 29: Morpholine as end-cap. Performed via SNAr and Buchwald-Hartwig amination. 
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3.2.3 Towards analogues of tRNA synthetase inhibitors 
After our carbonylation strategy for pyrazine based oligoamide α-helix 
mimetics was published, we were looking for other applications where amino 
acid mimics could prove useful. A report by Finn and coworkers described 
the first example of threonine tRNA synthetase inhibitors with the actual 
nucleoside scaffold being replaced by a heterocycle. Some of their 
compounds showed excellent bacterial over human selectivity providing a 
potential tool in the development of novel antibiotics (Figure 20a). The 
compounds were developed using structure-based drug design.146 A crucial 
part of these threonyl-tRNA synthetase (ThrRS) inhibitors is threonine, which 
is attached via an N-aminoacyl sulfonamide (Figure 20b). This functional 
group is reported as a non-hydrolysable bioisoster of a phosphate in 
aminoacyl adenylates.147 The idea was to develop methodology to modify 
tRNA synthetase inhibitors with pyrazine analogues of the amino acids. 
 
Figure 20: (a) Reported compound with excellent selectivity (bacterial to human). (b) Crucial 
interaction part of threonine tRNA synthetase inhibitors. 
Since colleagues at KU Leuven had a stable isoleucine tRNA synthetase (IleRS) 
crystal, a proposal was made to develop a methodology for the synthesis of 
pyrazine 3.29 (Figure 21). This compound bears an isoleucine analogue, is 
end-capped with an N-acylsulfonamide and could be tested as a substructure 
of an isoleucine tRNA synthetase (IleRS) inhibitor. Other groups also make 
use of N-acylsulfonamides as linker moiety in IleRS inhibitors.148 In a later 
stage, the ethyl group could be replaced with heterocycles described the 
report by Finn and coworkers (Figure 20a).146 In this preliminary work we 
wanted to explore methodology to generate the modified amino acid based 
N-acylsulfonamide structure. 
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Figure 21: Proposed pyrazine as potential IleRS inhibitor. 
A retrosynthetic analysis of the acylsulfonamide was performed and is 
depicted in Scheme 30. Several methods should be suitable to synthesize 
3.30, ranging from carbonylation to coupling reagent chemistry, etc. 
 
Scheme 30: Retrosynthetic analysis of the crucial step: the acylsulfonamide synthesis. 
The synthesis commenced from 3,5-dibromoaminopyrazine (3.10), by again 
starting with the fully regioselective nucleophilic aromatic substitution, using 
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sec-butanol as nucleophile, isolating the product in a 75% yield (Scheme 31). 
Monomer 3.1g was subsequently Boc-protected (77%). 
 
Scheme 31: Regioselective SNAr followed by Boc-protection. 
With the protected monomer (3.2e) in hand, it was decided to first attempt 
to synthesize the primary amide by carbonylation and subsequent 
sulfonylation to yield 3.30. Nongaseous precursors for both carbon 
monoxide and ammonia were used similar to a procedure reported by the 
Skrydstrup group, however our own CO precursor was used (Scheme 32).149 
The product was isolated in moderate yield. After this, the sulfonylation of 
the primary amide was attempted. Even at reflux conditions, no conversion 
was observed.  
 
Scheme 32: Synthesis of primary amide via carbonylation and subsequent sulfonylation. 
At this point, another route was chosen. A report from the Manabe group 
used potassium fluoride to carbonylatively generate acyl fluorides from aryl 
bromides, with subsequent amidation by means of adding an amine.61 This 
procedure provided us with 3.30, albeit in very low yield (about 10%, Scheme 
33). In a later stage it was realized that the low yield might have been due to 
purification: (i) no starting material was retrieved after column 
chromatography, (ii) the product had an extremely low UV response and (iii) 
the product smeared out on the column. The combination of almost no UV 
response and the smearing made us hypothesize that the product did not 
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dissolve well in the eluent used (Heptanes:Ethyl acetate). In summary, this 
purification would probably work better in other eluent systems. 
 
Scheme 33: Aminocarbonylation route. 
In a final step, the Boc groups were cleaved off by refluxing in water135 
(Scheme 34). This attempt delivered the product in an excellent yield.  
 
Scheme 34: Neutral Boc deprotection as a final step. 
Pyrazine 3.29 was tested for antibacterial activity on 6 different pathogens 
(see Experimental Section). Unfortunately, it proved to be inactive up to 100 
µM. It was hypothesized that once the nucleoside part of the inhibitor is 
attached, we have a higher chance of finding a hit. Development of such 
'complete' scaffolds will be pursued in further research. 
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3.3 Conclusions and future perspectives 
In conclusion, a modular synthesis protocol has been developed towards 
previously unreported oligoamide pyrazine based α-helix peptidomimetics. 
A coupling-deprotection sequence was used, utilizing a palladium-catalyzed 
aminocarbonylation to form the amide bonds between poorly nucleophilic 
aminopyrazine type building blocks. This methodology enables the flexible 
synthesis of a diverse set of (hetero)aryl oligoamide α-helix peptidomimetics. 
The synthesis also features the introduction of various end-capping 
strategies via (carbonylative) cross-coupling reactions. Furthermore, a 
pyrazine monomer with an isoleucine residue was end-capped with an N-
acylsulfonamide moiety as new methodology towards non-nucleoside tRNA 
synthetase inhibitors for the development of new antibiotics. 
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CHAPTER 4 
 
 
 
 
 
 
 
 
 
 
THE USE OF SULFUR DIOXIDE 
IN ORGANIC SYNTHESIS 
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4 The use of sulfur dioxide in organic synthesis 
4.1 Literature and objectives 
Sulfur dioxide is a ubiquitous commodity chemical which has several 
chemical applications in industrial processes. Until recently, it was not often 
used in an academic lab setting.150 This can partly be ascribed to the gaseous 
state of sulfur dioxide, as well as its notorious toxicity and smell. It should of 
course be noted that the foul smell is one of the reasons why sulfur dioxide 
is less dangerous than carbon monoxide (chapter 2 & chapter 3). Sulfur 
dioxide is easily detected by the nose, while carbon monoxide is odorless. 
Considering the importance of functional groups such as sulfones and 
sulfonamides in agrochemicals, pharmaceuticals and materials (Figure 22),4 
there is a high interest in new and enhanced synthesis methods.151  
 
Figure 22: Important industrial compounds containing an SO2 group. 
The reactivity of SO2 in synthetic organic chemistry is diverse. This is a result 
of the unique structure of SO2 (Figure 23).152 The sulfur atom has amphoteric 
properties: a lone pair in a high-lying HOMO (black) resulting in 
nucleophilicity (σ-donor) and a low-lying LUMO (white & grey) with the 
largest orbital coefficient on the sulfur atom, implying electrophilic 
properties. Moreover, SO2 can possess a relatively stable SOMO, which 
allows it to participate in radical reactions.  
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Figure 23: Frontier orbitals of SO2. HOMO in black and LUMO in white and grey. 
The use of sulfur dioxide in synthetic organic chemistry is reviving. It is 
believed that the advancement of convenient and stable SO2 surrogates is an 
important driver in the rejuvenation of organic synthesis research involving 
SO2.153 The Willis group was the first to demonstrate the utility of 
DABCO·(SO2)2 (abbreviated as DABSO, Figure 24), a bench-stable solid 
reagent, as a sulfur dioxide equivalent with more than 50 w% SO2 and an 
excellent vacuum stability. DABSO is used in the synthesis of N-
aminosulfonamides, sulfonamides, sulfones and sulfamides.54, 154 Since then, 
numerous synthetic studies using DABSO as SO2 equivalent have been 
published.155-160 Moreover, in some cases the use of DABSO was more 
successful than using SO2 gas, presumably due to catalyst poisoning by the 
excess sulfur dioxide when gas is used.155 
 
Figure 24: DABSO, a bench-stable SO2 gas surrogate. 
Most reactions involving SO2 insertion are performed with hydrazines as 
nucleophiles.54, 154-156, 159 Both transition-metal catalyzed and radical SO2 
insertions did not yield product when using amines. This is mostly ascribed 
due to increased nucleophilicity of hydrazines. Some literature examples are 
depicted in Scheme 35.73, 155, 161-162 Most reports also include one or two 
simple amines in the scope which show no reactivity. Also, to the best of our 
knowledge, no mention is made of hydroxylamines as nucleophiles. This is 
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surprising, since their nucleophilicity is higher than that of amines (though 
lower than that of hydrazines). Moreover, nucleophilicity is probably not the 
only factor, since a report determined that methylamine is more nucleophilic 
than hydrazine.163 Moreover, the hydrazine scope is not very elaborate. It 
was noticed that in all cases no hydrazines with a hydrogen on both nitrogens 
were used, which surprised us as well. 
 
Scheme 35: Examples from literature of both radical and transition-metal catalyzed SO2 
insertion for the synthesis of N-aminosulfonamides. 
As mentioned above, hydroxylamines were never reported as nucleophiles 
in SO2 insertion chemistry. However, a report by King and coworkers showed 
that N-sulfonylhydroxylamines are easily N-alkylated.164 This is in contrast 
with alkylation/arylation of sulfonamides which requires transition metals 
(e.g. Chan-Lam coupling)165 and/or elevated temperatures.166-167 We 
hypothesized that when combining this with an earlier report from our group 
to selectively cleave a hydroxylamine,168 this could lead to a three step 
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synthesis to highly functionalized sulfonamides (Scheme 36) starting from 
aryl halides. 
 
Scheme 36: Proposal for the synthesis of functionalized sulfonamides. 
Another objective of this chapter is the following. As already stated, no 
hydrazine with at least one hydrogen on each nitrogen is reported in SO2 
insertion literature (Scheme 37). This could however be interesting for 
cyclizations for the synthesis of sulfonyl containing heterocycles (Scheme 
37). As it appears, these heterocycles are rare in literature. It could be of 
interest to synthesize these scaffolds using SO2 insertion chemistry (Scheme 
38). Indeed, these reports154-155 included examples of functional groups in the 
ortho position and a complete selectivity of aryl iodides over aryl bromides. 
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Scheme 37: Upper: Unreported hydrazines for these chemistries. Below: Selected sulfonyl 
containing heterocycles and their synthesis. 
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Scheme 38: Synthesis proposals for the selected sulfonyl containing heterocycles with 
unreported hydrazines. 
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4.2 Results and discussion 
Two literature procedures for aminosulfonylation were adapted, changing 
the nucleophile to O-benzylhydroxylamine (4.2, Scheme 39). First, a two-
chamber procedure was attempted by generating sulfur dioxide from sodium 
sulfite and sulfuric acid,73 but did not lead to product formation, even at 
higher temperatures than reported. Also the reported UV reaction162 did not 
yield any product. After column chromatography, a complex mixture was 
obtained without recovering the starting material. As it appears, 
hydroxylamines do not undergo these type of SO2 insertions, which makes 
them similar in reactivity to amines in this respect.  
 
Scheme 39: SO2 insertions with a hydroxylamine as nucleophile. 
Since 1,1-diphenylhydrazine and 1,1-methylphenylhydrazine are used as 
nucleophiles in multiple transition metal catalyzed SO2 insertion reports, it 
was decided to try using phenylhydrazine (4.13) as test case (Scheme 40). 
The reaction between p-tolyliodide (4.1) and phenyl hydrazine (4.13) was 
tried in the presence of DABSO in order to produce compound 4.14. Note 
that an HCl-salt was used, therefore one extra equivalent of DABCO was 
added. In a first attempt white crystals were formed upon evaporation of the 
eluent from chromatographic purification. However, when breaking the 
vacuum, the crystals turned purple. NMR analysis indicated that the product 
degraded. Intrigued by this result, it was decided to break the vacuum in the 
rotavapor using a nitrogen atmosphere, keeping the crystals in a protective 
environment. The purple color was not intense, and NMR indicated the 
product had formed and was isolated in 25% yield.  
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Scheme 40: Palladium-catalyzed SO2 insertion with a hydrogen on both nitrogens. 
Keeping this sensitivity in mind, in a similar fashion, we attempted to 
synthesize o-bromo derivative 4.16 (Scheme 41). To our delight the product 
was isolated when applying higher temperatures, albeit in a very low yield. 
However, significant amounts of starting material were recovered. When N-
aminomorpholine (4.15) was used as nucleophile, 4.17 was isolated in 19% 
yield. The low yield is surprising since N-aminomorpholine is the standard 
nucleophile in literature reports, and examples with ortho substituents are 
known.155 
 
Scheme 41: Synthesis of ortho-bromo derivatives. 
Due to these disappointing yields, another substrate (4.18) was used for 
generating the precursors for cyclization (Scheme 42). The low yield (14%) of 
the substitution is surprising since we did not obtain dimer product and the 
starting material appeared to be consumed. It was hypothesized that a lot of 
product was lost during extraction workup. Indeed, in the water layer both 
product and dimer product were found. This is due to increased acidity of the 
NH, resulting in significant product loss during work-up. In a next step, with 
the little amount of product obtained, ring closures via carbonylation and 
Buchwald-Hartwig amination were attempted. Both carbonalytion and 
Buchwald-Hartwig amination were palladium-catalyzed and carried out at 
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100 °C in toluene. In neither case however, conversion was observed and 
starting materials were recovered.  
 
Scheme 42: Cyclizations attempts via carbonylation (a) and Buchwald-Hartwig coupling (b). 
(a): two chamber reaction, HCOOH, MsCl, Et3N, Pd(OAc)2, Xantphos, Na2CO3, toluene, 100 °C. 
(b) NaOtBu, K2CO3, Pd(PPh3)4, toluene, 100 °C. 
The double SO2 insertion of o-diiodobenzene (4.7) was also attempted 
(Scheme 43). Both benzyl hydrazine and phenylhydrazine appeared to be 
ineffective, as significant amounts of o-diiodobenzene were retrieved after 
reaction. A higher temperature in combination with hydrazine had the same 
outcome: no conversion. 
86 
 
 
Scheme 43: Double SO2 insertion attempt on ortho-diiodobenzene. 
At this point, it was decided to abandon the SO2 insertion chemistry, mainly 
due to the disappointing yields. In our hands, when exactly repeating 
literature procedures, much lower yields were obtained, implying the 
sensitivity of this chemistry. 
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4.3 Preparation of DABSO 
This section is based on: 
S. Van Mileghem and W. M. De Borggraeve, A convenient multigram 
synthesis of DABSO using sodium sulfite as SO2 source, Org. Process Res. Dev., 
2017, 785-787.169 
In chapter 4.2, DABSO was used as a SO2 gas surrogate. Since DABSO is a 
relatively expensive chemical, some research groups synthesize it on site.154, 
170-171 We also had the intention to synthesize it ourselves. However, the 
reported procedures include the use of sulfur dioxide gas, implying safety 
considerations regarding the handling and storage of sulfur dioxide 
pressurized vessels and using a large excess of the gas. Usually DABSO 
precipitates out of solution when formed. The Bischoff group circumvented 
the use of SO2 vessels by synthesizing DABSO with the commercially available 
Karl-Fischer reagent.172-173 However, since this reagent is a solution of a base 
(usually pyridine) and an alcohol (usually methanol) containing 15-20% of 
SO2, this protocol leads to more complex mixtures and a low atom economy. 
Moreover, DABSO is soluble in methanol, resulting in a less efficient 
precipitation. To the best of our knowledge, no protocol for the synthesis of 
DABSO is reported where SO2 is generated in a controlled fashion and 
consumed in a closed system, omitting multiple safety issues of working with 
this toxic gas. 
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Figure 25: Reaction set-up. SO2 is gradually generated in chamber B and is consumed in 
chamber A to form DABSO. 
By making use of the elegant two-chamber system (COware) reported by 
Skrydstrup et al.6-7 it is possible to generate sulfur dioxide ex situ. The 
reaction set-up is depicted in Figure 25 and the results are summarized in 
Table 10. Metal sulfite salts are known to release SO2 when reacting them 
with strong acids.4 Moreover, the use of sodium sulfite as an SO2 surrogate 
has been applied in palladium-catalyzed aminosulfonylation.73 Due to its 
simplicity and cheap nature, this was our SO2 surrogate of choice. Since the 
release of SO2 from sodium sulfite and strong acid is fast,4 a gradual release 
is needed to avoid generating too high pressure in the reactor. Furthermore, 
sulfur dioxide is far more soluble in water and organic solvents than other 
gases used in synthesis (e.g. CO and H2).174-176 Therefore, sodium sulfite is 
solubilized in water, and sulfuric acid is slowly added by means of a syringe 
pump, resulting in a gradual release of SO2.  
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Table 10: Results of two-chamber synthesis of DABSO. 
 
Entry 
mmol 
DABCO 
VTHF 
(mL) 
VWater 
(mL) 
vSulfuric acid 
(µL/min) 
VSulfuric acid 
(µL) 
eq 
Na2SO3 
t (h) 
Yield 
(%) 
aa 6 8 8 100 960 2.5 2 94 
ba 6 8 8 100 960 0 2 0 
ca 6 8 8 100 800 2.2 2 92 
db 45 30 25 50 6000 2.2 ovn 63 
eb 45 60 40 50 6000 2.2 ovn 99 
fb 45 60 40 50 6000 2.2 3 53 
ovn = overnight, V = volume, v = syringe flow rate. a 20 mL inner volume two-chamber 
reactor. b 400 mL inner volume two-chamber reactor 
In a first trial, DABCO (673 mg, 6 mmol) was added in THF (8 mL) in chamber 
A while 2.5 equivalents (1.89 g) of sodium sulfite were added in water in 
chamber B (entry a). Next, sulfuric acid (960 µL, 3 equivalents) was added 
dropwise over 10 minutes to chamber B. After 15 minutes, a white 
precipitate was observed, indicating DABSO formation. After 2 hours of 
stirring at room temperature, filtration and overnight drying, DABSO was 
obtained in a yield of 94%. (It should be noted that the overnight drying was 
performed either on a Schlenk line or in a dessicator. When drying under high 
vacuum (lyophilizer), a lot of product was lost!) To make sure no other 
impurities were precipitating in chamber A, a blank reaction was performed 
without the use of sodium sulfite (entry b). No precipitate was formed in 
chamber A. Using a lower excess of both sodium sulfite and sulfuric resulted 
in a nearly identical yield (entry c). At this stage, it was desirable to perform 
this reaction at a larger scale. Therefore, the flow rate of sulfuric acid was 
lowered to 50 µL min-1 to avoid pressure build-up and the reaction was 
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stirred overnight. A first scale-up resulted in a disappointing yield of 63% 
(entry d). It was hypothesized that this result could be attributed to 
increasing the molarity of DABCO in THF. After stirring overnight, DABSO was 
precipitated and barely any THF was visible. This could have led to a physical 
barrier (DABSO matrix) between the remaining DABCO and SO2. To our 
delight, when more THF was used, this issue was resolved and a quantitative 
yield was obtained (entry e). Since first signs of precipitation of DABSO are 
apparent after about 2 hours of reaction, an attempt to decrease the 
reaction time was tested (entry f). A disappointing yield of 53 % was obtained 
and hence more time is needed to bring the reaction to completion.  
A price comparison between the two protocols can be found in Table 11. 
Comparison was done on a 45 mmol scale reaction. Reagents of the Bischoff 
protocol are carefully adopted.173 Note that these price calculations are only 
indicative, as they will change over time. Commercial prices are based on the 
online catalogues of Sigma-Aldrich (date of consultation: 24th January 2017). 
Remark that costs of glassware, desiccators and working hours are not 
implemented. Since the difference in yield is very small, this is neglected in 
the calculation. As it appears, our protocol is about two and a half times less 
expensive. Furthermore, commercially available DABSO is about 27 times 
more expensive. Results are summarized in the table below. The most 
significant price difference is the use of anhydrous solvents: other reports 
stress the use of anhydrous solvents. In our hands however, no difference 
was found between anhydrous and wet solvents towards DABSO purity 
(determined by CHN-analysis). 
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Table 11: Price comparison between reported DABSO syntheses. 
 
 
Cost per gram DABSO from Sigma Aldrich: € 28.9 / g. Relative cost: 27  
Our protocol Bischoff protocol 
Reagent Quantity Cost Reagent Quantit
y 
Cost 
DABCO 5.05 g € 1.21 DABCO 5.05 g € 1.21 
THF 60 mL € 1.88 
THF 
(anhydrous) 
60 mL € 7.79 
Na2SO3 12.48 g € 1.47 
Karl-Fisher 
reagent 
40 mL € 5.40 
H2SO4 6 mL € 0.28 
Et2O 
(anhydrous) 
200 mL € 15.88 
Et2O 200 mL € 6.70    
  € 11.54   € 30.28 
 
Relative 
cost: 
1   2.62 
 
Cost per 
gram 
DABSO 
€ 1.07 / g   € 2.81 / g 
92 
 
As an example the theoretical maximum generated pressure will be 
calculated. Therefore, it was assumed that N2 and SO2 behave as ideal gases, 
and that no gas is soluble in our solvents of choice (which is not the case for 
SO2, which dissolves very well in water). In entry e, (see Table 10), the total 
solvent volume is 100 mL (60 mL THF, 40 mL H2O). At this point, since the 
inner volume of our two-chamber reactor is 400 mL, the remaining volume 
is 300 mL. Therefore, according to the ideal gas law: 
𝑛 =
𝑝𝑉
𝑅𝑇
=
1 𝑎𝑡𝑚 × 0.300 𝐿
0.082 
𝐿 × 𝑎𝑡𝑚
𝐾 × 𝑚𝑜𝑙 × 298 𝐾
= 12.28 𝑚𝑚𝑜𝑙 𝑛𝑖𝑡𝑟𝑜𝑔𝑒𝑛 
Thus, 12.28 mmol N2 is present before adding sulfuric acid. When all sulfuric 
acid is added (neglecting the pressure generated by 6 mL extra liquid) and 
assuming that the conversion of H2SO4 and Na2SO3 is 100%, we generate 99 
mmol of SO2 (2.2 equivalents of 45 mmol DABCO). When assuming that no 
DABSO is formed, 113 mmol of gas is present (14 mmol N2 + 99 mmol SO2). 
Hence the pressure is, 
𝑝 =
𝑛𝑅𝑇
𝑉
=
0.113 𝑚𝑜𝑙 × 0.082 
𝐿 × 𝑎𝑡𝑚
𝐾 × 𝑚𝑜𝑙 × 298 𝐾
0.300 𝐿
= 9.2 𝑎𝑡𝑚 
Thus, the theoretical maximum generated pressure in the two-chamber set-
up is 9.2 atm. However, the two-chamber reactors septa can resist up to 5 
bar, and no pressure release was observed when reactions were carried out 
at this scale. This is, of course, a consequence of a combination of factors 
such as gradual SO2 release, high solubility of SO2 in water and immediate 
SO2 capture by DABCO.  
In conclusion, we have developed a convenient multigram synthesis of 
DABSO. Sulfur dioxide is generated and consumed in a closed two chamber 
system, hereby avoiding a lot of safety issues of working with the toxic gas. 
The danger of pressure build-up is avoided by gradually releasing SO2. No 
heating or cooling is required, nor is working with anhydrous solvents. High 
to quantitative yields are obtained. This protocol is suited for synthesizing 
DABSO on a 10 gram scale. 
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TOWARDS A CONTINUOUS 
SYNTHESIS OF GLYCEROL 
CARBONATE USING GLYCEROL 
AND DIMETHYL CARBONATE 
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5 Towards a continuous synthesis of glycerol carbonate using 
glycerol and dimethyl carbonate 
This research was performed during a 6 month internship at Durham 
University under the supervision of Prof. Ian R. Baxendale. 
5.1 Literature and objectives 
There is a lot of industrial interest in the valorisation of glycerol in recent 
years, mainly due to glycerol (5.1) being a waste product from biodiesel 
production. The growth of this industry accounted for 2247 kilotons of 
glycerol in 2013 and the global glycerol market is expected to reach $2.52 
billion by 2020.177 The conversion of glycerol to value-added products has 
therefore received considerable attention. Some examples are 
hydrogenolysis to 1,2-propanediol,178 dehydration to allyl alcohol179 and 
gasification to syngas.180 Glycerol carbonate (5.2, abbreviated as GLC) is 
another interesting product derived from glycerol, and is considered a 
renewable building block due to its versatility.181 Applications of GLC include 
its use as curing agent,182 surfactant,183 chemical intermediate for polymer 
production184 and electrolyte liquid carrier.185 GLC is also becoming 
increasingly popular as a safe bio-based alternative to organic solvents, due 
to a high boiling point (115 °C at 0.1 mbar) and low volatility (vapour pressure 
of 8 mbar at 177 °C).186 Moreover, GLC is water-soluble, non-toxic, readily 
biodegradable and non-flammable. 
The conversion of glycerol to GLC has been extensively studied (Scheme 
44).181 Examples of its synthesis include the use of phosgene, carbon 
monoxide and carbon dioxide.181 Other reagents such as organic carbonates 
and urea have also been used. The direct use of carbon dioxide is desirable, 
but known processes for direct GLC synthesis from CO2 often include the use 
of toxic tin reagents and glycerol conversions are low (up to 30%). These 
processes are therefore not feasible for application on an industrial scale.187 
Dimethyl carbonate (DMC) is widely studied as a carbonyl source to 
synthesise GLC since it is considered an environmentally benign chemical. It 
is also used in industry to synthesise GLC.188,189-192 A lot of catalysts are known 
for this transformation, e.g. inorganic bases,193-196 tertiary amines,197-199 
lipases,200-202 and N-heterocyclic carbenes.203 However, to our surprise only a 
few continuous processes are known for this transformation.204-205 In general, 
continuous processes more often meet the basic criteria for potential 
industrial feasibility and scale up. To the best of our knowledge, inorganic 
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bases are the catalysts of choice for industrial preparation of GLC from 
glycerol and DMC.189-192  
 
Scheme 44: Main routes for the synthesis of glycerol carbonate from glycerol. 
The objective of this project was the development of a continuous flow 
process starting from glycerol to synthesize either glycerol carbonate or 
glycidol in a scalable, green manner. The goal was to optimize a protocol 
which has industrial applicability. Therefore, dimethyl carbonate, due to its 
considered greenness, was the phosgene surrogate of choice to be combined 
with glycerol an industrial waste product from biodiesel synthesis. Different 
catalysts had to be screened, keeping in mind that industry prefers easy to 
separate, cheap and non-toxic ones. Both reported catalysts and new 
catalysts had to be tested.  
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5.2 Results and discussion 
Our applied strategy existed of first repeating reported batch procedures, 
and second, translating them to an optimized flow process. As a starting 
point of our investigation, reported neat batch experiments with 
homogeneous catalysts were performed, in order to get a better 
understanding of this transformation and testing if this chemistry was 
reproducible (Table 12). It quickly became clear that basicity of the catalyst 
is an important parameter: the stronger the base, the higher the observed 
GC yield, which is in accordance with the literature findings (entries 1-4).181 
Increasing the temperature also yields better results (entries 4-5). In previous 
work performed on the attempted synthesis of glycidol, an experiment of 
Tao and coworkers was repeated:206 tetraethyl ammonium amino acid ionic 
liquids were reported as efficacious catalysts for the one-pot neat synthesis 
of glycidol, starting from glycerol and dimethyl carbonate under reflux 
conditions. However, when we repeated their experiments, we were not 
able to get selectivity towards glycidol. Instead, a high selectivity towards 
GLC was obtained (entries 6-7). Intrigued by the results of this type of 
catalyst, some alternatives were used for this transformation (entries 8-10). 
The low yields could suggest that both an NH-moiety and carboxylate are 
required for efficient catalysis, which is in line with the mechanism proposed 
for the formation of the GLC intermediate in the paper by Zhou et al (Scheme 
45).206  
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Table 12: Initial batch investigation.a 
 
 
Scheme 45: Proposed mechanism from reference 206. As stated, the catalytic cycle ended 
with GLC formation (only traces of glycidol were observed). Reprinted with permission from 
Cat. Commun., 2015, 25-29. Copyright Elsevier. 
With these preliminary results at hand, it was desirable to translate these 
experiments to a continuous flow process. Compound 5.3 (Table 12, entry 6) 
  
Entry Catalyst Temp Duration GC Yield (%) 
1 KOH rt ovn 79 
2 nBuLi rt ovn 93 
3 NEt4I rt ovn 20 
4 tBuOK rt ovn 66 
5 tBuOK 60 ovn 95 
6 
 
reflux 2h 92 
7 
 
reflux 2h 91 
8 NBu4OAc reflux 2h 5 
9 
 
reflux 2h Trace 
10 
 
reflux 2h 5 
a rt = room temperature, ovn = overnight. Conditions: 5 mmol scale, 3.5 
equivalents DMC, 5 mol% catalyst 
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was chosen as the catalyst of choice for homogeneous catalysis flow 
experiments since it is a cheap and mild catalyst. A Vapourtec® R-series 
system which was equipped with a PTFE coil reactor was used as flow 
platform. Since DMC and glycerol are immiscible at room temperature, a two 
stream setup was used as depicted in Table 13. The relative flow rate was 
adjusted in such a way to obtain 3.5 equivalents of DMC. Initially we adopted 
the protocol from the de Souza group,204 using neat glycerol with catalyst, 
preheated at 70°C (entry 1). It was immediately observed that pumping this 
viscous mixture was not possible. A solvent which is able to dissolve both 
glycerol and DMC was desired, e.g. aliphatic alcohols. Therefore glycerol and 
5.3 were dissolved in ethanol for further experiments. It quickly became clear 
that GLC formation increased with temperature. Applying a temperature of 
140 °C yielded a 90% conversion and 85% selectivity (entry 4). When 
repeating these conditions in absence of catalyst 5.3, almost no GLC 
formation was observed (entry 5). Variation of residence time resulted in 
small differences in conversion , while a slight decrease in selectivity was 
seen when increasing residence time (entries 6-7). It is worth noting that 
small amounts of diethyl carbonate were formed in experiments involving 
ethanol as evidenced by 1H NMR. In a final experiment, water instead of 
ethanol was used as solvent and a low conversion was obtained (entry 8). 
This might be due to a biphasic segmented flow, while a homogeneous flow 
was observed when ethanol was used as solvent. Another reason is that 
under these conditions water could have hydrolized GLC. The synthesis of 
GLC using catalyst 5.3 gave some nice results in flow. A key aspect of 
industrial applicability however is ease of purification of the product. In this 
case, the catalyst removal was not very straightforward. However, this 
catalyst would be easily removed from the reaction mixture if it were 
heterogeneous.  
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Table 13: Homogeneous catalysis flow experiments.a 
 
As stated above, the ease of separation of catalyst after reaction is one of the 
key requirements for industrial applicability and we therefore wanted to see 
if good results would be obtained as well when making use of a 
heterogeneous catalyst, similar to 5.3. Therefore, additional batch 
experiments were carried out, this time using polymer supported catalysts 
(Table 14). Pipecolic acid was loaded on to a solid support via a simple 
neutralisation reaction of Ambersep® 900 Hydroxide (5.5) to generate 
catalyst 5.4 (Table 14). When testing this catalyst in a batch reaction under 
neat reflux conditions, a nearly quantitative conversion towards GLC was 
obtained (entry 1). To rule out the catalytic effect was due to residual 
hydroxide present in the catalyst starting material, a blank experiment was 
performed using Ambersep® 900 Hydroxide as catalyst (5.5, entry 2). Low 
conversion was obtained, attributing the catalytic effect to the pipecolic acid. 
Note that this result differs greatly from potassium hydroxide as catalyst, 
where a good conversion was obtained (Table 12, entry 1). This could be 
 
Entry Catalyst  
Temp 
(°C) 
tR 
(min) 
VR 
(mL) 
C 
(%) 
S 
(%) 
1b 
 
100 30 10 / / 
2 
 
100 30 10 15 71 
3 
 
120 30 10 53 84 
4 
 
140 30 10 90 85 
5 None 140 30 10 <5 / 
6 
 
140 40 20 85 83 
7 
 
140 15 10 82 92 
8c 
 
140 30 10 10 75 
a tr = residence time, VR = reactor volume, C = conversion, S = selectivity. Conditions: 
3.5 equivalents of DMC. BPR = 100 psi. b Neat glycerol + catalyst preheated at 70 
°C used. c Water (1M) used instead of ethanol. 
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explained due to mass transport limitations. Only a slight increase in yield 
was observed when methanol was used as cosolvent (entry 3) or when the 
reaction was carried out at 120 °C in a microwave reactor (entry 4). These 
results strongly suggest that a different mechanism takes place when using 
weakly basic catalysts of type 5.4 than strongly basic catalysts, as proposed 
by the report of Tao and coworkers.206 
Table 14: Heterogeneous catalysis experiments in batch.a 
 
As 5.4 was deemed a suitable catalyst for this transformation, it was again 
attempted to translate this to a continuous flow process. A column reactor 
was filled with catalyst and heated to the appropriate temperature while the 
reagents are being pumped through. The results are summarised in Table 15. 
[It should be noted that mentioned residence times might be slightly 
underestimated since the polymer beads have the tendency to contract when 
being heated!] Methanol was the solvent of choice for dissolving glycerol, 
since it is more easily removed than ethanol and results in less complex 
mixtures as methanol is generated as by-product in the reaction as well. 
Moreover, this time a more concentrated solution than in Table 13 was used, 
since minimisation of solvent volume is also desired in industrial applications. 
Also, reaction of methanol and GLC yields the starting materials instead of 
side products. In a first trial, the reaction was run with a residence time of 15 
minutes at 100 °C and resulted in 85% conversion with a 89% selectivity for 
 
Entry Catalyst GC Yield (%) 
1 
 
95 
2 
 
10 
3b 
 
27 
4c 
 
40 
a Conditions: reflux (2h), 20 mmol scale, 3.5 equivalents DMC, 1 g polymer (about 
1 mol%). b Methanol used as cosolvent. c Microwave, 1 hour, 120 °C. 
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GLC (entry 1). Since we were interested if the observed tendencies in batch 
would be equal in flow, these conditions were repeated with the strongly 
basic catalyst 5.5. A 73% conversion and 93% selectivity were obtained (entry 
2), which is in stark contrast to the results in batch (Table 14, entries 1-2), 
where the difference in efficacy between both catalysts was far more 
pronounced. Moreover, in the continuous flow setup, the differences in the 
results are relatively small. Also, polymer supported basic catalysts have 
been used before for the neat batch synthesis of GLC, without much 
success.196 It should be noted that there is of course a significant difference 
in the reported batch processes and our flow experiments since no methanol 
is used in the batch experiments. Moreover, 5.5 is a cheap and commercially 
available catalyst. It was therefore decided to further optimise this process 
with catalyst 5.5 instead of with catalyst 5.4. High conversion and selectivity 
were obtained when raising the reactor temperature to 120 °C (entry 3). To 
our delight, when further increasing the temperature to 140 °C, the 
residence time could be lowered to 3 minutes without significant differences 
in GLC formation (entry 4). It was observed that a higher excess of DMC 
resulted in higher glycerol conversion, but decreased the selectivity due to 
formation of diglycerol tricarbonate, in accordance with the literature (entry 
5).207 Using neat glycerol was attempted by making use of peristaltic pumps 
(VapourTec E-series system) and following the the protocol of de Souza et 
al.,204 i.e. preheating glycerol to 70°C (entry 6). Only 30% conversion was 
obtained. Methanol seems to be a required cosolvent enhancing the 
homogeneity of the liquid phase and therefore, allowing better mixing and 
short residence times in combination with high conversion and selectivity. 
This is in this case not possible when using neat glycerol. Ochoa-Gómez et al. 
hypothesized that formation of GLC only occurs if the glyceroxide anion is 
formed.196 Therefore, close contact between the catalytic sites and glycerol 
is required, which is of course enhanced by homogeneity of the liquid phase. 
According to the Ochoa-Gómez group, mass transport limitations also 
explain why their results are poor when using heterogeneous strongly basic 
ion exchange resins Amberlyst A260H and Amberjet 4400 OH in batch.196 Also 
in our hands only low conversion in batch under reflux conditions was 
obtained with our heterogeneous, strongly basic catalyst, Ambersep 900 
Hydroxide (5.5, entry 2). The success of the flow methodology is 
hypothesized to be a combined effect of (a) using higher temperatures, (b) 
inducing a homogeneous liquid phase by adding methanol and (c) performing 
the reaction in a continuous column reactor, thus inducing more turbulence 
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than conventional batch stirring. Motivated by these findings, it was decided 
to keep using methanol as cosolvent. 
Table 15: Heterogeneous catalysis flow experiments.a 
 
Since conversion and selectivity were quite similar in both homogeneous and 
heterogeneous flow catalysis, but residence time was longer for the former, 
attempts to demonstrate the scalability of the heterogeneous flow setup 
were performed. As depicted in Scheme 46a, the use of parallel columns was 
tested. As it appears, no significant differences in GLC formation were 
obtained, both at 120 and 140 °C and using 3.5 equivalents of DMC, in 
comparison with single column usage. Distribution of the flow stream to two 
parallel reactors with theoretically same residence times often gives 
different results in our experience. In a first scale up experiment a total flow 
rate of 2 mL min-1 was used at 140 °C and using 4 equivalents of DMC, 
resulting in a residence time of 4 minutes (Scheme 46b). A conversion of 95% 
and selectivity of 80% were obtained and maintained for 4 hours without 
losing efficiency, consuming 82 grams of glycerol. GLC was isolated in a 75% 
yield and this resulted in a space-time yield of 2.50 kg GLC per L reactor per 
hour. When repeating this experiment but lowering the residence time to 2 
minutes, 62% isolated yield of GLC was obtained, resulting in a space-time 
yield of 3.38 kg GLC per L reactor per hour. A useful further extension 
involved the reusability of the catalyst (see chapter 7 Experimental Section). 
 
Entry Catalyst  
Temp 
(°C) 
tR 
(min) 
C 
(%) 
S 
(%) 
1 
 
100 15 85 89 
2 
 
100 15 73 93 
3 
 
120 15 90 94 
4 
 
140 3 90 83 
5b 
 
120 5 100 67 
6c 
 
120 5 30 90 
a 3.5 equivalents DMC. tR = residence time, BPR = back pressure regulator (250 psi 
used at 140 °C, otherwise 100 psi), C = conversion, S = selectivity. b 10 equivalents 
DMC used. c Neat glycerol preheated at 70 °C used. 
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The catalyst was used 4 times at 120 °C for about 60 minutes per run without 
losing efficiency. In between runs, the catalyst beads were rinsed with 
methanol and dried overnight. At 140 °C a 10% decrease in conversion was 
observed at fourth usage. It appears that the catalyst is robust and air-stable 
after use. 
 
Scheme 46: (a) The use of parallel columns. (b) Set up for scale up experiments. 
While these results are not bad, further investigation is needed because of 
issues with reproducibility of the results. In a number of runs, for unclear 
reasons, we observed a significantly lower conversion when repeating 
certain conditions. This is of course problematic for both publication and 
industrial application. Indeed, reproducibility is considered one of the biggest 
issues in organic chemistry literature.208 In the meantine, follow up research 
in the Baxendale group showed that even better results were obtained with 
other heterogeneous catalysts such as polymer supported tetraalkyl 
ammonium derivatives with anions such as fluorides, malononitriles and 
triflated amines.209  
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6. Conclusions & Future Perspectives 
6.1 General conclusions 
In general, contributions were made to make working with very dangerous 
gases in an academic lab environment more accessible. These developed 
procedures exceed reported ones in cost and safety. 
First, a convenient and safe method was developed to generate carbon 
monoxide, This new method uses formic acid, mesyl chloride and 
triethylamine to generate carbon monoxide, 3 commodity chemicals 
available in every organic synthesis lab and is one of the cheapest ways 
known to generate carbon monoxide on laboratory scale (chapter 2.1). This 
methodology was applied by means of a two-chamber reactor where in the 
other chamber the carbon monoxide was consumed via a palladium-
catalyzed carbonylation (chapter 2.2). High yields were achieved and some 
biologically active compounds were synthesized via this method, with the 
existing possibility of labelling carbon monoxide with commercially available 
13C-enriched formic acid. Moreover, attempts were undertaken to use this 
CO precursor in continuous flow, however without much success. This is 
summarized in Scheme 47.84 
 
Scheme 47: CO generation and applications. 
Second, the developed methodology in chapter 2 was applied to the 
synthesis of minimalist α-helix peptidomimetics, scaffolds that can display 
amino acid side chains in a geometrically similar way as a protein α-helix 
108 
 
(chapter 3). Palladium-catalyzed aminocarbonylation reactions were used to 
assemble the helix mimetics. Previously unreported pyrazine based 
oligoamide α-helix mimetics were generated in this fashion, as well as hybrid 
type multimers (Scheme 48).88 
 
Scheme 48: A protein α-helix (left) and our developed modular synthesis of the mimetics 
(right). 
Next, the use of sulfur dioxide as reactant in organic synthesis was examined 
(chapter 4.2). Facing similar dangers as working with carbon monoxide, we 
developed a method for the large scale laboratory synthesis of DABSO, a 
common gas surrogate for sulfur dioxide, again making use of two-chamber 
reactors (chapter 4.3 and Scheme 49).169 
 
Scheme 49: Two-chamber protocol of the DABSO synthesis using sodium sulfite as SO2 source. 
Finally, flow chemistry was used to expand classic batch synthetic tools. The 
application of flow chemistry for the synthesis of glycerol carbonate from 
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glycerol. Glycerol is an industrial waste product of the production of biodiesel 
while glycerol carbonate is considered a green chemical. In literature 
however, a lot of batch processes are known for this transformation while 
almost no flow protocols were reported. This led to the development of a 
flow protocol where high conversion and selectivity were achieved by making 
use of a heterogeneous basic catalyst in a packed bed column reactor 
(chapter 5). The residence could be lowered to 3-5 minutes, leading to high 
space-time yields. Reuse of catalyst (up to 4 times) was possible with only 
slight decrease in conversion (from 90% to 80%). 
 
Scheme 50: Continuous flow protocol for the synthesis of glycerol carbonate (GLC) from 
glycerol and dimethyl carbonate (DMC) using a solid supported catalyst in a packed bed 
reactor.  
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6.2 Future perspectives 
Our group aims to continue to contribute to the enhancement of safe ways 
of working with (dangerous) gases for the organic synthesis researcher. 
Recently, a safe protocol of working with sulfuryl fluoride (SO2F2) was 
published, again making use of a two-chamber reactor setup.210 Other ideas 
with gases are emerging as we speak and this topic will undoubtedly continue 
to prove its utility in our research group during future work. Figure 26 
summarizes the ideal requirements for new two-chamber ideas. 
 
Figure 26: Ideal requirements for new two-chamber projects. 
One specific idea is the generation of SOF4, a rather exotic but highly useful 
gas. Indeed, the Sharpless group developed click chemistry using this gas, and 
is phrased SuFEx: sulfur (VI) fluoride exchange.211 A demonstration of this 
highly selective chemistry is depicted in Scheme 51. First, SOF4 reacts with 
primary amines/anilines under basic conditions to form iminosulfur 
oxydifluorides 6.1. Next, one can couple silyl ethers in the presence of DBU 
with 6.1, resulting in sulfurofluoridoimidates 6.2, substituting one fluorine in 
the process. Another possibility is reacting 6.1 with secondary amines. This 
yields in 6.3 type compounds. These steps (amination or phenolation) can be 
repeated on the remaining fluorine of 6.3 (not shown). All these steps are 
very selective, occur at room temperature and often require no column 
chromatography with mostly excellent yields. In our opinion, the main 
disadvantage is the storage and handling of a pressurized gas vessel 
containing SOF4. As stated before, this implies a lot of safety considerations. 
Therefore, it would be highly interesting to develop a method to make this 
recent chemistry more accessible in academic laboratories by means of 
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generating and consuming SOF4 in a closed system, thereby avoiding the use 
of a lecture gas bottle. 
 
Scheme 51: SuFEx click chemistry using SOF4. 
In agreement with the general consensus of continuous flow chemistry as a 
novel emerging field for organic synthesis, our group will continue to 
contribute to research with this tool as well. In the case of the continuous 
flow synthesis of glycerol carbonate (GLC), further investigation is required. 
Currently, other catalysts are being screened and additional experiments are 
being carried out. In addition to the project discussed in chapter 5, the 
development of chiral catalysts for the asymmetric synthesis of GLC or 
glycidol would be highly interesting, since these are relevant chiral industrial 
building blocks (Scheme 52). A couple N-heterocyclic carbenes (NHCs) are 
known for the synthesis of (racemic) GLC from glycerol and DMC.203, 212 
Interestingly, chiral NHCs are popular catalysts in asymmetric synthesis,213-214 
and could, in our opinion, be a good starting point for further investigation. 
Moreover, NHCs could be easily immobilized on a polymer support, such as 
hyperbranched polymers, a topic which our group is also investigating. 
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Scheme 52: Flow process proposal for the synthesis of chiral GLC or glycidol. 
  
113 
 
CHAPTER 7 
 
 
 
 
 
 
 
 
 
 
EXPERIMENTAL 
  
114 
 
  
115 
 
7. Experimental 
7.1 General 
All reagents and solvents were purchased from commercial sources (Sigma-
Aldrich, Acros, FluoroChem, TCI, Strem, Fluka, AK Scientific, Manchester 
Organics) and used without further purification. All anhydrous solvents were 
purchased from commercial sources with the exception of diethyl ether, 
toluene and THF, which were dried in large quantities using an Mbraun SPS 
800 drying setup. 
1H NMR, 13C NMR and 2D measurements were recorded on a Bruker Avance 
300 MHz (operating at 75 MHz for 13C measurements) and a Bruker Avance 
400 MHz spectrometer (operating at 100 MHz for 13C measurements). 
Chemical shifts are reported in parts per million (ppm) and are referenced to 
the internal standard tetramethylsilane (TMS) in CDCl3 and DMSO. 
Alternatively, the deuterated solvent was used as internal standard. s = 
singlet, d = doublet, t = triplet, q = quartet, bs = broad singlet. 
IR spectra were recorded using a Bruker Alpha-P coupled to OPUS software. 
GC-MS measurements were performed with a ThermoFinnigan Trace GC Gas 
Chromatographer with non-automated PTV injector, temperature program 
from 40 to 300 °C (rate: 20 °C/min, hold 5 min), coupled to a ThermoScientific 
ITQ900 full scan EI mass spectrometry detector.  
Melting points were obtained using a Mettler Toledo DSC1 system. 
Alternatively, a Reichert-Jung Thermovar electrochemical 9200 instrument 
was used. The measurements are not corrected.  
High-resolution mass spectra (HRMS) were measured with a Waters Synapt 
G2 HDMS quadrupole orthogonal acceleration time-of-flight mass 
spectrometer. Samples were infused at 3 µL/min and spectra were obtained 
in positive ionization mode with a resolution of 15000 (FWHM) using leucine 
encephalin as lock mass. Alternatively, a Kratos MS50TC machine was used 
with an ionization energy of 70 eV at 150-250 °C (as required), coupled to a 
MASSPEC II data acquiring system. The high resolution mass spectra were 
recorded with a resolution of 10000. 
Column chromatography was carried out using self-packed flash columns 
containing flash silica (Davisil® Chromatography Silica, Medium Type LC 60A, 
40-63 micron) on a Büchi Sepacore™ flash apparatus, consisting of a C-660 
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Büchi fraction collector, C-615 pump manager, C-635 UV-photometer, two C-
605 pump modules and a Linseis D120S plotter. Thin layer chromatography 
(TLC) was carried out on pre-coated plates SIL G-25 (Machery-Nagel) with 
UV254 fluorescence indicator. 
Reverse phase HPLC was performed on a Waters Delta 600 
analytical/preparative system equipped with Waters 996 Photo Diode Array 
Detector. Preparative column size: Alltech C18 Prevail 5 µm, 150x22 mm, and 
Phenomenex Luna C18, 5 µm, 150x22 mm 
Crystal structures were determined on a Agilent SuperNova diffractometer 
(single source at offset, Eos detector). Using Olex2, the structure was solved 
with the ShelXS structure solution program using Direct Methods and refined 
with the ShelXL refinement package using least-squares minimization. 
For flow experiments a VapourTec R2+R4 unit, a VapourTec E-series unit with 
peristaltic pumps or DIY reactors with PTFE tubing were used. Omnifit glass 
columns (10 mm i.d. x 100 mm length) were used as reactors for 
heterogeneous catalysis experiments. 
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7.2 Chemical safety 
All experimental work in this thesis was carried out in accordance with the 
Code of Practice for Safety in the Lab,215 and the Departmental Safety 
Brochure.216 Special care and attention are needed when manipulating toxic 
substances, laboratory glassware and explosive substances. Further 
information can be found on the web page of The Department of Chemistry, 
and of the HSE department (Health, Safety & Environment). Additional 
information and existing risk analyses can be found on a user-contributed 
sharepoint.217 
In this thesis, a significant contribution was made towards lab safety by 
making it less dangerous to work with toxic gases. Therefore, two gases will 
be briefly discussed in this section of which we have made frequent use, but 
are highly dangerous. 
Carbon monoxide 
The incorporation of carbon monoxide as a carbonyl moiety in organic 
molecules is the main reason why this gas is so synthetically useful, especially 
from an atom efficiency point of view. However, CO gas is also known as ‘the 
silent killer’, attributing to numerous deaths each year. Carbon monoxide is 
highly flammable, odorless and colorless. Upon exposure, CO binds to 
hemoglobin, the enzyme responsible for oxygen transport throughout a 
living organism. It binds 200 times stronger than oxygen and is called 
carboxyhemoglobin (COHb). On top, COHb binds oxygen more stongly than 
hemoglobin itself (4 binding places in total), leading to an even more 
pronounced reduced release of oxygen delivery. This quickly leads to oxygen 
deprivation, and as a consequence, death. Table 16 gives an overview of the 
signs and symptoms when one is exposed to carbon monoxide. 
In the early days of this research in our group, reactions where toxic gases 
such as carbon monoxide were used needed to be performed in the so-called 
‘cyanide room’ with special fumehoods and multiple alarms and detectors, 
using a balloon setup. This required a special safety training and physical 
presence of a trained supervisor. Ever since the development of our new CO 
precursor two-chamber system, it is strongly encouraged to apply this in our 
lab when carbon monoxide is needed. As stated, this protocol is significantly 
safer, as the carbon monoxide is produced ànd consumed, using only near-
stoichiometric amounts. Therefore, this two-chamber protocol is not 
required to be carried out in the ‘cyanide room’. 
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Table 16: Overview of symptoms related to carbon monoxide exposure. 
Concentration 
(ppm) 
Symptoms 
35 
Headache and dizziness within 6 to 8 hours of constant 
exposure 
100 Slight headache in 2 to 3 hours 
200 Slight headache within 2 to 3 hours, loss of judgement 
400 Frontal headache within 1 to 2 hours 
800 
Dizziness, nausea and convulsions within 45 minutes. 
Insensible within 2 hours 
1600 
Headache, tachycardia, dizziness and nausea within 20 
minutes, death in less than 2 hours 
3200 
Headache, dizziness and nausea in 5 to 10 minutes, 
death in less than 30 minutes 
6400 
Headache and dizziness in 1 to 2 minutes. Death within 
20 minutes 
12800 Death within 3 minutes 
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Sulfur dioxide 
Sulfur dioxide is a ubiquitous commodity chemical which has several 
chemical applications in industrial processes. Until recently, it was not often 
used in an academic lab setting.150 This can partly be ascribed to the gaseous 
state of sulfur dioxide, as well as its notorious toxicity and smell. Inhaling 
sulfur dioxide is associated with increased respiratory symptoms and 
disease, difficulty in breathing, and death.218 In 2010, the EPA revised the 
primary SO2 standards by establishing a new one-hour standard at a level of 
75 parts per billion (ppb). 
However, the use of sulfur dioxide in synthetic organic chemistry is reviving. 
It is believed that the advancement of convenient and stable SO2 surrogates 
(such as DABSO) is an important driver in the rejuvenation of organic 
synthesis research involving SO2. In this sense, our developed protocol 
helped contribute to safer usage of sulfur dioxide in organic chemistry. A safe 
alternative to synthesize DABSO on site, which is relatively expensive, is 
described. Key in this protocol is of course the removal of a pressurized SO2 
gas vessel, which implies serious safety concerns. The SO2 source was in this 
case the innocent salt sodium sulfite. In analogy with our two-chamber 
protocol of using carbon monoxide, sulfur dioxide is generated ànd 
consumed in a closed two-chamber setup. The generation occurs quite slow, 
leading to a gradual release of the gas, and thereby avoiding pressure 
buildup.  
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7.3 In search of a new CO precursor 
Pentafluorophenyl formate (4.14) 
 
Pentafluorophenol (1 g, 5.43 mmol) was dissolved in 6 mL of dry chloroform. 
The solution was cooled to 0 °C, DCC (1.35 g, 6.52 mmol) and formic acid 
(0.25 mL, 6.52 mmol) was added slowly while keeping the temperature at 
0°C. Afterwards the reaction was stirred for an additional 90 minutes at 0 °C. 
The suspension was then filtered and the filtrate was evaporated in vacuo. 
The residue was redissolved in Et2O and the organic phase was washed with 
5% aq. NaHCO3, water and brine. It was then dried over MgSO4, filtered and 
the filtrate was evaporated in vacuo to give the product as a colorless oil (1 
g, 87% yield). The product is not stable and decomposes on standing, even at 
-20°C. 
7.3.1 Flow approach 
Procedure for aminocarbonylation in flow using a Teflon coilreactor 
Three solutions were prepared: A) Tosyl Chloride (0.3 M) and DIPEA (0.4 M), 
B) Formic acid (0.3 M) and C) PhBr (0.2 M), aniline (0.3 M), Pd(OAc)2 (0.01 
M), Xantphos (0.02 M) in the solvent of choice. Solutions A and B were loaded 
in separate syringes and pumped, using a Chemyx Fusion 200 syringe pump. 
The solutions were mixed in an PTFE T-tube fitting and passed through a 
Chemtrix glass reactor chip (residence time 18 s), heated using the Chemtrix 
Start Unit, with temperature control provided by a Laird Technologies 
MTTC1410 unit. Next, the reagent stream was mixed with solution C 
(pumped via a separate syringe pump) in another T-tube fitting before being 
passed through a Teflon coil reactor (residence time 280 s). The product was 
then collected at the outlet and subjected to GC-MS analysis to determine 
conversion. 
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Scheme 53: In situ CO precursor flow protocol. 
Procedure for aminocarbonylation using a Tube-in-Tube reactor 
Tosyl Chloride (0.5 M) and DIPEA (1.0 M), B) Formic acid (0.5 M) and C) 
Bromobenzene (0.2 M), benzylamine (0.4 M), Pd(OAc)2 (0.01 M), Xantphos 
(0.02 M) and DIPEA (0.6 M) were dissolved in the solvent of choice. Solutions 
A and B were loaded in separate syringes and pumped, using a Chemyx 
Fusion 200 syringe pump. The solutions were mixed in an PTFE T-tube fitting 
(Dolomite219 part r. 3000397) and passed through the inner tube of the Tube-
in-Tube reactor (residence time 1 min). Simultaneously, solution C was 
passed through the outer tube of the Tube-in-Tube reactor (residence time 
10 min). The outlet stream of the inner tube was disposed as waste, the 
outlet stream of the outer tube was collected and subjected to GC-MS 
analysis to determine conversion.  
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Scheme 54: Ex situ CO precursor flow protocol: making use of a tube-in-tube reactor. 
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7.3.2 Two chamber approach 
General procedure 
Chamber A of a flame-dried two-chamber reactor was filled with 1 mg 
Palladium(II) acetate (5 µmol, 1 mol%), 3 mg Xantphos (5 µmol, 1 mol %) and 
159 mg sodium carbonate (1.5 mmol, 3 eq). The reactor was brought under 
argon atmosphere by two consecutive vacuum-argon cycles. Next, chamber 
B was filled with 2 mL dried degassed toluene, 51 µL mesyl chloride (0.65 
mmol, 1.3 eq) and 25 µL formic acid (0.65 mmol, 1.3 eq). In chamber A, 1 mL 
dried degassed toluene was added, followed by 0.5 mmol aryl bromide (1 eq) 
and 0.75 mmol amine (1.5 eq). Then the reactor was placed in an oil-bath at 
100 °C. Finally, 181 µL triethylamine (1.3 mmol, 2.6 eq) was added by 
injection through the septum in chamber B and instant gas formation was 
observed. After this, the reactor was brought to room temperature and the 
generated pressure was released by removing one of the caps. As carbon 
monoxide is a highly toxic gas, the reaction was stirred at room temperature 
for 15 minutes to ensure that all carbon monoxide gas was extracted out of 
the fume hood. Next, the content of chamber A was transferred to a 100 mL 
round bottomed flask. This chamber was washed 5 times with 2 mL of EtOAc, 
these fractions were added to the same flask. After the addition of 1 gram 
Celite® 535, the solvent was removed under reduced pressure. The crude 
product was purified by solid-phase flash column chromatography on silica 
gel. 
 
Representation of the two-chamber reactor. Inner volume = 20 mL. 
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N-benzylbenzamide (2.6) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 82 µL phenylmethanamine (0.75 mmol, 1.5 eq). The crude mixture 
was purified by solid-phase flash column chromatography on silica gel (85:15 
heptanes/ethyl acetate). The title compound was obtained as a white solid 
(96 mg, 91%). 1H NMR (400 MHz, DMSO) 9.04 (bs, 1H), 7.95 – 7.86 (m, 2H), 
7.58 – 7.43 (m, 3H), 7.33 (d, J = 4.3 Hz, 4H), 7.24 (dd, J = 8.6 & 4.4 Hz, 1H), 
4.49 (d, J = 6.0 Hz, 2H). 13C NMR (101 MHz, DMSO) 166.2, 139.7, 134.3, 131.2, 
128.3, 128.2, 127.2, 127.2, 126.7, 42.6, 39.5. Melting point: 105-107 °C. 
N-hexylbenzamide (2.10) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 99 µL n-hexylamine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (85:15 
heptanes/ethyl acetate). The title compound was obtained as a waxy solid 
(101 mg, 98%). 1H NMR (300 MHz, CDCl3) 7.85 – 7.30 (m, 5H), 6.65 (m, 1H), 
3.39 (m, 2H), 1.65 – 1.50 (m, 2H), 1.42 – 1.16 (m, 6H), 0.86 (t, J = 6.7 Hz, 
3H).13C NMR (75 MHz, CDCl3) 167.7, 134.9, 131.2, 128.5, 127.0, 40.2, 31.6, 
29.6, 26.7, 22.6, 14.1. Melting point: 42-44 °C. 
N-methoxy-N-methylbenzamide (2.11) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 mmol, 1.5 
eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (80:20 heptanes/ethyl acetate). The title 
compound was obtained as a colorless oil (73 mg, 89%). 1H NMR (300 MHz, 
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CDCl3) 7.69 – 7.34 (m, 5H), 3.54 (s, 3H), 3.35 (s, 3H). 13C NMR (75 MHz, CDCl3) 
170.1, 134.2, 130.7, 128.2, 128.1, 61.1, 33.9.  
N-allyl-N-methylbenzamide (2.12) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 71 µL N-methylprop-2-en-1-amine (0.75 mmol, 1.5 eq). The crude 
mixture was purified by solid-phase flash column chromatography on silica 
gel (80:20 heptanes/ethyl acetate). The title compound was obtained as a 
colorless oil (71 mg, 81%). 1H NMR (600 MHz, DMSO) 7.47 – 7.35 (m, 5H), 
5.89 – 5.75 (m, 1H), 5.24 – 5.15 (m, 2H), 3.94 (s, 2H), 2.90 (s, 3H). 13C NMR 
(151 MHz, DMSO) 170.0, 136.3, 133.1, 128.8, 127.8, 126.1, 116.5, 50.8, 34.0. 
N-butylbenzamide (2.13) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 74 µL N-butylamine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (85:15 
heptanes/ethyl acetate). The title compound was obtained as a colorless oil 
(79 mg, 89%). 1H NMR (400 MHz, DMSO) 8.42 (bs, 1H), 7.48 (m, 5H), 3.26 (dd, 
J = 12.8 & 6.9 Hz, 2H), 1.57 – 1.45 (m, 2H), 1.39 – 1.27 (m, 2H), 0.90 (t, J = 7.3 
Hz, 3H). 13C NMR (101 MHz, DMSO) 166.1, 134.7, 130.9, 128.2, 127.1, 38.8, 
31.2, 19.6, 13.7. Melting point: 41-42 °C. 
Phenyl(piperidin-1-yl)methanone (2.14) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 74 µL piperidine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (80:20 
heptanes/ethyl acetate). The title compound was obtained as a colorless oil 
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(88 mg, 93%). 1H NMR (300 MHz, CDCl3) 7.36 (m, 5H), 3.68 (m, 2H), 3.31 (m, 
2H), 1.64 (m, 4H), 1.49 (m, 2H). 13C NMR (75 MHz, CDCl3) 170.3, 136.5, 129.3, 
128.4, 126.8, 48.7, 43.1, 26.5, 25.7, 24.6. Melting point: 47-48 °C. 
4-chloro-N-methoxy-N-methylbenzamide (2.15) 
 
The general procedure was followed using 144 mg 1-bromo-4-chlorobenzene 
(0.75 mmol, 1.5 eq) and 49 mg N,O-dimethylhydroxylamine hydrochloride 
(0.50 mmol, 1.0 eq). The crude mixture was purified by solid-phase flash 
column chromatography on silica gel (80:20 heptanes/ethyl acetate). The 
title compound was obtained as a colorless oil (83 mg, 83%). 1H NMR (300 
MHz, CDCl3) 7.64 (d, J = 8.7 Hz, 2H), 7.36 (d, J = 8.7 Hz, 2H), 3.52 (s, 3H), 3.34 
(s, 3H). 13C NMR (75 MHz, CDCl3) 168.7, 136.8, 132.3, 129.9, 128.4, 77.2, 61.2, 
33.6. 
4-cyano-N-methoxy-N-methylbenzamide (2.16) 
 
The general procedure was followed using 91 mg 4-bromobenzonitrile (0.5 
mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (60:40 heptanes/ethyl acetate). The title 
compound was obtained as a light yellow oil (87 mg, 92%). 1H NMR (300 MHz, 
CDCl3) 7.72 (dd, J = 20.6 & 8.5 Hz, 4H), 3.50 (s, 3H), 3.35 (s, 3H). 13C NMR (75 
MHz, CDCl3) 168.0, 138.3, 131.9, 128.9, 118.2, 114.2, 61.4, 33.3. 
Methyl 2-benzamidoacetate (2.17) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 94 mg methyl glycinate hydrochloride (0.75 mmol, 1.5 eq). The 
crude mixture was purified by solid-phase flash column chromatography on 
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silica gel (80:20 heptanes/ethyl acetate). The title compound was obtained 
as a white solid (93 mg, 96%). 1H NMR (300 MHz, CDCl3) 7.82 – 7.75 (m, 2H), 
7.52 – 7.34 (m, 3H), 7.06 (bs, 1H), 4.18 (d, J = 5.3 Hz, 2H), 3.73 (s, 3H). 13C 
NMR (75 MHz, CDCl3) 170.2, 167.3, 133.2, 131.4, 128.2, 126.7, 52.0, 41.3. 
Melting point: 82-83 °C. 
Morpholino(phenyl)methanone (2.18) 
 
The general procedure was followed using 53 µL bromobenzene (0.5 mmol, 
1 eq) and 66 µL morpholine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (50:50 
heptanes/ethyl acetate). The title compound was obtained as a colorless oil 
(91 mg, 95%). 1H NMR (400 MHz, CDCl3) 7.38 (m, 5H), 3.63 (m, 8H). 13C NMR 
(101 MHz, CDCl3) 170.5, 135.7, 129.9, 128.6, 127.2, 67.0, 46.9. Melting point: 
73-74 °C. 
N-methoxy-N-methylthiophene-3-carboxamide (2.19) 
 
The general procedure was followed using 47 µL 3-bromothiophene (0.5 
mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (80:20 heptanes/ethyl acetate). The title 
compound was obtained as a light yellow oil (77 mg, 90%). 1H NMR (300 MHz, 
CDCl3) 8.06 (dd, J = 3.0 & 1.2 Hz, 1H), 7.56 (dd, J = 5.1 & 1.2 Hz, 1H), 7.27 (dd, 
J = 5.1 & 3.0 Hz, 1H), 3.64 (s, 3H), 3.35 (s, 3H). 13C NMR (75 MHz, CDCl3) 163.4, 
134.1, 130.5, 128.7, 124.5, 60.9, 32.9. 
N-methoxy-N-methyl-3-nitrobenzamide (2.20) 
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The general procedure was followed using 101 mg 1-bromo-3-nitrobenzene 
(0.5 mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (75:25 heptanes/ethyl acetate). The title 
compound was obtained as a light yellow oil (90 mg, 86%). 1H NMR (300 MHz, 
CDCl3) 8.57 – 8.53 (m, 1H), 8.34 – 8.27 (m, 1H), 8.05 – 7.99 (m, 1H), 7.60 (t, J 
= 8.0 Hz, 1H), 3.54 (s, 3H), 3.38 (s, 3H). 13C NMR (75 MHz, CDCl3) 167.3, 147.9, 
135.6, 134.4, 129.3, 125.4, 123.6, 61.5, 33.3. Melting point: 41-43 °C. 
2-cyano-N-methoxy-N-methylbenzamide (2.21) 
 
The general procedure was followed using 92 mg 2-bromobenzonitrile (0.5 
mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (70:30 heptanes/ethyl acetate). The title 
compound was obtained as a colorless oil (85 mg, 89%). 1H NMR (400 MHz, 
CDCl3) 7.74 – 7.45 (m, 4H), 3.52 (s, 3H), 3.36 (s, 3H). 13C NMR (101 MHz, CDCl3) 
166.9, 139.1, 132.9, 132.5, 129.9, 128.0, 116.9, 110.9, 61.5, 33.4.  
N-4-dimethoxy-N-methylbenzamide (2.22) 
 
The general procedure was followed using 63 µL 1-bromo-4-
methoxybenzene (0.5 mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine 
hydrochloride (0.75 mmol, 1.5 eq). The crude mixture was purified by solid-
phase flash column chromatography on silica gel (80:20 heptanes/ethyl 
acetate). The title compound was obtained as a colorless oil (85 mg, 87%). 1H 
NMR (300 MHz, CDCl3) 7.70 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 3.81 (s, 
3H), 3.53 (s, 3H), 3.32 (s, 3H). 13C NMR (75 MHz, CDCl3) 169.0, 161.1, 130.1, 
125.6, 112.8, 60.5, 54.9, 33.5. 
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N-methoxy-N-methyl-2-naphthamide (2.23) 
 
The general procedure was followed using 104 mg 2-bromonaphtalene (0.5 
mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine hydrochloride (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (85:15 heptanes/ethyl acetate). The title 
compound was obtained as a colorless oil (94 mg, 88%). 1H NMR (300 MHz, 
CDCl3) 8.22 (s, 1H), 7.92 – 7.73 (m, 4H), 7.58 – 7.47 (m, 2H), 3.55 (s, 3H), 3.40 
(s, 3H). 13C NMR (75 MHz, CDCl3) 169.9, 134.2, 132.5, 131.4, 128.9, 128.7, 
127.7, 127.6, 127.4, 126.5, 125.1, 61.2, 33.9. 
N-methoxy-N,3,5-trimethylbenzamide (2.24) 
 
The general procedure was followed using 68 µL 1-bromo-3,5-
dimethylbenzene (0.5 mmol, 1 eq) and 73 mg N,O-dimethylhydroxylamine 
hydrochloride (0.75 mmol, 1.5 eq). The crude mixture was purified by solid-
phase flash column chromatography on silica gel (70:30 heptanes/ethyl 
acetate). The title compound was obtained as a colorless oil (86 mg, 89%). 1H 
NMR (300 MHz, CDCl3) 7.22 (s, 2H), 7.06 (s, 1H), 3.56 (s, 3H), 3.31 (s, 3H), 2.32 
(s, 6H). 13C NMR (75 MHz, CDCl3) 170.5, 137.7, 134.2, 132.2, 125.6, 77.2, 61.0, 
34.1, 21.3. 
 (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(piperidin-1-yl)methanone or CX-546 
(2.25a) 
 
The general procedure was followed using 67 µL 6-bromo-2,3-
dihydrobenzo[b][1,4]dioxine (0.5 mmol, 1 eq) and 74 µL piperidine (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (80:20 heptanes/ethyl acetate). Compound 
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2.25a was obtained as a white solid (111 mg, 90%). 1H NMR (600 MHz, CDCl3) 
6.95 – 6.82 (m, 3H), 4.25 (m, 4H), 3.52 (m, 4H), 1.68 – 1.64 (m, 2H), 1.57 (m, 
4H). 13C NMR (151 MHz, CDCl3) 170.0, 144.9, 143.6, 130.0, 120.6, 117.3, 
116.7, 64.6, 64.5, 46.0, 26.3, 24.8. 
Carbon-13 labelled (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)(piperidin-1-
yl)methanone or CX-546 (2.25b) 
 
The general procedure was followed using 67 µL 6-bromo-2,3-
dihydrobenzo[b][1,4]dioxine (0.5 mmol, 1 eq) and 74 µL piperidine (0.75 
mmol, 1.5 eq). The crude mixture was purified by solid-phase flash column 
chromatography on silica gel (80:20 heptanes/ethyl acetate). Compound 
2.25b was obtained as a white solid (124 mg, 94%). Remark: for the C-13 
labelled CX-546, 25 µL of 13C-HCOOH (95 wt. % in H2O) was used. 1H NMR 
(600 MHz, CDCl3) 6.94 – 6.81 (m, 3H), 4.26 – 4.20 (m, 4H), 3.66 – 3.38 (m, 4H), 
1.68 – 1.62 (m, 2H), 1.61 – 1.52 (m, 4H). 13C NMR (151 MHz, CDCl3) 169.9 (s), 
144.9 (s), 143.5 (s), 129.9 (d, J = 67.7 Hz), 120.6 (s), 117.20 (d, J = 4.9 Hz), 
116.6 (d, J = 2.3 Hz), 64.6 (s), 64.5 (s), 46.2(bs), 26.2 (s), 24.8 (s). 
4-chloro-N-(2-morpholinoethyl)benzamide or Moclobemide (2.26a) 
 
The general procedure was followed using 98 mg 1-bromo-4-chlorobenzene 
(0.5 mmol, 1 eq) and 99 µL 2-morpholinoethan-1-amine (0.75 mmol, 1.5 eq). 
The crude mixture was purified by solid-phase flash column chromatography 
on silica gel (96:4 dichloromethane/methanol). Compound 2.26a was 
obtained as a white solid (130 mg, 97%). 1H NMR (300 MHz, CDCl3) 7.75 – 
7.68 (m, 2H), 7.45 – 7.37 (m, 2H), 6.76 (bs, 1H), 3.77 – 3.68 (m, 4H), 3.57 – 
3.48 (m, 2H), 2.63 – 2.56 (m, 2H), 2.54 – 2.43 (m, 4H). 13C NMR (75 MHz, 
CDCl3) 166.4, 137.8, 133.1, 129.0, 128.5, 67.1, 56.9, 53.4, 36.2. Melting point: 
137 °C. 
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Carbon-13 labelled 4-chloro-N-(2-morpholinoethyl)benzamide or 
Moclobemide (2.26b) 
 
The general procedure was followed using 98 mg 1-bromo-4-chlorobenzene 
(0.5 mmol, 1 eq) and 99 µL 2-morpholinoethan-1-amine (0.75 mmol, 1.5 eq). 
The crude mixture was purified by solid-phase flash column chromatography 
on silica gel (96:4 dichloromethane/methanol). Compound 2.26b was 
obtained as a white solid (126 mg, 94%). Remark: for the C-13 labelled 
Moclobemide, 25 µL of 13C-HCOOH (95 wt. % in H2O) was used. 1H NMR (300 
MHz, CDCl3) 7.70 (m, 2H), 7.39 (m, 2H), 6.80 (bs, 1H), 3.78 – 3.64 (m, 4H), 
3.59 – 3.48 (m, 2H), 2.58 (m, 2H), 2.54 – 2.41 (m, 4H). 13C NMR (75 MHz, 
CDCl3) 166.4 (s), 137.7 (s), 133.0 (d, J = 65.2 Hz), 128.9 (d, J = 4.4 Hz), 128.5 
(d, J = 2.5 Hz), 67.1 (s), 56.9 (s), 53.4 (s), 36.2 (s). 
N,N-diethylnicotinamide or Nikethamide (2.27a) 
 
The general procedure was followed using 49 µL 3-bromopyridine (0.5 mmol, 
1 eq) and 78 µL diethylamine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (97:3 
dichloromethane/methanol). Compound 2.27a was obtained as a yellow oil 
(68 mg, 76%). 1H NMR (300 MHz, CDCl3) 8.58 (m, 2H), 7.71 – 7.62 (m, 1H), 
7.34 – 7.26 (m, 1H), 3.36 (m, 4H), 1.14 (m, 6H). 13C NMR (75 MHz, CDCl3) 
168.6, 150.3, 147.2, 134.3, 133.0, 123.4, 43.4, 39.6, 14.3, 12.9. 
Carbon-13 labelled N,N-diethylnicotinamide or Nikethamide (2.27b) 
 
The general procedure was followed using 49 µL 3-bromopyridine (0.5 mmol, 
1 eq) and 78 µL diethylamine (0.75 mmol, 1.5 eq). The crude mixture was 
purified by solid-phase flash column chromatography on silica gel (97:3 
132 
 
dichloromethane/methanol). Compound 2.27b was obtained as a yellow oil 
(73 mg, 82%). Remark: for the C-13 labelled Nikethamide, 25 µL of 13C-
HCOOH (95 wt. % in H2O) was used. 1H NMR (300 MHz, CDCl3) 8.60 (m, 2H), 
7.78 – 7.57 (m, 1H), 7.38 – 7.26 (m, 1H), 3.37 (m, 4H), 1.15 (m, 6H). 13C NMR 
(75 MHz, CDCl3) 168.6 (s), 150.3 (s), 147.2 (d, J = 3.0 Hz), 134.3 (d, J = 1.6 Hz), 
133.0 (d, J = 66.7 Hz), 123.5 (s), 43.5 (s), 39.6 (s), 14.3 (s), 12.9 (s).  
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7.3.3 Economic comparison 
 
Note that these prices are calculated for the generation of 1 mmol of CO 
(implying a 100 % conversion) 
1- Low-Cost Instant CO Generation at Room Temperature from Formic Acid, 
Mesyl Chloride and Triethylamine84 
Chemicals mmol Commercial price 
Commercial 
price per mmol 
Price 
Formic acid 1 € 43.50 per 1 L € 0.002 € 0.002  
Mesyl chloride 1 € 24.10 per 100 mL € 0.019 € 0.019  
Triethylamine 2 € 107.00 per 1 L € 0.015 € 0.03  
   Total price per mmol CO: € 0.051 
 
2- Chloroform as a Carbon Monoxide Precursor: In or Ex Situ Generation.66 
Chemicals mmol Commercial price 
Commercial 
price per mmol 
Price 
Chloroform 1 € 72.20 per 1 L € 0.003 € 0.003  
CsOH·H2O 3.33 € 40.9 per 10 grams € 0.688 € 2.291  
   Total price per mmol CO: € 2.294 
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3- Silacarboxylic Acids as Efficient Carbon Monoxide Releasing Molecules: 
Synthesis and Application in Palladium-Catalyzed Carbonylation Reactions.6 
The yield of 77% for the first synthesis step (CO2 + Lithium + chlorodiphenyl 
(methyl)silane) was taken into account. 
 
Chemicals mmol Commercial price 
Commercial 
price per mmol 
Price 
Lithium 5.844 € 82.9 per 25 grams € 0.023 € 0.134 
Chlorodiphenyl 
(methyl)silane 
1.299 € 91.50 per 25 grams € 0.855 € 1.111 
Potassium 
Fluoride 
1.06 
€ 734.00 per 100 
grams 
€ 0.246 € 0.261 
   Total price per mmol CO: € 1.506 
 
4- Ex Situ Generation of Stoichiometric and Substoichiometric 12CO and 13CO 
and Its Efficient Incorporation in Palladium Catalyzed Aminocarbonylations.7 
The CO generating system in this article consists of 1 eq of 9-methyl-9H-
fluorene-9-carbonyl chloride, 5 mol% Pd(dba)2, 5 mol% P(tBu)3 and 1.5 eq of 
DIPEA.  
Chemicals mmol Commercial price 
Commercial 
price per mmol 
Price 
9-methyl-9H-
fluorene-9-
carbonyl 
chloride 
1 € 128.50 per 5 grams € 6.24 € 6.24 
Pd(dba)2 0.05 € 93.00 per 2 grams € 26.72 € 1.336 
P(tBu)3 0.05 € 79.50 per 1 gram € 16.09 € 0.805 
DIPEA 1.5 € 371 per 1 L € 0.065 € 0.098 
   Total price per mmol CO: € 8.479 
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5- Efficient Fluoride-Catalyzed Conversion of CO2 to CO at Room 
Temperature.76 
The CO generating system in this article consists of 1.5 eq of 
tetraphenyldimethyldisilane, 2 eq of carbon dioxide and 0.1 eq of cesium 
fluoride. However the tetraphenyldimethyldisilane additive is not 
commercially available, but can be prepared via one extra synthesis step 
(lithium + chlorodiphenyl (methyl)silane). The yield of 60% of this synthesis 
step was taken into account. 
Chemicals mmol Commercial price 
Commercial 
price per mmol 
Price 
Lithium 1.67 € 83.90 per 25 grams € 0.023 € 0.038 
Chlorodiphenyl 
(methyl)silane 
2.31 € 91.50 per 25 grams € 0.855 € 1.975 
Cesium Fluoride 0.1 € 63.00 per 25 grams € 0.38 € 0.038 
   Total price per mmol CO: € 2.051 
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7.4 The assembly of pyrazine based oligoamide alpha-helix 
mimetics 
3,5-Dibromo-2-aminopyrazine (3.10) 
 
Pyrazin-2-amine (5 g, 52.6 mmol) was dissolved in a mixture of DMSO (100 
mL) and water (2.5 ml). The solution was subsequently cooled to <15 °C. NBS 
(20 g, 112 mmol) was added slowly over a period of approximately 50 min. 
Afterwards the reaction was stirred at RT for 6 hours. The reaction mixture 
was then poured into 300 mL of ice water. The aqueous phase was extracted 
with EtOAc. The organic fraction was washed with sat. NaHCO3 solution, 
water and afterwards dried over MgSO4. The solvent was evaporated in 
vacuo to obtain a brown colored solid. The crude product was purified by 
column chromatography (60:40 heptanes/EtOAc) to give 3,5-
dibromopyrazin-2-amine (11.5 g, 72%) as white-yellow crystals. Melting 
point: 86-88 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 8.04 (s, 1H), 5.06 (bs, 2H). 
13C NMR (75 MHz, CDCl3, ppm): δ 151.9, 143.1, 123.9, 123.6. FT-IR (cm-1): 
3338, 2953. HR-MS: Calculated mass: 251.8768  Mass found: 251.8779. 
5-Bromo-3-methoxypyrazin-2-amine (3.1a) 
 
A solution of 3,5-dibromopyrazin-2-amine (1 g, 3.95 mmol) in 3 mL of dry 
methanol was prepared and cooled to 0 °C. NaOMe (1 mL of a 25% solution 
in MeOH) was then added dropwise while vigorous stirring the mixture. After 
addition, the reaction mixture was set to reflux for 16 hours. Afterwards the 
solution was allowed to cool to RT and left standing overnight. The resulting 
precipitate was filtered, washed with ice-cold methanol and air-dried to give 
5-bromo-3-methoxypyrazin-2-amine 3.1a (670 mg, 83%) as a white solid. All 
analytical data were found to be in accordance with the literature.220 Melting 
point: 137-139 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 7.64 (s, 1H), 4.78 (s, 2H),  
4.01 (s, 3H). 13C NMR (75 MHz, CDCl3, ppm): δ 147.7, 144.2, 134.4, 121.0, 
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54.4. FT-IR (cm-1): 3484 (s, -NH2). HR-MS: Calculated mass: 202.9694  Mass 
found: 202.9703. 
General Procedures for SNAr with alcohols on 3,5-dibromo-2-
aminopyrazine 
Procedure A: with NaH: The alcohol (1.5 eq) was dissolved in dry THF (0.25 
M) under an argon atmosphere. This solution was then cooled to 0 °C and 
NaH (1.5 eq) was slowly added (Caution: evolution of hydrogen gas!), keeping 
the temperature at 0 °C. The suspension was then allowed to stir at 0 °C for 
30 min. 3,5-dibromo-2-aminopyrazine (3.10, 1 eq), dissolved in dry THF (0.4 
M), was then slowly added while keeping the temperature at 0 °C. After 
addition, the reaction mixture is allowed to heat to RT and then heated at 50 
°C for 18 hours. The reaction mixture was subsequently cooled to RT and 
diluted with EtOAc. The organic phase was then washed with water and brine 
before being dried over MgSO4 and evaporated in vacuo. The crude product 
was then purified using MPLC.  
 
Procedure B: with NaHMDS: The alcohol (1.5 eq) was dissolved in dry THF 
(0.15 M) under an argon atmosphere. This solution was then cooled to 0 °C 
and NaHMDS (1.5 eq, 1 M solution in THF) was slowly added, keeping the 
temperature at 0 °C. The suspension was then allowed to stir at RT for 30 
min. 3,5-dibromo-2-aminopyrazine (3.10, 1 eq), dissolved in dry THF (0.4 M), 
was then slowly added while keeping the temperature at 0 °C. After addition, 
the reaction mixture is allowed to heat to RT and then heated at 50 °C for 18 
hours. The reaction mixture was subsequently cooled to RT and diluted with 
EtOAc. The organic phase was then washed with water and brine before 
being dried over MgSO4 and evaporated in vacuo. The crude product was 
then purified using MPLC. 
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5-Bromo-3-isobutoxypyrazin-2-amine (3.1b) 
 
Using procedure B, purified by reverse phase HPLC in ACN/water (from 0% 
to 80% ACN in 30 minutes), 3.1b was obtained as a red oil (88%). 1H NMR 
(300 MHz, CDCl3, ppm): δ 7.62 (s, 1H), 4.77 (bs, 2H), 4.13 (d, J = 6.7 Hz, 2H), 
2.12 (m, 1H), 1.02 (d, J = 6.7 Hz, 6H). 13C NMR (150MHz, CDCl3, ppm): δ 147.5, 
144.2, 134.1, 121.1, 73.4, 27.8, 19.2. HR-MS: Calculated mass: 246.0237  
Mass found: 246.0254. 
 
3-(Benzyloxy)-5-bromopyrazin-2-amine (3.1c) 
 
Using general procedure A, purified using MPLC (7/3 heptanes/EtOAc), 3.1c 
was obtained as yellow crystals (81%). All analytical data were found to be in 
accordance with the literature.221 
 
5-Bromo-3-[(4-fluorobenzyl)oxy]pyrazin-2-amine (3.1d) 
 
Using procedure B, purified using MPLC (7/3 heptanes/EtOAc), 3.1d obtained 
as a yellow solid (64%). Melting point: 102-104 °C. 1H NMR (300 MHz, CDCl3, 
ppm): δ 7.69 (s, 1H), 7.45 (dd, J = 8.8 Hz, 11 Hz, 2H), 7.10 (t, J = 8.8 Hz, 2H),  
5.37 (s, 2H), 4.79 (bs, 2H). 13C NMR (75 MHz, CDCl3, ppm): δ 147.7 (d, J = 
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148.5Hz), 146.9, 144.1, 134.7, 130.7 (d, J = 7 Hz), 127.8, 120.8, 115.6 (d, J= 
21.4 Hz), 68.3. HR-MS: Calculated mass: 296.9913  Mass found: 296.9918. 
5-Bromo-3-[(1-trityl-1H-imidazol-4-yl)methoxy]pyrazin-2-amine (3.1e) 
 
Using procedure A, purified using MPLC (40:60 heptanes/EtOAc), 3.1e was 
obtained as a white solid (35%). Melting point: 213-215 °C. 1H NMR (300 
MHz, CDCl3, ppm): δ 7.61 (s, 1H), 7.48 (s, 1H), 7.32-7.36 (bm, 9H), 7.10-7.14 
(bm, 6H), 7.00 (s, 1H), 5.32 (s, 2H), 4.88 (bs, 2H). 13C NMR (75 MHz, CDCl3, 
ppm): δ 146.9, 144.4, 143.5, 142.2, 139.2, 135.4, 134.3, 129.7, 128.2, 128.1, 
122.5, 75.6, 62.8. HR-MS: Calculated mass: 165.0651  Mass found: 165.0646 
(M – C21H15Br). 
5-bromo-3-[4-(tritylamino)butoxy]pyrazin-2-amine (3.1f) 
 
Using procedure B, purified using MPLC (90:10 heptanes/EtOAc), 3.1f was 
obtained as a light yellow solid (10%). Melting point: 148-150 °C. 1H NMR 
(300 MHz, CDCl3, ppm): δ 7.61 (s, 1H), 7.47 (m, 6H), 7.27 (m, 6H), 7.18 (m, 
3H), 4.73 (bs, 2H), 4.33 (t, J = 6.80 Hz, 2H), 2.20 (t, J = 7.4 Hz, 2H), 1.84 (m, 
2H), 1.62 (m, 2H). 13C NMR (75 MHz, CDCl3, ppm): δ 147.3, 146.2, 144.1, 
134.2, 128.6, 127.8, 126.3, 121.1, 70.9, 67.4, 43.3, 27.4, 26.6. HR-MS: 
Calculated mass: 260.1201  Mass found: 260.1222. 
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5-Bromo-3-[2-(1-trityl-1H-tetrazol-5-yl)ethoxy]pyrazin-2-amine (3.1g) 
 
Using procedure B, purified using MPLC (50:50 heptanes/EtOAc), 3.1g was 
obtained as a yellow solid (54%). Melting point: 153-156 °C. 1H NMR (300 
MHz, CDCl3, ppm): δ 7.62 (s, 1H), 7.28-7.36 (bm, 9H), 7.06-7.09 (bm, 6H), 4.72 
(t, J = 6.19 Hz, 2H), 4.56 (bs, 2H), 3.43 (t, J = 6.19 Hz, 2H). 13C NMR (75 MHz, 
CDCl3, ppm): δ 162.0, 146.6, 144.2, 141.2, 134.8, 130.2, 128.6, 128.4, 128.0, 
127.8, 120.7, 83.0, 64.6, 25.7. HR-MS: [M-Trt] Calculated mass: 286.1416  
Mass found: 286.1442.  
 
5-Bromo-3-isopropoxypyrazin-2-amine (3.1h) 
 
Using general procedure A (but 10 eq IPA and 3 eq NaH), 3.1h was obtained 
as a yellow solid (91%) and was used after extraction (EtOAc/H2O) without 
further purification. Melting point: 105-106 °C. 1H NMR (300 MHz, CDCl3, 
ppm): δ 7.60 (s, 1H), 5.32 (m, J = 6 Hz,1H), 4.77 (bs, 2H), 1.37 (s, 6H). 13C NMR 
(75 MHz, CDCl3, ppm): δ 146.9, 144.3, 133.3, 121.0, 70.5, 21.8. 
 
Procedure C: For diBoc protection of pyrazine building blocks: 
The amine (1 eq) and DMAP (0.1 eq) were dissolved in dry DCM (0.2 M) under 
an argon atmosphere. Boc2O (2.5 eq) was then slowly added at RT, while 
stirring vigorously. Afterwards the reaction was heated to reflux for 16 hours. 
The mixture was then cooled to RT and the solvent was evaporated in vacuo. 
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The residue was suspended in EtOAc and washed with water and brine. The 
organic phase was then dried over MgSO4, filtered and evaporated in vacuo. 
di-tert-Butyl (5-bromo-3-methoxypyrazin-2-yl)imidodicarbonate (3.2a) 
 
5-Bromo-3-methoxypyrazin-2-amine (3.1a) (1 g, 4.90 mmol) was dissolved in 
THF (Volume: 20 mL) and cooled to <5 °C in an ice bath. Boc2O (2.84 mL, 12.25 
mmol) was slowly added and the mixture was stirred for 1 hour in the ice 
bath. Afterwards the solution was allowed to warm to RT and left stirring 
overnight. Water was added (20 mL) and the aqueous phase was extracted 
with EtOAc. The combined EtOAc fractions were washed with sat. NaHCO3, 
water and subsequently dried over MgSO4. The solvent was evaporated in 
vacuo to give the crude product. Purification was carried out by MPLC (9/1 
heptanes/EtOAc) to give 3.2a as white crystals (1.8 g, 91%). Melting point: 
74-76 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 8.12 (s, 1H), 4.02 (s, 3H), 1.42 (s, 
18H). 13C NMR (75 MHz, CDCl3, ppm): δ 155.2, 149.9, 136.9, 136.3, 134.9, 
83.6, 54.9, 27.8. FT-IR (cm-1): 1797 (s, carbamate). HR-MS: Calculated mass: 
403.0768  Mass found: 403.0743.  
 
di-tert-Butyl (5-bromo-3-isobutoxypyrazin-2-yl)imidodicarbonate (3.2b) 
 
Prepared using procedure C, purified using MPLC (8/2 heptanes/EtOAc), 3.2b 
was obtained as an off-white solid (81%). Melting point 73-76 °C. 1H NMR 
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(300 MHz, CDCl3, ppm): δ 8.09 (s, 1H), 2.08 (m, 1H), 4.16 (d, J = 6.5Hz, 2H), 
1.41 (s, 18H), 1.00 (d, J = 6.5 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 155.4, 
149.9, 136.8, 136.0, 135.1, 83.6, 74.0, 27.9, 27.4, 19.1. HR-MS: Calculated 
mass: 445.1212  Mass found: 445.1246. 
di-tert-Butyl [3-(benzyloxy)-5-bromopyrazin-2-yl]imidodicarbonate (3.2c) 
 
Prepared using procedure C, purified using MPLC (8/2 heptanes/EtOAc), 3.2c 
was obtained as orange crystals (77%). Melting point: 69-72 °C. 1H NMR (300 
MHz, CDCl3, ppm): δ 8.13 (1H), 7.36 (5H), 5.45 (2H), 1.35 (18H). 13C NMR (75 
MHz, CDCl3, ppm): δ 154.7, 149.9, 136.9, 136.5, 135.3, 134.8, 128.4, 128.3, 
83.7, 69.3, 27.8. HR-MS: Calculated mass: 502.0949  Mass found: 502.0949. 
 
di-tert-Butyl (5-bromo-3-ispropoxypyrazin-2-yl)imidodicarbonate (3.2d) 
 
Prepared using procedure C (but 4 eq of Boc2O), purified using MPLC (8/2 
heptanes/EtOAc), 3.2d was obtained as yellow crystals (79%). Melting point: 
81-83 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 8.07 (s, 1H), 5.46-5.28 (m, 1H), 
1.41 (s, 18H), 1.35 (d, J = 6 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 154.7, 
149.8, 137.0, 135.7, 134.9, 83.4, 71.3, 27.9, 21.7. HR-MS: Calculated mass: 
454.0949  Mass found: 454.0939 [M+Na].  
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General procedures for carbonylative coupling 
Procedure D: Alkoxycarbonylation of monomers with CO balloon. 
All solid reagents (Pd(OAc)2 (5 mol%), the pyrazine monomer (1 eq) and 
Xantphos (10 mol%)) were brought into an oven-dried 2-necked flask with a 
septum, under an atmosphere of argon. The flask was evacuated and 
backfilled with argon, this was repeated 2 times. Methanol (10 eq) and 
triethylamine (0.2 M) were added with a syringe via the septum. The 
resulting mixture was purged with carbon monoxide for 2 minutes (Caution! 
Carbon monoxide is a highly toxic and flammable gas). The reaction was then 
placed under a carbon monoxide atmosphere by means of a balloon and 
heated to 80 °C in an oil bath for 24 hours. After this time, the mixture was 
cooled, diluted with EtOAc and filtered over Celite®. The resulting filtrate was 
evaporated in vacuo to obtain the crude product. Purification was carried out 
by MPLC. 
Procedure E: General procedure for CO precursor two-chamber system 
Chamber A of a flame-dried two-chamber reactor was filled with 1 mg 
palladium(II) acetate (0.005 mmol, 1 mol%), 3 mg Xantphos (0.005 mmol, 1 
mol%) and 159 mg sodium carbonate (1.50 mmol, 3 eq). The reactor was 
brought under argon atmosphere by two consecutive vacuum-argon cycles. 
Next, chamber B was filled with 2 mL dry degassed toluene, 51 µL mesyl 
chloride (0.65 mmol, 1.3 eq) and 25 µL formic acid (0.65 mmol, 1.3 eq). In 
chamber A, 1 mL dry degassed toluene was added, followed by 0.50 mmol 
aryl bromide (1 eq) and 0.75 mmol amine/alcohol (1.1 eq). Then the reactor 
was placed in an oil-bath at 100 °C. Finally, 181 µL triethylamine (1.30 mmol, 
2.6 eq) was added by injection through the septum in chamber B and instant 
gas formation was observed. 
[Remark: when the aryl bromide and/or amine are solids at room 
temperature, they were added to Chamber A after the addition of 
palladium(II) acetate and Xantphos.]  
After 2 to 24 hours, the reactor was brought to room temperature and the 
residual pressure was released carefully by removing one of the caps. As 
carbon monoxide is a highly toxic gas, the reaction was stirred at room 
temperature for 15 minutes to ensure that all carbon monoxide gas was 
extracted out of the fume hood. Next, the content of chamber A was 
transferred to a 100 mL round bottomed flask. Chamber A was rinsed five 
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times with 2 mL of EtOAc and these fractions were added to the same flask. 
After the addition of 1 g Celite®, the solvent was removed under reduced 
pressure. For purification, the crude product was dry-loaded onto the MPLC 
system.  
 
 
Representation of the two-chamber reactor. Inner volume = 20 mL. 
Procedure F: Aminocarbonylative coupling of monomers with CO balloon 
All solid reagents: monomer A (1 eq), monomer B (1 eq), Pd(OAc)2 (5 mol%), 
Na2CO3 (3 eq) and Xantphos (5 mol%) were brought in a dry two-necked flask 
with a cooler and a septum, under an atmosphere of argon. The flask was 
evacuated and subsequently purged with argon. This was repeated 2 times. 
Dry degassed toluene (0.2 M) was added via a syringe. The mixture was 
purged with carbon monoxide for 2 minutes via a needle through the 
septum. (Caution! Carbon monoxide is a highly toxic and flammable gas). 
Then a carbon monoxide atmosphere was created by means of a balloon. The 
mixture was stirred at 80 °C, for 24 hours. Afterwards, the reaction was 
cooled to room temperature, diluted with EtOAc and filtered over a plug of 
Celite®. The filtrate was evaporated to afford the crude product which was 
purified by MPLC. 
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Methyl 5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazine-2-
carboxylate (3.3a) 
 
Using Procedure D, after purification by MPLC (8/2 heptanes/EtOAc), 3.3a 
was obtained as white crystals (88%). Melting point: 99-102 °C. 1H NMR (300 
MHz, CDCl3, ppm): δ 8.55 (s, 1H), 4.10 (s, 3H), 4.05 (s, 3H), 1.40 (s, 18H). 13C 
NMR (75 MHz, CDCl3, ppm): δ 164.2, 155.4, 149.6, 141.4, 139.0, 136.6, 83.7, 
75.5, 54.5, 52.9. FT-IR (cm-1): 1742, 1705 (carbamate). HR-MS: Calculated 
mass: 283.1180  Mass found: 283.1182 [M – Boc].  
 
Methyl 5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazine-2-
carboxylate (3.3b) 
 
Using Procedure D, after purification by MPLC (8/2 heptanes/EtOAc), 3.3b 
was obtained as a white solid (89%). Melting point 59-62 °C. 1H NMR (300 
MHz, CDCl3, ppm): δ 8.71 (s, 1H), 4.26 (d, J = 6 Hz, 2H), 4.00 (s, 3H), 2.10 (m, 
1H), 1.39 (s, 18H), 1.01 (d, J = 6.8 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 
164.2, 155.6, 149.6, 141.3, 139.1, 136.3, 83.7, 73.5, 52.9, 27.9, 27.8, 19.1. HR-
MS: Calculated mass: 425.2162  Mass found: 425.2125. 
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Methyl 5-amino-6-methoxypyrazine-2-carboxylate (3.4a) 
 
Methyl 5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazine-2-carboxylate 
(3.3a) (800 mg, 2.1 mmol) was dissolved in 10 mL of dry DCM and the solution 
was cooled in an ice bath. To this TFA (3.2 mL, 41.7 mmol) was added 
dropwise while stirring. After the addition of TFA, the reaction was stirred at 
RT for 6 hours. Afterwards, the solvent was evaporated in vacuo. The residue 
was purified using MPLC (7/3 EtOAc/heptanes) to obtain the pure product 
3.3b as off-white crystals (350 mg, 92%). Melting point: 87-88 °C. 1H NMR 
(300 MHz, CDCl3, ppm): δ 8.35 (s, 1H), 5.81 (bs, 2H), 4.11 (s, 3H), 3.93 (s, 3H). 
13C NMR (75 MHz, CDCl3, ppm): δ 165.3, 147.8, 147.3, 138.1, 128.6, 54.0, 
52.2. FT-IR (cm-1): 3338, 3111, 2953, 2876, 1715, 1551, 1447. HR-MS: 
Calculated mass: 183.0644  Mass found: 183.0650. 
 
Methyl 5-amino-6-isobutoxypyrazine-2-carboxylate (3.4b) 
 
In a sealed vessel under an argon atmosphere, methyl 5-[bis(tert-
butoxycarbonyl)amino]-6-isobutoxypyrazine-2-carboxylate (3.3b) (220 mg, 
0.517 mmol) was suspended in 15 mL of water. The mixture was stirred 
vigorously while heating to 100 °C for 24 hours. The suspension was then 
allowed to cool to RT and extracted three times with EtOAc. The combined 
organic phases were washed with water, brine and dried over MgSO4. After 
filtration, the filtrate was evaporated in vacuo to give the pure product (3.4b) 
as white crystals (90 mg, 77%). Melting point: 115-117 °C. 1H NMR (300 MHz, 
CDCl3, ppm): δ 8.37 (s, 1H), 5.33 (bs, 2H), 4.25 (d, J = 6.6 Hz, 2H), 3.92 (s, 3H), 
2.13 (m, 1H), 1.04 (d, J = 6.6 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 165.3 
147.8, 147.2, 137.9, 128.6, 72.9, 52.2, 29.7, 27.9, 19.3. HR-MS: Calculated 
mass: 226.11860  Mass found: 226.1201.  
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Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazin-2-yl)11-
carbonyl)amino]-6-methoxypyrazine-2-carboxylate (3.5a) 
 
Using procedure F, after purification using MPLC (9/1 heptanes/EtOAc), 3.5a 
was obtained as white crystals (60%). Melting point: 242 °C (decomposition). 
1H NMR (300 MHz, CDCl3, ppm): δ 10.53 (s, 1H), 8.98 (s, 1H), 8.81 (s, 1H), 4.21 
(s, 3H), 4.17 (s, 3H), 3.99 (s, 3H), 2.17 (s, 18H). 13C NMR (75 MHz, CDCl3, ppm): 
δ 164.3, 159.7, 154.2, 149.7, 149.1, 142.1, 140.3, 139.1, 137.6, 135.4, 134.0, 
84.0, 55.0, 54.2, 52.7, 27.8. HR-MS: Calculated mass: 534.2074  Mass found: 
534.2103. 
 
Methyl 5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-isobutoxypyrazine-2-carboxylate (3.5b) 
 
Using procedure F, after purification using MPLC (1/1 heptanes/EtOAc), 3.5b 
was obtained as a yellow oil (59%). 1H NMR (300 MHz, CDCl3, ppm): δ 10.39 
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(s, 1H), 8.98 (s, 1H), 8.80 (s, 1H), 4.37 (d, J = 6.4 Hz, 2H), 4.25 (d, J = 6.4 Hz, 
2H), 3.99 (s, 3H), 2.18 (bm, 2H), 1.43 (s, 18H), 1.10 (d, J = 7Hz, 6H), 1.07 (d, J 
= 7 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 164.4, 159.9, 154.5, 149.8, 
148.9, 142.2, 140.3, 139.4, 137.3, 135.4, 134.0, 83.9, 73.9, 73.5, 52.7, 28.1, 
21.1, 19.4, 19.2. HR-MS: Calculated mass: 618.3013, Mass found: 618.3000. 
 
Methyl‐[(5‐(bis[(tert‐butoxy)carbonyl]amino) ‐6‐(2‐
methylpropoxy)pyrazin‐2‐yl)amino]‐6‐(2‐methylpropoxy)pyrazine‐2‐
carboxylate (3.5b’) 
 
Using procedure F, after purification using MPLC (1/1 heptanes/EtOAc), 3.5b’ 
was obtained as off-white crystals (59%). Melting point: 130-133 °C. 1H NMR 
(300 MHz, CDCl3, ppm): δ 9.28 (s, 1H), 8.60 (s, 1H), 7.82 (s, 1H), 4.36 (d, J = 
6.7 Hz, 2H), 4.12 (d, J = 6.5 Hz, 2H), 3.95 (s, 3H), 2.32 – 2.16 (m, 1H), 2.15 – 
2.00 (m, J = 13.3, 6.7 Hz, 1H), 1.40 (s, 18H), 1.09 (d, J = 6.7 Hz, 6H), 1.01 (d, J 
= 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3, ppm): δ 165.1, 154.3, 150.6, 147.5, 
145.1, 142.3, 137.1, 132.6, 130.6, 123.8, 83.0, 73.7, 73.1, 52.5, 28.1, 28.0, 
19.4, 19.3. HR-MS: Calculated mass: 591.3137  Mass found: 591.3120 [M+H] 
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Methyl 5-[[(5-amino-6-methoxypyrazin-2-yl)carbonyl]amino]-6-
methoxypyrazine-2-carboxylate (3.6a) 
 
Methyl-5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl) amino]-6-isobutoxypyrazine-2-carboxylate (3.5a) (200 mg, 0.374 
mmol) was dissolved in 20 mL of DCM under an atmosphere of argon. The 
solution was cooled to 0 °C in an ice bath and TFA (0.577 mL, 7.48 mmol) was 
slowly added while stirring. The reaction mixture was then stirred at RT for 4 
hours. Afterwards, the solvent was evaporated in vacuo to give a white-
yellow powder, which was washed with water, MeOH, heptanes, EtOAc and 
DCM to afford 3.6a as an off-white powder (125 mg, quant.). Melting point: 
290 °C (decomposition). Due to the poor solubility of this product in all 
solvents tried, analytical data are not available. 
 
Methyl 5‐[5‐amino‐6‐(2‐methylpropoxy)pyrazine‐2‐amido]‐6‐(2‐
methylpropoxy) pyrazine‐2‐carboxylate (3.6b) 
 
In a sealed vessel under an argon atmosphere, methyl 5-[((5-[bis(tert-
butoxycarbonyl)amino]-6-isobutoxypyrazin-2-yl)carbonyl) amino]-6-
isobutoxypyrazine-2-carboxylate (3.5b) (115 mg, 0.186 mmol) was 
suspended in 7 mL of water. The mixture was stirred vigorously while heating 
to 100 °C for 72 hours. The suspension was then allowed to cool to RT and 
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extracted three times with EtOAc. The combined organic phases were 
washed with water, brine and dried over MgSO4. After filtration, the filtrate 
was evaporated in vacuo to give the pure product (3.6b) as white crystals (72 
mg, 92%). Melting point: 196-198 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 8.77 
(s, 1H), 8.59 (s, 1H), 5.60 (bs, 2H), 4.23 (d, J = 6 Hz, 2H), 3.97 (s, 3H), 2.19 (m, 
2H), 1.10 (d, J = 6.8 Hz, 6H), 1.09 (d, J = 6.8 Hz, 6H). 13C NMR (75 MHz, CDCl3, 
ppm): δ 164.9, 161.3, 148.8, 148.4, 146.0, 141.0, 137.4, 136.8, 133.0, 129.5, 
73.7, 72.9, 52.6, 28.1, 28.0, 19.5, 19.3. HR-MS: Calculated mass: 418.1965  
Mass found: 418.1971. 
 
Methyl 5-[((5-[((5-[bis(tert-butoxycarbonyl)amino]-6-methoxypyrazin-2-
yl)carbonyl)amino]-6-methoxypyrazin-2-yl)carbonyl)amino]-6-
methoxypyrazine-2-carboxylate (3.7a) 
 
Using procedure F, after purification using MPLC (9/1 EtOAc/heptanes), 3.7a 
was obtained as a white solid (17%). Peak assignments of the 13C and 1H NMR 
spectra were confirmed using 2D NMR experiments. 1H NMR (300 MHz, 
CDCl3, ppm): δ 10.50 (s, 1H, H37), 10.40 (s, 1H, H7), 9.04 (s, 1H, H5), 9.00 (s, 
1H, H25), 8.81 (s, 1H, H14), 4.27 (s, 3H, H17), 4.21 (s, 3H, H18), 4.18 (s, 3H, H26), 
3.99 (s, 3H, H16), 1.44 (s, 18H, H30-32, 34-37). 13C NMR (75 MHz, CDCl3, ppm): δ 
164.3 (C15), 159.8 (C19), 159.5 (C8), 154.2 (C22), 149.7 (C27,28), 149.0 (C11), 148.0 
(C2), 142.2 (C23), 140.9 (C3), 140.5 (C12), 139.0 (C20), 137.6 (C14), 136.3 (C25), 
135.5 (C5), 134.5 (C6), 133.8 (C9), 84.1 (C29,33), 55.0 (C26), 54.7 (C17), 54.2 (C18),  
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52.7 (C15), 27.9 (C30-32, 34-36). HR-MS: Calculated mass: 483.1266  Mass found: 
483.1278 [M-2Boc]. 
 
Methyl 5-[((5-[((5-[bis(tert-butoxycarbonyl)amino]-6-isobutoxypyrazin-2-
yl)carbonyl)amino]-6-isobutoxypyrazin-2-yl)carbonyl)amino]-6-
isobutoxypyrazine-2-carboxylate (3.7b) 
 
Using procedure F, after purification using MPLC (8/2 EtOAc/heptanes), 3.7b 
was obtained as an off-white wax (19%). 1H NMR (300 MHz, CDCl3, ppm): δ 
1.08 (d, J = 6.8 Hz, 6H), 1.11 (d, J = 6.8 Hz, 6H), 1.16 (d, J = 6.8 Hz, 6H), 1.44 
(s, 18H), 2.19 (m, 1H), 3.99 (m, 2H), 4.26 (d, J = 6.8 Hz, 2H), 4.35 (d, J = 6.8 Hz, 
2H), 4.37 (d, J = 6.8 Hz, 2H), 8.79 (s, 1H), 9.00 (s, 1H), 9.06 (s, 1H), 10.26 (s, 
1H), 10.37 (s, 1H). 13C NMR (75 MHz, CDCl3, ppm): δ 164.4, 160.0, 159.8, 
154.5, 149.8, 148.9, 147.9, 142.3, 141.0, 140.5, 139.3, 137.4, 136.3, 135.5, 
134.6, 133.8, 84.0, 73.8, 73.5, 52.7, 28.2, 28.1, 28.0, 27.9, 19.5, 19.4, 19.2.  
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Methyl‐[5‐(5‐(bis[(tert‐butoxy)carbonyl]amino)12‐6‐methoxypyrazine‐2‐
amido)‐6‐(2‐methylpropoxy)pyrazine‐2‐amido]‐6‐(2‐
methylpropoxy)pyrazine‐2‐carboxylate (3.7c) 
 
Using procedure F, after purification using MPLC (95/5 DCM/MeOH), 3.7c 
was obtained as a yellow solid (23%). Melting point: 215-219 °C. 1H NMR (400 
MHz, CDCl3) δ 10.43 (s, 1H), 10.25 (s, 1H), 9.05 (s, 1H), 9.01 (s, 1H), 8.78 (s, 
1H), 4.40 – 4.32 (m, 4H), 4.14 (s, 3H), 3.98 (s, 3H), 1.44 (s, 18H), 1.15 (d, J = 
6.6 Hz, 6H), 1.10 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 164.4, 160.0, 
159.6, 154.3, 149.8, 148.9, 147.9, 142.3, 141.0, 140.5, 139.1, 137.4, 136.4, 
135.8, 134.7, 133.8, 84.1, 73.8, 73.7, 54.2, 52.7, 28.2, 28.1, 27.9, 19.5, 19.4. 
HR-MS: Calculated mass: 770.3468  Mass found: 770.3480 [M+H]. 
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Methyl‐(5‐[6‐(benzyloxy)‐5‐(bis[(tert‐butoxy)carbonyl]amino)pyrazine‐2‐
amido]‐6‐(2‐ methylpropoxy)pyrazine‐2‐amido)‐6‐(2‐
methylpropoxy)pyrazine‐2‐carboxylate (3.7d) 
 
Using procedure F, after purification using MPLC (95/5 DCM/MeOH), 3.7d 
was obtained as a yellow solid (24%). 1H NMR (400 MHz, CDCl3) δ 10.45 – 
10.41 (m, 1H), 10.25 (s, 1H), 9.07 (s, 1H), 9.04 (s, 1H), 8.79 (s, 1H), 7.45 – 7.38 
(m, J = 5.2, 3.6 Hz, 5H), 5.54 (s, 2H), 4.40 – 4.28 (m, J = 10.5, 6.6 Hz, 4H), 3.98 
(s, 3H), 2.25 – 2.11 (m, J = 13.3, 6.6 Hz, 2H), 1.38 (s, 18H), 1.11 – 1.06 (m, J = 
6.7, 2.4 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 164.4, 160.0, 159.6, 153.9, 
149.8, 148.9, 147.9, 142.3, 141.0, 140.5, 139.1, 137.4, 136.4, 135.9, 134.7, 
133.8, 128.9, 128.8, 128.1, 84.1, 73.8, 73.8, 69.1, 52.7, 28.2, 28.1, 27.8, 19.5, 
19.5. HR-MS: Calculated mass: 846.3781  Mass Found: 846.3801 [M+H]. 
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Methyl-5‐[5‐(5‐amino‐6‐methoxypyrazine‐2‐amido)‐6‐(2‐
methylpropoxy)pyrazine‐2‐ amido]‐6‐(2‐methylpropoxy)pyrazine‐2‐
carboxylate (3.8a) 
 
3.7c was dissolved in dry DCM (0.2 M) and the solution was cooled in an ice 
bath. Subsequently, TFA (20 eq) was added dropwise while stirring. After the 
addition of TFA, the reaction was stirred at RT for 6 hours. Afterwards, the 
solvent was evaporated in vacuo to obtain the pure product (3.8a) as a yellow 
solid (98%). Due to the poor solubility of this product in all solvents tried, 
NMR data are not available. FT-IR (cm-1): 3499 (-NH2), 3338, 2919, 1719. HR-
MS: Calculated mass: 570.2419  Mass found: 570.2416 [M+H]. 
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Methyl-5‐(5‐[5‐amino‐6‐(benzyloxy)pyrazine‐2‐amido]‐6‐(2‐
methylpropoxy)pyrazine‐ 2‐amido)‐6‐(2‐methylpropoxy)pyrazine‐2‐
carboxylate (3.8b) 
 
3.7d was dissolved in dry DCM (0.2 M) and the solution was cooled in an ice 
bath. Subsequently, TFA (20 eq) was added dropwise while stirring. After the 
addition of TFA, the reaction was stirred at RT for 6 hours. Afterwards, the 
solvent was evaporated in vacuo to obtain the pure product (3.8b) as a 
yellow solid (quant.). Melting point: 244-246 °C .1H NMR (400 MHz, CDCl3) δ 
10.34 (s, 1H) 10.26 (s, 1H), 9.03 (s, 1H), 8.78 (s, 1H), 8.65 (s, 1H), 7.51 – 7.43 
(m, 5H), 5.48 (s, 4H), 4.39 – 4.28 (m, 4H), 3.97 (d, J = 2.3 Hz, 3H), 2.27 – 2.09 
(m, 2H), 1.13 – 1.04 (m, J = 6.7, 1.9 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 
164.6, 161.0, 160.4, 149.0, 148.5, 147.8, 145.7, 141.8, 140.8, 137.6, 137.6, 
137.5, 136.6, 135.2, 133.9, 133.8, 129.2, 129.1, 128.7, 73.9, 73.8, 69.0, 52.8, 
28.3, 28.2, 19.6, 19.5. HR-MS: Calculated mass: 846.3781  Mass found: 
846.3801 [M+H].  
 
3-methoxy-5-(3-methoxyphenyl)pyrazin-2-amine (3.11) 
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5-bromo-3-methoxypyrazin-2-amine (3.1a) (246 mg, 1.21 mmol), (2-
methoxyphenyl)boronic acid, (220 mg, 1.45 mmol), S-Phos (4 mol%), 
Pd(OAc)2 (2 mol%) and K2CO3 (500 mg, 3.62 mmol) were brought in a dry two-
necked flask with a cooler and a septum, under an atmosphere of argon. The 
flask was evacuated and subsequently purged with argon. This was repeated 
two times. A degassed mixture of ACN/water (3/2, 6.5 mL, 0.2 M) was added 
via a syringe. The mixture was stirred at 100 °C, for 24 hours. Afterwards, the 
reaction was cooled to RT, diluted with EtOAc and filtered over a plug of 
Celite®. The filtrate was dried over MgSO4, filtered and evaporated in vacuo. 
The reaction mixture was purified using MPLC (75/25 heptanes/EtOAc) to 
give 3-methoxy-5-(3-methoxyphenyl)pyrazin-2-amine (3.11) as a white solid 
(203 mg, 73%). Melting point: 92-94 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 
8.03 (s, 1H), 7.48 (m, 2H), 7.33 (m, 1H), 6.87 (m, 1H), 4.95 (s, 2H), 4.08 (s, 3H), 
3.87 (s, 3H). 13C NMR (75 MHz, CDCl3, ppm): δ 156.0, 147.7, 144.4, 138.7, 
138.0, 130.0, 129.7, 117.8, 112.9, 111.3, 55.3, 53.4. HR-MS: Calculated mass: 
231.1008  Mass found: 231.1007. 
 
di-tert-butyl [3-(benzyloxy)-5-([[3-methoxy-5-(3-methoxyphenyl)pyrazin-
2-yl]amino]carbonyl)pyrazin-2-yl]imidodicarbonate  
 
Using procedure F, after purification using MPLC (9/1 heptanes/EtOAc), the 
product was obtained as white crystals (21%). Melting point: 101-103 °C. 1H 
NMR (300 MHz, CDCl3, ppm): δ 10.19 (s, 1H), 8.98 (s, 1H), 8.54 (s, 1H), 7.58 - 
7.37 (m, 9H), 5.62 (s, 2H), 4.20 (s, 3H), 3.90 (s, 3H), 1.37 (s, 18H). 13C NMR (75 
MHz, CDCl3, ppm): δ 160.1, 153.6, 149.7, 149.4, 144.1, 141.7, 139.6, 137.4, 
136.0, 135.4, 135.3, 131.2, 130.0, 128.7, 128.6, 127.9, 118.8, 114.4, 112.4, 
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83.9, 68.9, 55.4, 54.2, 27.8. HR-MS: Calculated mass: 659.2824  Mass found: 
659.2829. 
 
Methyl 5-([[5-amino-6-(benzyloxy)pyrazin-2-yl]carbonyl]amino)-6-
methoxypyrazine-2-carboxylate (3.12)  
 
di-tert-butyl [3-(benzyloxy)-5-([[3-methoxy-5-(3-methoxyphenyl)pyrazine-2-
yl]amino] carbonyl)pyrazin-2-yl]imidodicarbonate (65 mg, 0.01 mmol) was 
dissolved in 8 mL of DCM under an atmosphere of argon. The solution was 
cooled to 0 °C in an ice bath and TFA (0.15 mL, 1.97 mmol) was slowly added 
while stirring. The reaction mixture was then stirred at RT for 4 hours. 
Afterwards, the solvent was evaporated to give a white-yellow powder, 
which was dissolved in EtOAc and extracted with NaHCO3. The organic phase 
was evaporated in vacuo to give 3.12 as a yellow powder (45 mg, quant.). 
Melting point: 240-243 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 10.0 (s, 1H), 
8.60 (s, 1H), 8.51 (s, 1H), 7.59 - 7.37 (m, 5H), 6.98 - 6.94 (m, 4H), 5.55 (bs, 2H), 
5.40 (s, 2H), 4.17 (s, 3H), 3.89 (s, 3H),. 13C NMR (75 MHz, CDCl3, ppm): δ 161.0, 
160.1, 149.2, 148.0, 145.3, 143.1, 137.7, 136.8, 136.5, 135.6, 131.1, 129.9, 
129.8, 128.8, 128.7, 128.5, 118.7, 114.1, 112.2, 68.6, 55.4, 54.1. HR-MS: 
Calculated mass: 459.1775  Mass found: 459.1772. 
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5-bromo-2-nitrophenol (3.14) 
 
KOtBu (5.54 g, 49.40 mmol) was added to 20 mL of NH3(l) under an argon 
atmosphere while stirring. A solution of cumene hydroperoxide (1.56 mL, 
10.86 mmol) and 1-bromo-4-nitrobenzene (2 g, 9.90 mmol) in 7 mL of dry 
THF was then added dropwise. The reaction mixture was refluxed at -33 °C 
for 30 minutes, after which the reaction was quenched by first slowly adding 
solid NH4Cl, followed by sat. aqueous NH4Cl. Aqueous HCl (1 M) was then 
added until an acidic pH was observed on a pH indicator strip. The mixture 
was subsequently extracted with EtOAc (3x50 mL), dried and evaporated in 
vacuo. Purification was performed using MPLC (9/1 heptanes/EtOAc) to give 
3.14 as bright yellow crystals (1.23 g, 57%). Melting point: 28-29 °C. 1H NMR 
(300 MHz, CDCl3, ppm): δ 7.14 (dd, J = 2.9Hz, 1H), 7.38 (d, J = 2Hz, 1H), 7.98 
(d, J = 9Hz, 1H), 10.63 (s, 1H). 13C NMR (75 MHz, CDCl3, ppm): δ 155.3, 132.7, 
132.3, 126.1, 123.9, 123.0. FT-IR (cm-1): 1521, 1310 (s, -NO2). HR-MS: 
Calculated mass: 215.9302  Mass found: 215.9294.  
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4-bromo-2-[(4-fluorobenzyl)oxy]-1-nitrobenzene (3.15) 
 
5-Bromo-2-nitrophenol (3.14) (500 mg, 2.29 mmol), p-fluorobenzylalcohol 
(318 mg, 2.52 mmol) and PPh3 (902 mg, 3.44 mmol) were dissolved in 4 mL 
of dry THF under an argon atmosphere. The solution was then cooled to 0 °C 
and DIAD (696 mg, 3.44 mmol) was slowly added while keeping the 
temperature at 0 °C. Afterwards the reaction mixture was allowed to warm 
to RT and stirred for an additional 18 hours. Then the solvent was evaporated 
and the residue was redissolved in EtOAc and filtered over silica gel. The 
filtrate was once again evaporated in vacuo to deliver the crude product. 
Purification was performed using MPLC (9/1 heptanes/EtOAc) to give 
product 3.15 as a yellow solid (462 mg, 62%). Melting point: 80-82 °C. 1H NMR 
(300 MHz, CDCl3, ppm): δ 7.78 (d, J = 8.6 Hz, 1H), 7.44 (dd, J = 8.8, 5.3 Hz, 2H), 
7.29 (d, J = 1.9 Hz, 1H), 7.21 (dd, J = 8.6, 1.9 Hz, 1H), 7.10 (t, J = 8.7 Hz, 2H), 
5.18 (s, 2H). 13C NMR (75 MHz, CDCl3, ppm): 162.8 (d, J = 247.2 Hz), 152.4 (s), 
139.0 (s), 130.6 (d, J = 3.2 Hz), 129.0 (d, J = 8.3 Hz), 128.4 (s), 127.0 (s), 124.1 
(s), 118.5 (s), 115.8 (d, J = 21.7 Hz), 71.0 (s). HR-MS: Several ionization 
methods tried. Suspicion that compound is not ionisable.  
 
3-[(4-fluorobenzyl)oxy]-N-(3-methoxy-5-morpholin-4-ylpyrazin-2-yl)-4-
nitrobenzamide (3.16) 
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Using procedure F, after purification using reverse phase HPLC in ACN/water 
(from 0% to 80% ACN in 30 minutes), 3.16 was obtained as yellow crystals 
(65%). Melting point: 83-85 °C. 1H NMR (300 MHz, CDCl3, ppm): δ 8.50 (s, 1H), 
8.45 (s, 1H), 7.94 (d, J = 9Hz, 1H), 7.79 (s, 1H), 7.60-7.54 (m, 2H), 7.51-7.37 
(m, 3H), 7.09 (t, J = 9Hz, 2H), 6.99 (d, J = 9Hz, 1H), 5.30 (s, 2H), 4.18 (s, 3H), 
3.90 (s, 3H). 13C NMR (75 MHz, CDCl3, ppm): δ 162.7 (d, J = 123.7 Hz), 162.6 
(s), 160.1 (s), 151.9 (s), 149.6 (s), 144.9 (s), 142.3 (s), 139.2 (s), 137.2 (s), 135.8 
(s), 131.0 (s), 130.7 (d, J = 3.3 Hz), 13.0 (s), 129.2 (d, J = 8.3 Hz), 125.9 (s), 
118.8 (s), 118.4 (s), 115.8 (d, J = 21.7 Hz), 115.3 (s), 114.6 (s), 112.4 (s), 70.9 
(s), 55.4 (s), 54.2 (s). HR-MS: Calculated mass: 505.1518  Mass found: 
505.1520. 
4-bromo-2-isobutoxy-1-nitrobenzene (3.17) 
 
5-Bromo-2-nitrophenol (3.14) (500 mg, 2.29 mmol), isobutyl alcohol (318 mg, 
2.52 mmol) and PPh3 (902 mg, 3.44 mmol) were dissolved in 4 mL of dry THF 
under an argon atmosphere. The solution was then cooled to 0 °C and DIAD 
(696 mg, 3.44 mmol) was slowly added while keeping the temperature at 0 
°C. Afterwards the reaction mixture was allowed to warm to RT and stirred 
for an additional 18 hours. Then the solvent was evaporated and the residue 
was redissolved in EtOAc and filtered over silica gel. The filtrate was once 
again evaporated in vacuo to deliver the crude product. Purification was 
performed using MPLC (9/1 heptanes/EtOAc) to give product 3.17 as a yellow 
solid (60%). Melting point: 80-82 °C. 1H NMR (300 MHz, CDCl3) δ 7.74 (d, J = 
8.6 Hz, 1H), 7.24 – 7.06 (m, 2H), 3.85 (d, J = 6.4 Hz, 2H), 2.16 (m, 1H), 1.06 (d, 
J = 6.7 Hz, 6H).  
ditert-butyl (6-bromo-2-methoxypyridin-3-yl)carbamate (3.18) 
 
Prepared from 6-bromo-2-methoxypyridin-3-amine using procedure C, 
purified using MPLC (8/2 heptanes/EtOAc), 3.18 was obtained as a yellow oil 
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(67%). 1H NMR (300 MHz, CDCl3, ppm): δ 7.38 (d, J = 7.8 Hz, 1H), 7.24 (d, J = 
7.8 Hz, 2H), 3.94 (s, 3H), 1.41 (s, 18H). 
3-[isobutoxy]-N-(3-methoxy-5-morpholin-4-ylpyrazin-2-yl)-4-
nitrobenzamide (3.19) 
 
Using procedure E, after purification using reverse phase HPLC (100% H2O  
100% MeCN in 20 minutes), 3.19 was obtained as yellow crystals (10%). 1H 
NMR (300 MHz, CDCl3, ppm): δ 8.50 (s, 2H), 7.91 (d, J = 8.3 Hz, 1H), 7.69 (s, 
1H), 7.58 (d, J = 7.2 Hz, 2H), 7.42 (d, J = 8.2 Hz, 1H), 6.99 (d, J = 8.6 Hz, 1H), 
4.18 (s, 2H), 3.97 (d, J = 6.4 Hz, 1H), 3.90 (s, 2H), 2.27 – 2.07 (m, 1H), 1.07 (d, 
J = 6.7 Hz, 4H).  
3.20 
 
Using procedure E, after purification using reverse phase HPLC (100% H2O  
100% MeCN in 20 minutes), 3.20 was obtained as a white solid (15%). 1H NMR 
(300 MHz, CDCl3, ppm): δ 10.66 (s, 1H), 8.51 (s, 1H), 8.07 – 7.88 (m, 2H), 7.69 
– 7.28 (m, 4H), 4.19 (s, 3H), 4.13 (s, 3H), 3.90 (s, 3H), 1.42 (s, 18H). 13C NMR 
(75 MHz, CDCl3) δ 160.6, 160.1, 157.8, 150.5, 149.4, 145.3, 143.5, 138.5, 
137.66, 136.6, 131.1, 129.9, 127.2, 118.7, 116.6, 114.2, 112.3, 83.4, 55.4, 
54.1, 53.7, 27.9. 
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tert‐Butyl N‐[(tert‐butoxy)carbonyl]‐N‐[5‐(cyclopropylcarbamoyl)‐3‐(2‐
methylpropoxy)pyrazin‐2‐yl]carbamate (3.21) 
 
General procedure E was followed using 3.2a (75 mg, 0.168 mmol). As 
cyclopropylamine is a liquid, it was injected after addition of dry degassed 
toluene to chamber A. The crude product was purified using MPLC (8/2 
heptanes/EtOAc) to obtain the title compound (3.21) as a yellow solid (79%). 
1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 7.47 (bs, 1H), 4.12 (d, J = 6.4 Hz, 2H), 
2.94 – 2.79 (m, J = 7.0, 3.3 Hz, 1H), 2.21 – 1.95 (m, 1H), 1.36 (s, 18H), 1.00 (d, 
J = 6.7 Hz, 6H), 0.94 – 0.83 (m, J = 6.9 Hz, 2H), 0.73 – 0.59 (m, 2H). 13C NMR 
(101 MHz, CDCl3) δ 164.1, 154.3, 149.8, 141.0, 140.2, 134.0, 83.6, 73.3, 27.9, 
27.8, 22.6, 19.2, 6.8. 
3‐methoxy‐5‐(4‐methylpiperazine‐1‐carbonyl)pyrazin‐2‐amine (3.25a) 
 
General procedure E was followed using 3.1a (75 mg, 0.368 mmol). As N-
methylpiperazine is a liquid, it was injected after addition of dry degassed 
toluene to chamber A. The crude product was purified using MPLC (95/5 
dichloromethane/methanol) to obtain the title compound (3.25a) as a yellow 
solid (53%). 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 5.32 (bs, 2H), 3.94 (s, 
3H), 3.76 (bs, 4H), 2.46 (bs, 4H), 2.30 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
166.1, 146.2, 145.8, 136.2, 133.3, 55.0, 54.6, 53.7, 47.2, 46.0, 42.6. FTIR     
(cm-1): 3394 (-NH2), 2996, 2805, 1611. Melting Point: 167-170 °C. HRMS: 
Calculated mass: 252.1455  Found mass: 252.1453 (M+H) 
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5‐amino‐N‐cyclopropyl‐6‐methoxypyrazine‐2‐carboxamide (3.25b) 
 
General procedure E was followed using 3.1a (50 mg, 0.245 mmol). As 
cyclopropylamine is a liquid, it was injected after addition of dry degassed 
toluene to chamber A. The crude product was purified using MPLC (99/1 
ethyl acetate/triethylamine) to obtain the title compound (3.25b) as a yellow 
solid (41%). 1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 7.30 (bs, 1H), 5.35 (bs, 
2H), 4.00 (s, 3H), 2.92 – 2.82 (m, J = 10.5, 3.5 Hz, 1H), 0.92 – 0.79 (m, 2H), 
0.69 – 0.56 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 165.7, 147.8, 146.3, 134.9, 
130.4, 53.8, 22.5, 6.8. Melting Point: 175-177 °C. HRMS: Calculated mass: 
209.1033  Found mass: 209.1031 (M+H) 
(5-amino-6-isopropoxypyrazin-2-yl)(4-methylpiperazin-1-yl)methanone 
(3.26) 
 
Using procedure E, after purification using MPLC (95/5 DCM/MeOH), 3.26 
was obtained as yellow crystals (62%). 1H NMR (300 MHz, CDCl3, ppm): δ 8.02 
(s, 1H) 5.30 – 5.21 (m, 1H), 5.04 (s, 2H), 3.76 (s, 3H), 2.46 (s, 4H), 2.32 (s, 4H), 
1.38 (d, J = 6.2 Hz, 6H). 13C NMR (75 MHz, CDCl3, ppm): δ 166.2, 146.2, 145.0, 
135.7, 133.6, 77.2, 77.0, 69.6, 46.1, 22.0.  
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tert‐butyl N‐[(tert‐butoxy)carbonyl]‐N‐(5‐([5‐(4‐methylpiperazine‐1‐
carbonyl)‐3‐ (propan‐2‐yloxy)pyrazin‐2‐yl]carbamoyl)‐3‐(2‐
methylpropoxy)pyrazin‐2‐yl)carbamate  
 
Using procedure E and 3.2b as aryl bromide, after purification using MPLC 
(95/5 DCM/MeOH), the product was obtained as yellow crystals (16% (43% 
with recovery of starting material)). 1H NMR (400 MHz, CDCl3, ppm): δ 10.33 
(s, 1H), 8.95 (s, 1H), 8.36 (s, 1H), 5.46 – 5.35 (m, 1H), 4.26 (d, J = 6.5 Hz, 2H), 
3.81 (s, 2H), 3.61 (s, 2H), 2.52 (s, 2H), 2.41 (s, 2H), 2.33 (s, 4H), 2.23 – 2.10 (m, 
1H), 1.79 (s, 2H), 1.45 (d, J = 6.2 Hz, 6H), 1.42 (s, 18H), 1.07 (d, J = 6.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) 165.2, 159.7, 154.4, 149.8, 147.3, 141.9, 139.5, 
138.3, 135.2, 134.7, 83.9, 73.5, 70.9, 46.1, 28.1, 27.9, 22.1, 19.3. HR-MS: 
Calculated mass: 673.3668  Mass found: 673.3690 [M+H]. 
5-amino-6-isobutoxy-N-(3-isopropoxy-5-(4-methylpiperazine-1-
carbonyl)pyrazin-2-yl)pyrazine-2-carboxamide (3.26) 
 
tert‐butyl N‐[(tert‐butoxy)carbonyl]‐N‐(5‐([5‐(4‐methylpiperazine‐1‐
carbonyl)‐3‐ (propan‐2‐yloxy)pyrazin‐2‐yl]carbamoyl)‐3‐(2‐
methylpropoxy)pyrazin‐2‐yl)carbamate (20 mg, 0.030 mmol) was dissolved 
in 1 mL of DCM under an atmosphere of argon. The solution was cooled to 0 
°C in an ice bath and TFA (46 µL, 0.60 mmol) was slowly added while stirring. 
The reaction mixture was then stirred at RT for 4 hours. After evaporation, 
the residue was diluted in saturated Na2CO3-solution and extracted with 
DCM. Afterwards, the organic phase was dried and evaporated in vacuo to 
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give 3.26 as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H) 8.57 (s, 
1H), 8.34 (s, 1H), 5.43 (bs, 2H), 5.42 – 5.31 (m, 1H), 3.82 (s, 2H), 3.64 (s, 2H), 
2.52 (s, 2H), 2.42 (s, 1H), 2.34 (s, 3H), 2.26 – 2.16 (m, 1H), 1.45 (d, J = 6.2 Hz, 
6H), 1.10 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 19.4, 22.1, 28.0, 
29.7, 46.0, 54.7, 55.3, 70.6, 72.9, 129.8, 134.8, 136.4, 138.4, 139.1, 145.9, 
147.1, 148.2, 161.1, 165.4. HR-MS: Calculated mass: 473.2619  Mass found: 
473.2617 [M+H]. 
tert‐Butyl N‐[(tert‐butoxy)carbonyl]‐5-morpholine‐3‐(2‐
methylpropoxy)pyrazin‐2‐yl]carbamate (3.28) 
 
A solution of 3.2a (100 mg), morpholine (33 µL, 1.5 eq) and triethylamine (52 
µL, 1.5 eq) in 1 mL of dry THF was prepared and was set to reflux for 18 hours. 
Afterwards the solution was allowed to cool to RT. THF was evaporated and 
a water/ethyl acetate extraction was performed. After this, the mixture was 
purified using MPLC (heptanes/EtOAc 7:3) to give 3.28 (30 mg, 10%) as a 
yellow oil. 1H NMR (400 MHz, CDCl3) δ 7.45 (s, 1H), 3.91 (s, 3H), 3.83 (m, 4H), 3.58 
– 3.50 (m, 4H), 1.43 (s, 18H). 
5-bromo-3-(sec-butoxy)pyrazin-2-amine (3.1g)  
 
A flame-dried flask was charged with a stirring bar and NaH (285 mg, 3 eq) 
was added. The atmosphere was evacuated and back-filled with nitrogen 
three times. 10 mL sec-BuOH was slowly added at 0 °C (Caution: evolution of 
hydrogen gas!). The mixture was stirred for 30 minutes at room temperature. 
After this, a solution of 1 g 3,5-dibromo-2-aminopyrazine in 10 mL THF:sec-
BuOH (1:1) was added dropwise at 0 °C. The mixture was then stirred 
overnight at 50 °C. Evaporation of THF and sec-BuOH was followed by an 
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EtOAc/H2O extraction. The products were purified via MPLC 
(heptanes/EtOAc 85:15). 3.1g was obtained as a red oil (735 mg, 76%). 1H 
NMR (300 MHz, CDCl3, ppm): δ 7.59 (s, 1H), 5.15 (m, 1H), 4.82 (bs, 2H), 1.72 
(m, 2H), 1.34 (d, J = 6.2 Hz, 3H), 0.96 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, 
CDCl3, ppm): δ 147.0, 144.4, 133.7, 121.0, 77.0, 75.0, 28.8, 19.2, 9.7. 
di-tert-Butyl (5-bromo-3-(sec-butoxypyrazin-2-yl)imidodicarbonate (3.2e) 
 
5-bromo-3-(sec-butoxy)pyrazin-2-amine (3.1g) (1.39 g) and DMAP (70 mg, 
0.1 eq) were dissolved in dry DCM (20 mL, 0.2 M) under an argon 
atmosphere. A solution of Boc2O (4.93 g, 4 eq) in 10 mL dry DCM was then 
slowly added at RT, while stirring vigorously. Afterwards the reaction was 
refluxed overnight. The mixture was then cooled to RT and the solvent was 
evaporated in vacuo. The residue was suspended in EtOAc and washed with 
water and brine. The organic phase was then dried over Na2SO4, filtered and 
evaporated in vacuo. MPLC (heptanes/EtOAc 85:15) afforded product 3.2e 
as a yellow solid (1.95 g, 77%). 1H NMR (300 MHz, CDCl3, ppm): δ 8.06 (s, 1H), 
5.25 – 5.12 (m, 1H), 1.69 (m, 2H), 1.40 (s, 18H), 1.32 (d, J = 6.2 Hz, 3H), 0.94 
(t, J = 7.4 Hz, 3H). 13C NMR (75 MHz, CDCl3, ppm): δ 155.0, 149.8, 136.9, 
135.6, 134.9, 83.4, 75.9, 28.8, 27.8, 19.2, 9.6. 
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di-tert-Butyl (5-carboxamide-3-(sec-butoxypyrazin-2-yl)imidodicarbonate 
(3.31) 
 
di-tert-Butyl (5-bromo-3-(sec-butoxypyrazin-2-yl)imidodicarbonate (3.2e) 
(179 mg), Pd(dba)2 (12 mg, 5 mol%), Xantphos (12 mg, 5 mol%), ammonium 
carbamate (41 mg, 1.3 eq), sodium bicarbonate (44 mg, 1.3 eq) were added 
in chamber A of a two-chamber reactor (inner volume = 20 mL). The reactor 
was brought under a nitrogen atmosphere by two consecutive vacuum-
nitrogen cycles. Anhydrous degassed toluene (2 mL), formic acid (20 µL, 1.3 
eq) and mesyl chloride (41 µL, 1.3 eq) were added to chamber B and 
anhydrous degassed dioxane (2 mL) to chamber A. At this point, Et3N (145 
µL, 2.6 eq) was added to chamber B and vigorous gas formation is observed. 
The reaction was stirred overnight at 100 °C. After this, chamber A was rinsed 
with EtOAc and evaporated over Celite®. Solid phase MPLC (heptanes/EtOAc 
9:1 to 4:6 in 30 minutes) afforded 3.31 as yellow crystals (55 mg, 33%). 1H 
NMR (400 MHz, CDCl3) δ 8.80 (s, 1H), 7.35 (s, 1H), 6.38 (s, 1H), 5.20 (m, 1H), 
1.84 – 1.66 (m, 2H), 1.40 (s, 18H), 1.37 (d, J = 6.1 Hz, 3H), 0.97 (t, J = 7.4 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 165.4, 154.1, 149.7, 141.4, 139.9, 134.1, 
83.6, 75.4, 28.9, 27.8, 19.2, 9.7. 
di-tert-Butyl (5-N-[ethylsulfonyl]carboxamide-3-secbutoxypyrazin-2-
yl)imidodicarbonate (3.30) 
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3.2e (268 mg, 0.6 mmol), Pd(OAc)2 (4 mg, 3 mol%), Xantphos (16 mg, 5 mol%) 
and potassium fluoride (87 mg, 2.5 eq) were charged in chamber A of a flame-
dried two chamber reactor. Air was evacuated three times and back-filled 
with argon. Degassed anhydrous DMF (3 mL, 0.2 M) was added to chamber 
A under positive pressure by means of a balloon. Next, formic acid (35 µL, 1.5 
eq), mesyl chloride (70 µL, 1.5 eq) and degassed anhydrous DMF (2mL) were 
added to chamber B. The balloon was removed and thiethylamine (251 µL, 3 
eq) was added to chamber B. The two-chamber reactor was submerged in an 
oil bath of 80 °C and was left stirring overnight. After this, the mixture was 
allowed to cool to room temperature and ethylsulfonamide (98 mg, 1.5 eq) 
and triethylamine (209 µL, 2.5 eq) dissolved in degassed anhydrous DMF (1 
mL) was added dropwise to the reaction mixture in chamber A. This was 
stirred for 3 hours at room temperature. After this, Celite® was added and 
DMF was evaporated. MPLC (heptanes/ethyl acetate 70:30  20:80) was 
used to give pure 3.30 as a yellow oil (30 mg, 10%). 1H NMR (300 MHz, CDCl3) 
δ 9.32 (s, 1H), 8.81 (s, 1H), 5.20 (m, 1H), 3.63 (d, J = 7.4 Hz, 2H), 1.75 (m, 2H), 
1.49 (t, J = 6.8 Hz, 3H), 1.42 (s, 18H), 1.37 (t, J = 6.2 Hz, 3H), 0.98 (t, J = 7.4 Hz, 
3H). 
5-amino-6-(sec-butoxy)-N-(ethylsulfonyl)pyrazine-2-carboxamide (3.29) 
 
3.30 was dissolved in water (0.2 M) and refluxed overnight. After cooling to 
room temperature, this was extracted three times with ethyl acetate, dried 
and evaporated. MPLC (DCM  5% MeOH in 30 minutes) was used to give 
pure product 3.29 as a yellow oil (95%). 1H NMR (300 MHz, CDCl3) δ 9.19 (s, 
1H), 8.42 (s, 1H), 5.72 (bs, 2H), 5.17 (m, 1H), 3.60 (q, J = 7.4 Hz, 2H), 1.86 – 
1.69 (m, 3H), 1.45 (t, J = 7.4 Hz, 3H), 1.39 (d, J = 6.2 Hz, 2H), 1.00 (t, J = 7.5 Hz, 
3H). 
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Bacterial tests of compound 3.29 
1. Bacterial strains 
• Staphylococcus aureus ATCC 6538P 
• Staphylococcus epidermidis RP62A 
• Escherichia coli NCIB 8743 
• Pseudomonas aeruginosa PAO1 
• Candida albicans CO11 
• Sarcina lutea ATCC9341 
 
2. Stock solutions of products 
• 16 mg of compound was dissolved in 1 mL DMSO to afford 52.92 mM 
solution. 
• Further 10 mM solution was prepared in DMSO. 
• From this stock solutions, working stock solutions (2 mM, 1 mM and 0.5 
mM) were prepared by diluting with water.  
• All solutions are stored at -20 °C. 
 
3. Growth of bacteria 
• Inoculate 10 μL of glycerol stock ~ 5 ml liquid LB and shake (at 180 rpm) 
at 37°C for overnight. 
• Inoculate 50-100 µl of the overnight-culture in 5 ml liquid LB (1/50-1/100 
dilution). 
• Grow cultures till OD ~ 0.5 (at 180 rpm and 37 °C) and dilute 1/100 in LB 
(OD ~ 0.005) 
 
4. Microdilution method (MIC determination in 96-well plate with 100 µl/well) 
A) Preliminary test 
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For preliminary testing 2 mM, 1 mM and 0.5 mM working solutions of each 
compound were chosen to see if the compound possesses antibacterial 
activity. 
• 5 μL of inhibitor solution was added to 96-well microtitre plate well 1-3 
(as shown in plate layout).  
• 5 μL DMSO was used as a control in well 4. 
• Further 85 μL of LB medium was added from row 1 to 4.  
• 90 μL of LB medium was added to well 5. 
• 100 μL of LB was added to well 6 (sterility control). 
• 10 μL of bacterial suspension (OD ~ 0.005) was added to well 1-5.  
• The microtitre plate was incubated at 37 °C for overnight. 
• Next day, OD was measured at 600nm between 20 to 24 h. 
Notes:  
1. final dilution will be 20-fold (5 μL to 100 μL). Therefore, final concentration 
in the well will be 100 μM, 50 μM and 25 μM respectively. 
2. As 3.29 did not show inhibitory activity up to 100 μM (final concentration) 
against tested bacterial strains, detailed MIC determination was abandoned. 
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X-ray structures 
 
Molecular structure of 3.6b (CCDC 1512413) with ellipsoids drawn at the 50% 
probability level. Dashed lines represent hydrogen bonds. 
 
Empirical formula   C19H28N6O6 
Formula weight   436.47 
Temperature/K   120.0 
Crystal system   orthorhombic 
Space group   Pbca 
a/Å    17.7469(6) 
b/Å    8.5054(3) 
c/Å    28.7562(10) 
α/°    90 
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β/°    90 
γ/°     90 
Volume/Å³   4340.6(3) 
Z     8 
ρcalcg/cm³   1.336 
μ/mm 1    0.101 
F(000)    1856.0 
Crystal size/mm³   0.5 × 0.15 × 0.15 
Radiation    MoKα (λ = 0.71073 Å) 
2Θ range for data collection/° 5.496 to 52.742 
Index ranges   -22 ≤ h ≤ 22, -9 ≤ k ≤ 10, -34 ≤ l ≤ 35 
Reflections collected  28743 
Independent reflections  4434 [Rint = 0.0375, Rsigma = 0.0257] 
Data/restraints/parameters 4434/0/288 
Goodness-of-fit on F2  1.061 
Final R indexes [I>=2σ (I)]  R1 = 0.0530, wR2 = 0.1498 
Final R indexes [all data]  R1 = 0.0652, wR2 = 0.1607 
Largest diff. peak/hole / e Å-3 0.35/-0.74 
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Molecular structure of 3.5b’ (CCDC 1512412) with ellipsoids drawn at the 
50% probability level. Dashed lines represent hydrogen bonds. 
 
Empirical formula   C28H42N6O8 
Formula weight   590.67 
Temperature/K   110.02(13) 
Crystal system   monoclinic 
Space group   P21/c 
a/Å    9.6767(4) 
b/Å    13.4665(5) 
c/Å    25.2462(7) 
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α/°    90 
β/°    100.061(3) 
γ/°     90 
Volume/Å³   3239.3(2) 
Z     4 
ρcalcg/cm³   1.211 
μ/mm 1    0.090 
F(000)    1264.0 
Crystal size/mm³   0.5 × 0.3 × 0.3 
Radiation    MoKα (λ = 0.71073 Å) 
2Θ range for data collection/° 4.912 to 52.744 
Index ranges   -11 ≤ h ≤ 12, -16 ≤ k ≤ 11, -31 ≤ l ≤ 31 
Reflections collected  17986 
Independent reflections  6598 [Rint = 0.0307, Rsigma = 0.0440] 
Data/restraints/parameters 6598/0/390 
Goodness-of-fit on F2  1.095 
Final R indexes [I>=2σ (I)]  R1 = 0.0618, wR2 = 0.1284 
Final R indexes [all data]  R1 = 0.0904, wR2 = 0.1448 
Largest diff. peak/hole / e Å-3 0.45/-0.27  
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Molecular structure of 3.25a (CCDC 1512414) with ellipsoids drawn at the 
50% probability level.  
 
Empirical formula   C11H17N5O2 
Formula weight   251.29 
Temperature/K   150 
Crystal system   orthorhombic 
Space group   P212121 
a/Å    12.7749(11) 
b/Å    10.4901(10) 
c/Å    9.5080(13) 
α/°    90 
β/°    90 
γ/°     90 
Volume/Å³   1274.2(2) 
Z     4 
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ρcalcg/cm³   1.310 
μ/mm 1    0.094 
F(000)    536.0 
Crystal size/mm³   0.5 × 0.35 × 0.25 
Radiation    MoKα (λ = 0.71073Å) 
2Θ range for data collection/° 5.024 to 52.734 
Index ranges   -15 ≤ h ≤ 15, -13 ≤ k ≤ 11, -11 ≤ l ≤ 11 
Reflections collected  7542 
Independent reflections  2589 [Rint = 0.0267, Rsigma = 0.0346] 
Data/restraints/parameters 2589/0/165 
Goodness-of-fit on F2  1.064 
Final R indexes [I>=2σ (I)]  R1 = 0.0393, wR2 = 0.0869 
Final R indexes [all data]  R1 = 0.0511, wR2 = 0.0945 
Largest diff. peak/hole / e Å-3 0.13/-0.18 
Flack parameter   0.8(7) 
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7.5 The use of sulfur dioxide in organic synthesis 
4-methyl-N'-phenylbenzenesulfonohydrazide (4.14) 
 
A glass reaction tube was charged with 4-iodotoluene (4.1, 100 mg, 0.46 
mmol), phenylhydrazine hydrochloride (4.13, 1.5 eq), DABSO (0.6 eq), 
DABCO (1.5 eq), Pd(OAc)2 (0.1 eq) and P(tBu)3.HBF4 (0.2 eq) and sealed under 
nitrogen atmosphere. Dioxane (3.2 mL, 0.15 M) was added and the tube was 
heated to 70 °C by means of an oil bath. The reaction mixture was stirred for 
18 hours. After cooling, Celite® was added and the solvent was evaporated. 
Purification by MPLC (heptanes/ethyl acetate 80:20  60:40) afforded the 
product (4.14, 30 mg, 25%). When breaking the vacuum after evaporation, 
the product is immediately brought under nitrogen atmosphere. 1H NMR 
(400 MHz, CDCl3) δ 7.79 – 7.74 (m, 2H), 7.26 (m, 2H), 7.13 – 7.07 (m, 2H), 6.81 
(t, J = 7.4 Hz, 1H), 6.74 – 6.70 (m, 2H), 6.24 (bs, 1H), 5.65 (bs, 1H), 2.40 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 146.2, 144.5, 134.9, 129.7, 129.0, 128.3, 121.2, 
113.4, 21.6. 
2-bromo-N'-phenylbenzenesulfonohydrazide (4.16) 
 
A glass reaction tube was charged with 1-bromo-2-iodobenzene (4.9, 58 µL, 
0.45 mmol), phenylhydrazine hydrochloride (4.13, 1.5 eq), DABSO (0.6 eq), 
DABCO (1.5 eq), Pd(OAc)2 (0.1 eq) and P(tBu)3.HBF4 (0.2 eq) and sealed under 
nitrogen atmosphere. Dioxane (3.2 mL, 0.15 M) was added and the tube was 
heated to 90 °C by means of an oil bath. The reaction mixture was stirred for 
18 hours. After cooling, Celite® was added and the solvent was evaporated. 
Purification by MPLC (heptanes/ethyl acetate 80:20  60:40) afforded the 
product (4.16, 9 mg, 6%). When breaking the vacuum after evaporation, the 
product is immediately brought under nitrogen atmosphere. 1H NMR (400 
MHz, CDCl3) δ 7.91 – 7.87 (m, 2H), 7.47 (dd, J = 8.1, 1.8 Hz, 1H), 7.17 (d, J = 
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7.9 Hz, 1H), 7.09 (t, J = 7.9 Hz, 2H), 6.81 (t, J = 7.4 Hz, 1H), 6.71 (d, J = 7.7 Hz, 
2H), 6.23 (bs, 1H), 5.69 (bs, 1H). 
2-bromo-N-morpholinobenzenesulfonamide (4.17) 
 
A glass reaction tube was charged with 1-bromo-2-iodobenzene (4.9, 64 µL, 
0.5 mmol), DABSO (0.6 eq), DABCO (1.5 eq), Pd(OAc)2 (0.1 eq) and 
P(tBu)3.HBF4 (0.2 eq) and sealed under nitrogen atmosphere. Dioxane (3.5 
mL, 0.15 M) and N-aminomorpholine (72 µL, 1.5 eq) were added and the tube 
was heated to 70 °C by means of an oil bath. The reaction mixture was stirred 
for 18 hours. After cooling, Celite® was added and the solvent was 
evaporated. Purification by MPLC (heptanes/ethyl acetate 80:20  60:40) 
afforded the product (4.17, 30 mg, 6%). 1H NMR (400 MHz, CDCl3) δ 8.25 (dd, 
J = 7.7, 1.8 Hz, 1H), 7.74 (dd, J = 7.7, 1.2 Hz, 1H), 7.54 – 7.42 (m, 2H), 6.14 (s, 
1H), 3.60 – 3.53 (m, 4H), 2.73 – 2.68 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 
137.9, 135.0, 134.2, 133.3, 127.8, 120.0, 66.4, 56.6. 
2-bromobenzenesulfonohydrazide (4.19) 
 
A round bottomed flask was charged with o-bromobenzenesulfonyl chloride 
(4.18, 1.278 g, 5 mmol) and THF (25 mL). Hydrazine hydrate (486µL, 2 eq) 
was added at 0 °C. The mixture was stirred for 1 hour at room temperature 
and subsequently THF was evaporated. Water was added to the reaction 
mixture and this was extracted with DCM three times. Purification by MPLC 
(heptanes/ethyl acetace 70:30  50:50) afforded the product (4.19) in 14% 
yield. 1H NMR (400 MHz, CDCl3) δ 8.17 (dd, J = 7.5, 2.1 Hz, 1H), 7.76 (dd, J = 
7.6, 1.5 Hz, 1H), 7.54 – 7.44 (m, 2H), 6.66 (bs, 1H), 3.79 (bs, 2H).  
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DABCO·(SO2)2 (abbreviated as DABSO) 
 
A symmetrical two-chamber reactor (inner volume = 400 mL) is charged with 
a Teflon-coated oval stirring bar in each chamber. 5.050 g of DABCO (45 
mmol) is added in chamber A and 12.480 g of Na2SO3 (99 mmol, 2.2 eq) is 
added in chamber B. Two screw caps with septa are fitted on the reactor and 
air is evacuated and back-filled with nitrogen. This process is repeated three 
times. THF (60 mL) is added via a syringe in chamber A and similarly water 
(40 mL) is added in chamber B under a positive pressure by means of a 
nitrogen balloon. After 10 minutes of stirring at room temperature, the 
balloon was removed and H2SO4 (6 mL) is gradually added via a syringe pump 
(50 µL min-1, added over 2 hours). The mixtures were stirred overnight at 
room temperature. After this, the solution in chamber B is removed and the 
suspension in chamber A is transferred to a 100 mL sintered-glass funnel 
under reduced pressure. The white solid is washed five times with 50 mL 
diethyl ether. DABSO is known to be hygroscopic and therefore, it is 
transferred to a flask and dried in a desiccator under vacuum overnight to 
afford the product as a white powder (10.75 g, 99%). Analytical properties in 
accordance with the literature.173 mp 141-143 °C. 1H NMR (400 MHz, CD3OD): 
δ 3.22 (s). 13C NMR (100 MHz, CD3OD): δ 45.4. CHN-analysis: C 29.99, H 5.03, 
N 11.66; found C 30.38, H 5.24, N 11.60.  
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7.6 Towards a continuous synthesis of glycerol carbonate using 
dimethyl carbonate 
Flow equipment 
A VapourTec® R2 + R4 unit was used for all flow reactions. An exception to 
this was when using neat glycerol: a VapourTec E-series system with 
peristaltic pumps was used. Omnifit® glass columns (10 mm x 100 mm, inner 
diameter x length) were used as reactors for heterogeneous catalysis 
experiments. 
Large scale flow procedure  
Two Omnifit® glass columns (10 mm i.d. x 100 mm) are filled with 4.4 grams 
of Ambersep® 900 Hydroxide beads each. Both ends of each column were 
sealed using PTFE plugs and after linking the two columns, MeOH was 
pumped through at a rate of 1 mL min-1. After 10 minutes, temperature is 
gradually increased to 140 °C over a 10 minute period. After this, a solution 
of glycerol (5 M) in MeOH was pumped at 740 µL min-1 and combined via a 
T-piece with a second stream containing DMC (neat, 4 equivalents) at 1.26 
mL min-1. The combined stream was directed into the two linked columns 
(residence time of approximately 4 minutes) and a backpressure regulator of 
17 bar was added in-line. The output was collected for analysis and after 
evaporation of MeOH and DMC, GLC was purified via either vacuum 
distillation or column chromatography (DMC:MeOH 95:5). 
Analysis 
GC-MS experiments were carried out on a Shimadzu QP2010-Ultra. EI is 
carried at 70ev and the working mass range is 35 – 650 u for all experiments. 
The samples were prepared by dissolving 10 µL of collection volume in 1 mL 
of methanol. 0.5 µL of this sample was split injected (25:1) into the Shimadzu 
QP2010-Ultra equipped with a Rxi-17Sil MS column using helium as carrier 
gas (0.41 mL min-1). The temperature of the oven was increased from 30 to 
300 °C with a 50 °C min-1 rate. Finally, the oven was maintained at 300 °C for 
5 min.  
It was found that glycerol and GLC have the same response when plotting 
peak area in function of concentration (see Supporting Information). 
Therefore the following terms are defined as follows: conversion as the 
relative peak area of glycerol with all other peaks, selectivity as the relative 
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peak area excluding the glycerol signal and GC yield as the relative peak area 
ratio of GLC with glycerol. 
General procedure for the synthesis of homogeneous catalysts 
Catalysts are synthesized via simple acid-base neutralization reactions. A 
slight excess of carboxylic acid was added to a tetraethyl ammonium 
hydroxide aqueous solution. The mixture was then stirred at room 
temperature for 2 hours. After evaporation of water at 60 °C under reduced 
pressure, the residue was washed with ethanol. Ethanol was removed in 
vacuo after filtration and the residue was dried overnight under high 
vacuum. 
Tetraethylammonium piperidine-2-carboxylate (5.3) 
 
5.3 was prepared using the general procedure and all analytical data were 
found to be in accordance with the literature.206 
Tetraethylammonium prolinate  
 
The catalysts was prepared using the general procedure and all analytical 
data were found to be in accordance with the literature.206 
Tetraethylammonium picolinate  
 
The catalyst was prepared using the general procedure and obtained as a 
yellow solid. 1H NMR (300MHz, D2O, ppm): δ 8.55 (d, J = 3.5 Hz, 1H), 7.96 (td, 
J = 7.7, 1.6 Hz, 1H), 7.90 (d, J = 7.7 Hz, 1H), 7.56 – 7.50 (m, 1H), 3.23 (q, J = 7.3 
Hz, 7H), 1.28 – 1.19 (m, 11H). 
Polymer supported piperidine-2-carboxylate (5.4) 
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Ambersep® 900 Hydroxide (2 grams) and pipecolic acid (1.3 grams, 1.1 eq) 
were subsequently added to an RBF containing 20 mL methanol. The flask 
was then shaked overnight at room temperature (without stirring bar). After 
this, the polymer beads were filtered, rinsed with methanol and dried 
overnight to give 5.4. 
Calculation of relative flow rate for heterogeneous continuous column 
experiments 
When using 3.5 equivalents of DMC, the following ratio should be achieved 
when mixing: 
3.5 𝑚𝑜𝑙 𝐷𝑀𝐶
1 𝑚𝑜𝑙 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
 =
315 𝑔 𝐷𝑀𝐶
92 𝑔 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
=  
294 𝑚𝐿 𝐷𝑀𝐶
73 𝑚𝐿 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
= 4.03  
Note that this result is the required volume ratio when using both neat DMC 
and neat glycerol. This result changes when a solution of glycerol (5 M) in 
methanol is used. 
Therefore, the volume percent of glycerol is: 
5 𝑀 =
5 𝑚𝑜𝑙 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
𝐿
=  
460 𝑔 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
1 𝐿
=
365 𝑚𝐿 𝑔𝑙𝑦𝑐𝑒𝑟𝑜𝑙
1 𝐿
= 0.365 
Hence the relative flow rate becomes:  
4.03 ∗ 0.365 = 1.47  
The relative flow rate of neat DMC should be about 1.47 times the flow rate 
of glycerol (5 M) in MeOH when 3.5 equivalents DMC are desired. 
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Calibration curves for glycerol and glycerol carbonate 
Several samples were prepared for following GC-MS experiment. Glycerol 
was dissolved in MeOH (0.113 M) and serial diluted to have samples in 
between 0.1 M and 0.001 M, the typical concentration range for prepared 
GC-MS samples. In the same way glycerol carbonate samples were prepared. 
The same response curve for peak area in function of concentration was 
obtained for both glycerol and glycerol carbonate. This was considered 
sufficient for estimation of GC yield, conversion and selectivity. 
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